WO2018192535A1 - Application of thiazole derivative in treatment of nonlymphocytic leukemia - Google Patents

Application of thiazole derivative in treatment of nonlymphocytic leukemia Download PDF

Info

Publication number
WO2018192535A1
WO2018192535A1 PCT/CN2018/083596 CN2018083596W WO2018192535A1 WO 2018192535 A1 WO2018192535 A1 WO 2018192535A1 CN 2018083596 W CN2018083596 W CN 2018083596W WO 2018192535 A1 WO2018192535 A1 WO 2018192535A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
nmr
alkyl
compound
optionally substituted
Prior art date
Application number
PCT/CN2018/083596
Other languages
French (fr)
Chinese (zh)
Inventor
李洪林
陈卓
赵振江
齐甜甜
杨婷媛
宋文琳
韩乐
孙德恒
Original Assignee
华东理工大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 华东理工大学 filed Critical 华东理工大学
Publication of WO2018192535A1 publication Critical patent/WO2018192535A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the present invention relates to the field of medicinal chemistry; in particular, the present invention relates to a medicament for the preparation of a thiazole derivative for the treatment of leukemia and for the treatment of non-lymphocytic leukemia.
  • Acute leukemia is a malignant disease of abnormal hematopoietic stem cells, mainly due to its ability to lose further differentiation and maturation.
  • Acute myeloid leukemia (AML) is a manifestation of malignant proliferation of bone marrow hematopoietic stem cells. This abnormal stem cell ceases to function properly and continues to interfere with other normal hematopoietic systems, leading to infection, bleeding, and various tissue dysfunctions. If left untreated, the patient usually develops fatal injuries within a few weeks after diagnosis.
  • Acute myeloid leukemia is the second most common hematological malignancy and affects the elderly. The most important challenge is to improve the survival rate of patients over 65 years of age. Patients in this age group have higher morbidity and medicinal resistance than other patients.
  • Methods for treating AML include standard treatment, monoclonal antibody therapy, blockade signaling therapy, and epigenetic molecular mechanisms for treatment.
  • the traditional treatment method is based on the combination of anthracyclines and glucosinolates.
  • the common rule of use is (3+7) mode: daunorubicin is administered at a dose of 45 mg/m2 for 3 days, plus arabinose.
  • the sporoside was continuously injected for 7 days at a dose of 100-200 mg/m2. This method is used for young patients with a recovery rate of 60-70%, and the recovery rate for elderly patients is about 40%.
  • the object of the present invention is to provide a series of thiazole derivatives having excellent leukemia therapeutic activity, thereby laying a new material foundation for the development of drugs for treating non-lymphocytic leukemia.
  • the present invention provides the use of a compound of formula I for the manufacture of a medicament for the treatment of leukemia,
  • R a is selected from the group consisting of hydrogen, C 1 -C 3 alkyl,
  • R b is selected from the group consisting of: H, C 1 -C 6 alkyl, halogen-substituted C 1 -C 6 alkyl, C 1 -C 3 alkylcarbonyl, optionally substituted benzoyl, carboxyl, aminocarbonyl, C 1 -C 6 alkoxycarbonyl, hydroxy, C 1 -C 6 alkoxy, optionally substituted C 6 -C 10 aryl or heteroaryl, amino, NR 6 R 7 ;
  • R 6 and R 7 are each independently selected from: H, or an optionally substituted carbonyl C 1 -C 3 alkyl group (preferably a C 1 -C 3 alkyl group or a C 3 -C 6 cycloalkyl substituted carbonyl group; most preferably a ring) Propyl substituted carbonyl);
  • R 2 is selected from the group consisting of: H, C 1 -C 10 alkyl or C 1 -C 10 haloalkyl, C 1 -C 10 alkoxy or C 1 -C 10 haloalkoxy, or hydroxy C 1 -C 6 alkyl Or a hydroxy C 1 -C 6 haloalkyl group;
  • R c is selected from: Ar or
  • R 3 is selected from the group consisting of: H, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, C 1 -C 6 alkoxycarbonyl, optionally substituted phenyl, C 1 -C 4 alkylcarbonyl, any a substituted benzoyl group, a C 1 -C 3 alkylcarboxy group, an amide group, an optionally substituted benzoyl group;
  • Ar is selected from the group consisting of: an optionally substituted C 6 -C 14 aryl group, an optionally substituted C 6 -C 14 heterocyclic group, an optionally substituted C 6 -C 14 arylcarbonyl group, an optionally substituted C 6 -C a 14 heterocyclylcarbonyl group, an optionally substituted C 6 -C 14 aryloxyalkylcarbonyl group;
  • R 1 is selected from the group consisting of: H, halogen, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl;
  • R 5 is selected from the group consisting of: H, halogen, OH, NR 8 R 9 , C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy;
  • R 8 and R 9 are each independently selected from: H, or C 1 -C 3 alkyl, or C 1 -C 3 haloalkyl;
  • R is selected from the group consisting of: aldehyde group CHO, carboxyl group COOH, C 1 -C 6 alkoxycarbonyl group;
  • A is selected from the group consisting of C 1 -C 6 alkyl groups (preferably C 1 -C 3 alkyl groups).
  • the leukemia includes, but is not limited to, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML, formerly known as acute non-lymphocytic leukemia), chronic myeloid leukemia, chronic lymphocytic leukemia; Acute myeloid leukemia is preferred.
  • ALL acute lymphocytic leukemia
  • AML acute myeloid leukemia
  • chronic myeloid leukemia chronic lymphocytic leukemia
  • chronic lymphocytic leukemia chronic lymphocytic leukemia
  • Acute myeloid leukemia is preferred.
  • the compound of Formula I has the structure of Formula Ia:
  • R 3 is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxycarbonyl, optionally substituted phenyl, C 1 -C 4 alkylcarbonyl, optionally substituted benzoyl, C 1 - a C 3 alkylcarboxy group, an amide group, an optionally substituted benzoic acid group;
  • Ar, R b are as described above.
  • Ar has 0-5 substituents selected from the group consisting of: C 1 -C 10 alkyl, C 3 -C 8 cycloalkyl, C 1 -C 4 alkoxy, optionally substituted phenyl, optionally substituted phenoxy, benzyloxy, CF 3, halogen.
  • R b is selected from the group consisting of: C 1 -C 6 alkyl, CF 3 , phenyl, acetyl, benzoyl, carboxyl, carbamoyl, C 1 -C 6 alkoxycarbonyl, amino More preferred are methyl, CF 3 or phenyl.
  • R 3 is selected from the group consisting of: C 1 -C 6 alkyl, phenyl, C 1 -C 3 alkylcarbonyl, optionally substituted benzoyl, carboxy, C 1 -C 6 alkoxy A carbonyl group, an amide group, an optionally substituted benzocarbamoyl group; preferably a C 1 -C 3 alkylcarbonyl group, a C 1 -C 3 alkoxycarbonyl group.
  • the compound of formula I is selected from the group consisting of compounds 1-100.
  • the compound of Formula I has the structure of Formula Ib:
  • R 4 is selected from the group consisting of: H, halogen, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, or C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy;
  • R, R 1 , R 2 , R 3 , R 5 are as described above.
  • the compound of Formula I has the structure of Formula Ic:
  • R 1 is selected from H, F, Cl, Br, C 1 -C 3 alkyl or C 1 -C 3 haloalkyl;
  • R 2 is selected from H, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy, or hydroxy C 1 -C 3 alkyl or a hydroxy C 1 -C 3 haloalkyl group;
  • R 3 is from H, C 1 -C 3 alkyl or C 1-3 haloalkyl
  • R 4 is selected from H, F, Cl, Br, C 1 -C 3 alkyl or C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy or C 1 -C 3 haloalkoxy;
  • R 5 is selected from the group consisting of H, F, Cl, Br, OH, NH 2 , OCH 3 .
  • R 1 is selected from the group consisting of H, C 1 -C 3 alkyl
  • R 2 is selected from C 1 -C 3 alkyl
  • R 3 is selected from H, C 1 -C 3 alkyl
  • R 4 is selected from H or Cl
  • R 5 is selected from H.
  • the compound of Formula I is selected from the group consisting of:
  • the compound of Formula I is selected from the group consisting of:
  • the invention provides a method of treating non-lymphocytic leukemia comprising administering a therapeutically effective amount of a compound of the first aspect of the invention to a patient in need of treatment for leukemia.
  • the leukemia includes, but is not limited to, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia, chronic lymphocytic leukemia, and the like; preferably non-lymphocytic leukemia, including However, it is not limited to: acute myeloid leukemia, chronic myeloid leukemia; more preferably acute myeloid leukemia.
  • ALL acute lymphocytic leukemia
  • AML acute myeloid leukemia
  • chronic myeloid leukemia chronic lymphocytic leukemia
  • chronic lymphocytic leukemia preferably non-lymphocytic leukemia
  • Leukemia as used herein has the meaning commonly understood by those skilled in the art, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML, formerly known as acute non-lymphocytic leukemia), chronic myeloid leukemia, chronic lymphoid. Cellular leukemia, etc.
  • ALL acute lymphoblastic leukemia
  • AML acute myeloid leukemia
  • chronic myeloid leukemia chronic lymphoid.
  • Cellular leukemia etc.
  • leukemia can also be classified into three types: granulocyte, lymphocyte and monocyte.
  • the leukemia described herein is a non-lymphocytic leukemia, ie, leukemia other than lymphocytic leukemia is excluded.
  • the non-lymphocytic leukemia described herein refers to acute myeloid leukemia, chronic myeloid leukemia; more preferably acute myeloid leukemia.
  • alkyl refers to a saturated branched or straight-chain alkyl group having a carbon chain length of from 1 to 10 carbon atoms, and preferred alkyl groups include from 2 to 8 carbon atoms, from 1 to 6, and from 1 to An alkyl group having 4 carbon atoms and 1-3 carbon atoms.
  • alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, heptyl, and the like.
  • the alkyl group may be substituted by one or more substituents, for example by halogen or haloalkyl.
  • the alkyl group may be an alkyl group substituted with 1 to 4 fluorine atoms, or the alkyl group may be an alkyl group substituted with a fluoroalkyl group.
  • alkoxy refers to an oxy group substituted with an alkyl group.
  • Preferred alkoxy groups are alkoxy groups having from 1 to 6 carbon atoms, more preferably alkoxy groups having from 1 to 4 carbon atoms. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, and the like.
  • the alkoxy group can be a substituted alkoxy group, for example, a halogen substituted alkoxy group. In a specific embodiment, a halogen-substituted C1-C3 alkoxy group is preferred.
  • halogen refers to fluoro, chloro, bromo and iodo.
  • the halogen is chlorine or fluorine; more preferably chlorine.
  • amino refers to a group of the formula "NR x R y ", wherein R x and R y may be independently selected from H or C 1 -C 3 alkyl or C 1 -C 3 haloalkyl. In specific embodiments herein described in the “amino” refers to NH 2.
  • carbonyl refers to a group represented by RC(O)-, wherein R may be lower alkyl or lower alkoxy, such as C 1 -C 6 or C 1 -C 3 alkyl or C 1 -C 6 or C 1 -C 3 alkoxy; it is also known to those skilled in the art that when R in the carbonyl group represented by RC(O)- is an alkoxy group, the group represented by RC(O)- is an ester group. For example, when R is an ethoxy group, RC(O)- is an ethyl ester group.
  • the present inventors have found that a series of thiazole derivatives have excellent activity in inhibiting non-lymphocytic leukemia cell lines, and these thiazole derivatives have even better inhibitory effects on non-lymphocytic leukemia cell lines than positive control drugs, thereby treating non-lymphatic drugs.
  • the development of drugs for cellular leukemia has laid a new material foundation.
  • LiOH.H 2 O (1.25 g, 29.7 mmol) was weighed and dissolved in 50 mL of water, and the ester (2.5 g, 13.5 mmol) synthesized in one step was added under stirring, and the temperature was raised to 90 ° C. The solid gradually dissolved as the reaction proceeded. After 1 h, the reaction was stopped, the pH of the reaction solution was adjusted to neutral neutral acidity with dilute hydrochloric acid, a large amount of solid was precipitated, suction filtration, and the filter cake was washed with water and dried to give a pale yellow solid (2.05 g, yield 96.6%).
  • Post-treatment method 1 Add saturated ammonium chloride solution to the reaction solution, the solution gradually becomes turbid and a large amount of solid appears. Add saturated ammonium chloride solution until no more solids appear. Filter the reaction solution. The filter cake is first saturated with chlorination. The ammonium aqueous solution is washed, washed with a saturated aqueous solution of sodium hydrogencarbonate, and the cake is dried to give the object compound 1-9, 12.
  • Post-treatment method 2 Saturate ammonium chloride solution is added dropwise to the reaction solution, and the solution gradually becomes turbid and a large amount of solid appears. The saturated ammonium chloride solution is added dropwise until solids no longer appear. The reaction solution is filtered, and the filter cake is first saturated with chlorination. The ammonium aqueous solution was washed with a saturated aqueous solution of sodium hydrogencarbonate, and the cake was dried.
  • Post-treatment method 3 a large amount of the solvent of the reaction liquid is removed under reduced pressure, and the mixture is extracted with ethyl acetate / saturated ammonium chloride. The obtained organic phase is dried over anhydrous sodium sulfate and then evaporated. Purification by silica gel column chromatography gave Compound 11.
  • LiOH.H 2 O (1.25 g, 29.7 mmol) was weighed and dissolved in 50 mL of water, and the ester (2.5 g, 13.5 mmol) synthesized in one step was added under stirring, and the temperature was raised to 90 ° C. The solid gradually dissolved as the reaction proceeded. After 1 h, the reaction was stopped, and the pH of the reaction solution was adjusted to neutral neutrality with dilute hydrochloric acid. A large amount of solid was precipitated, suction filtered, and the filter cake was washed with water and dried to give a pale yellow solid.
  • Synthetic Method Compound 13-18 was prepared in a similar manner to the procedure of Example 1. Among them, compounds 13-15, 18 are treated with post-treatment one, compound 16 is treated with post-treatment method 2, and compound 17 is treated with post-treatment method three.
  • the aromatic amine (8 mmol, 1 eq) was dissolved in 24 mL of acetone, and the weighed triethylenediamine (24 mmol, 3 eq) was added under stirring, and then 20 mL of carbon disulfide was added dropwise. A large amount of solid appeared, and the mixture was stirred at room temperature for 24 h.
  • the solution and the filter cake were washed with petroleum ether. After drying, the cake was dissolved in 50 mL of chloroform, and BTC (2.7 mmol, 0.33 eq) was weighed and dissolved in 30 mL of chloroform, and added dropwise to the reaction solution over 1 h, and stirred at room temperature. The solution was overnight. After completion of the reaction, the reaction mixture was filtered under suction, and the filter cake was washed with dichloromethane, and the obtained filtrate was directly applied to silica gel and dried, and then dried (PE eluted).
  • the NCS was dissolved in a small amount of methylene chloride, a large excess of ammonia water was added, and the mixture was stirred at 0 ° C for 3 hours.
  • the reaction mixture was filtered, the filter cake was washed with water, and the filter cake was dried to obtain thiourea, which was directly used for the next reaction.
  • the ⁇ -cyclodextrin (590 mg, 0.52 mmol) was dissolved in 10 mL of H 2 O, and the solution was warmed to 50 ° C until the ⁇ -cyclodextrin was completely dissolved to form a colorless transparent solution, and the corresponding acetoacetate B was added.
  • the ester was diluted with 0.5 mL of acetone and added dropwise to the ⁇ -cyclodextrin aqueous solution. After stirring, NBS (138.9 mg, 0.780 mmol) was added to the mixed solution, and after stirring for 1 h, aromatic thiourea (0.52 mmol) was added.
  • the o-carboxybenzaldehyde (66 mg, 0.44 mmol) was weighed into a 25 mL eggplant-shaped flask, and the decomposed product 1d (70 mg, 0.37 mmol) was added, 15 mL of ethanol was added, two drops of acetic acid were added as a catalyst, and the mixture was stirred at room temperature under argon atmosphere, TLC The reaction was traced until the conversion of the starting material was complete, and the mixture was filtered rapidly. The filter cake was washed with iced ethanol to give a bright yellow powdery solid 100 mg, yield 85%. Mp 196.8-197.5 ° C.
  • O-phthalaldehyde (105 mg, 0.78 mmol) was weighed into a 50 mL two-necked flask, dissolved in 15 mL of ethanol, and 1 d (75 mg, 0.39 mmol) was added to the solution. The mixture was stirred at room temperature under argon atmosphere, and a bright yellow precipitate appeared after about 10 min. TLC followed the reaction until the starting material was completely converted, suction filtered, and the filter cake was washed with ethanol and dried to give 25 mg of product.
  • Synthetic method was the same as 1c to give a milky yellow powdery solid, yield 80%.
  • the synthesis method was the same as 1d, and the yellow needle-like crystals were obtained in an amount of 1.3 g, and the yield was 48%.
  • the product of the previous step (1.0 g, 4.1 mmol) was weighed into a 50 mL two-necked flask, 20 mL of ethanol was added, and a new 80% hydrazine hydrate (0.6 mL, 12.3 mmol) was added. After heating under reflux for 24 h under argon atmosphere, the reaction was stopped. After standing overnight, suction filtration, and the obtained crude ethanol was recrystallized to obtain 200 mg of yellow needle crystals, yield 26%.
  • the synthesis method was the same as that of S1, and 100 mg of a yellowish powdery solid was obtained, yield 76%. Mp 215.9-216.0 ° C.
  • the synthesis method was the same as that of 4d, and the crude product was separated into a green needle-like solid by a thin layer of silica gel, and the yield was 46%.
  • the synthesis method was the same as that of S1 to obtain 60 mg of a pale yellow powdery solid, yield 80%. Mp 220.0-220.3 ° C.
  • 2-Chlorobenzophenone (1.0 g, 5.5 mmol) was weighed into a 50 mL single-mouth bottle, 5 mL of diethyl ether was added, 2 drops of glacial acetic acid were added dropwise with stirring, and liquid bromine (0.88 g, 5.5 mmol) of diethyl ether was added dropwise thereto under ice bath. solution was stirred at room temperature overnight, TLC the reaction was followed to complete conversion of starting material, the reaction solution was extracted 3 times with saturated NaHC03, extracted three times with saturated NaCl, dried over anhydrous NaSO 4, rotary evaporation to give 1.04g yellow liquid, yield 89%.
  • the synthesis method was the same as 1c, and the brown viscous liquid was 0.6 g, and the yield was 85%.
  • the synthesis method was the same as that of S1 to obtain a bright yellow powdery solid of 70 mg, yield 68%. Mp 223.9-223.9 ° C.
  • the synthesis method was the same as that of S1, and a yellowish powdery solid of 75 mg was obtained in a yield of 70%. Mp 211.6-212.8 ° C.
  • the synthesis method was the same as that of S1 to obtain a bright yellow powdery solid of 75 mg, yield 70%. Mp 221.6-222.5 ° C.
  • reaction solution was cooled to room temperature, filtered, and the filtrate was added to 200 mL of water, extracted with ethyl acetate three times, and the organic layer was washed three times with saturated aqueous NaCl solution and dried over anhydrous NaSO 4 The solvent was evaporated to give a brown brown oil.
  • the synthesis method was the same as that of 8d, and 190 mg of a brown needle-like solid was obtained, and the yield was 76%.
  • the synthesis method was the same as that of S8, yielding a yellow powdery solid 130 mg, yield 93%. Mp185.6-187.0 °C.
  • the synthesis method was the same as that of 8d to obtain 120 mg of a yellow powdery solid, yield 50%.
  • the synthesis method was the same as that of S8 to obtain 93 mg of a yellowish powdery solid, yield 46%. Mp 187.9-188.9 ° C.
  • the synthesis method was the same as that of 8d, and a brown solid 100 mg was obtained in a yield of 75%.
  • the synthesis method was the same as that of S8 to obtain 60 mg of a yellow powdery solid, yield 76%. Mp 203.3-204.1 ° C.
  • the synthesis method was the same as that of 8d, and a brown viscous solid 100 mg was obtained with a yield of 62%.
  • the synthesis method was the same as that of S8, yielding a yellow powdery solid 105 mg, yield 80%. Mp 170.5-170.6 ° C.
  • the synthesis method was the same as that of 8d, and a brown viscous solid of 120 mg was obtained, and the yield was 65%.
  • the synthesis method was the same as that of 8d, and a brown viscous solid of 105 mg was obtained in a yield of 50%.
  • the synthesis method was the same as that of S8 to obtain a yellow solid, 130 mg, yield 65%. Mp 99.9-100.1 ° C.
  • the synthesis method was the same as that of S7, yielding a yellow powdery solid 78mg, yield 85%. Mp 200.6-201.8 ° C.
  • the synthesis method was the same as that of S7 to obtain a yellow powdery solid, 80 mg, yield 69%. Mp 244.7-245.4 ° C.
  • the synthesis method was the same as that of S7 to obtain 100 mg of a yellow powdery solid, yield 72%. Mp 268.4-269.5 ° C.
  • the synthesis method was the same as that of S7, yielding 78 mg of a yellow powdery solid, yield 70%. Mp 208.8-209.8 ° C.
  • the synthesis method was the same as that of S7 to obtain 0.5 g of a yellow powdery solid, yield 60%. Mp 222.7-224.9 ° C.
  • the synthesis method was the same as that of S7 to obtain 50 mg of a yellowish powdery solid, yield 56%. Mp 209.3-210.7 ° C.
  • the synthesis method was the same as 20f, yielding 0.4 g of a white powdery solid, yield 26%.
  • the synthesis method was the same as 20h, yielding a white powdery solid, 0.36g, yield 60%.
  • the synthesis method was the same as that of S7 to obtain a yellow powdery solid 120 mg, yield 76%. Mp 231.3-232.5 ° C.
  • the synthesis method was the same as that of S7 to obtain a yellow powdery solid of 0.46 g, yield 70%. Mp 243.2-245.2 ° C.
  • the synthesis method was the same as 20f, yielding a pale yellow powdery solid, 68 mg, yield 15%.
  • the synthesis method was the same as that of 8d, 1.2g of brown needle-like solid, and the yield was 61%.
  • the synthesis method was the same as that of S8 to give a bright yellow powdery solid, 35 mg, yield 57%. Mp 236.2-237.1 ° C.
  • the present inventors examined the compounds of the present invention as well as positive control drugs such as buquina, anthracyclines (daunorubicin, demethoxydaunorubicin or mitoxantrone) and cytarabine against acute myeloid cells.
  • positive control drugs such as buquina, anthracyclines (daunorubicin, demethoxydaunorubicin or mitoxantrone) and cytarabine against acute myeloid cells.
  • the half inhibitory concentration of leukemia cell lines are examples of leukemia cell lines.
  • CCK8 reagent was purchased from Beyotime; THP-1, MV4-11, RS4-11, HL60 cells were purchased from ATCC, MOLM13, MOLM14, SIG-M5, AML2, AML3, AML5, U937, MONOMAC6 was purchased from DSMZ, Germany; culture medium was purchased from Hylcone, USA; fetal bovine serum was purchased from Gibco, USA; CO 2 incubator was purchased from Thermo Company, USA, model TM3111; biosafety cabinet was purchased from Heal Force; ultrapure water was purchased.
  • a single cell suspension was prepared with a medium containing 10% fetal bovine serum, and inoculated into a 96-well culture plate at a volume of 80,000/mL per well at a volume of 100 ⁇ L per well, and then the culture plate was transferred to a CO 2 incubator.
  • the medium was cultured for 24 hours at 37 ° C, 5% CO 2 and saturated humidity.
  • the desired inhibitor concentration and dilution gradient generally starting at 10 ⁇ M
  • dilute with the medium to obtain a gradient dilution of the compound, and add to the corresponding well of the 96-well plate. Beat evenly, incubate with cells, incubate in a cell culture incubator for 72 h.
  • survival rate (%) (OD dosing - OD blank ) / (OD control - OD blank ) x 100%, fitting IC 50 and inhibition curve.
  • the compound of the present invention has an inhibitory effect on the proliferation of AML cells, and is generally superior to the positive control drug, wherein the compound S7 inhibits the proliferation of AML cells even better than the positive control drug Brequinar.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to an application of a thiazole derivative as represented by formula I as a therapeutic drug for leukemia. The thiazole derivative as represented by formula I has significant inhibitory effects on leukemia, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia, and chronic lymphocytic leukemia.

Description

噻唑衍生物在治疗非淋巴细胞性白血病中的应用Application of thiazole derivatives in the treatment of non-lymphocytic leukemia 技术领域Technical field
本发明涉及药物化学领域；具体地说，本发明涉及噻唑衍生物在制备治疗白血病中的药物以及在治疗非淋巴细胞性白血病中的应用。The present invention relates to the field of medicinal chemistry; in particular, the present invention relates to a medicament for the preparation of a thiazole derivative for the treatment of leukemia and for the treatment of non-lymphocytic leukemia.
背景技术Background technique
急性白血病是造血干细胞异常的恶性疾病，主要是其白血病细胞失去进一步分化和成熟的能力。急性骨髓性白血病(acute myeloid leukemia,AML)是骨髓造血干细胞恶性增殖的表现。这种异常的干细胞停止了正常工作，并不断干扰其他正常的造血***，导致感染、出血和多种组织功能紊乱。如果不进行治疗，患者一般在确诊之后的几周时间内出现致命性伤害。急性骨髓性白血病为第二大常见的血液恶性肿瘤疾病，并主要影响老年人。最重要的挑战主要是提高超过65岁患者的生存率，这个年龄段的患者比其他患者存在更高的发病率和药物化学抵抗性。Acute leukemia is a malignant disease of abnormal hematopoietic stem cells, mainly due to its ability to lose further differentiation and maturation. Acute myeloid leukemia (AML) is a manifestation of malignant proliferation of bone marrow hematopoietic stem cells. This abnormal stem cell ceases to function properly and continues to interfere with other normal hematopoietic systems, leading to infection, bleeding, and various tissue dysfunctions. If left untreated, the patient usually develops fatal injuries within a few weeks after diagnosis. Acute myeloid leukemia is the second most common hematological malignancy and affects the elderly. The most important challenge is to improve the survival rate of patients over 65 years of age. Patients in this age group have higher morbidity and medicinal resistance than other patients.
治疗AML的方法有标准治疗、单克隆抗体治疗、阻断信号传递途径治疗和表观遗传分子机制进行治疗等一系列方法。传统的治疗方法是基于蒽环类药物加上阿糖孢苷联合使用，常见的使用规则是(3+7)模式：柔红霉素以45mg/m2的剂量给药3天，加上阿糖孢苷以100-200mg/m2的剂量连续注射7天。这种方法用于年轻患者恢复率达60-70％左右，年老患者恢复率达40％左右。Methods for treating AML include standard treatment, monoclonal antibody therapy, blockade signaling therapy, and epigenetic molecular mechanisms for treatment. The traditional treatment method is based on the combination of anthracyclines and glucosinolates. The common rule of use is (3+7) mode: daunorubicin is administered at a dose of 45 mg/m2 for 3 days, plus arabinose. The sporoside was continuously injected for 7 days at a dose of 100-200 mg/m2. This method is used for young patients with a recovery rate of 60-70%, and the recovery rate for elderly patients is about 40%.
治疗AML的方法仍在不断地探索当中，运用一些较新的方案，比如药物靶向作用于信号通路成为了可行性方法，尤其是针对高风险难治愈性疾病。Therapeutic methods for AML are still being explored, and the use of newer protocols, such as drug targeting to signaling pathways, has become a viable approach, especially for high-risk, intractable diseases.
因此，人们需要通过不断地临床试验探索出更新更好的药物。Therefore, people need to explore new and better drugs through continuous clinical trials.
发明内容Summary of the invention
本发明的目的是提供一系列具备优异的白血病治疗活性的噻唑衍生物，从而为治疗非淋巴细胞性白血病的药物的开发奠定了新的物质基础。The object of the present invention is to provide a series of thiazole derivatives having excellent leukemia therapeutic activity, thereby laying a new material foundation for the development of drugs for treating non-lymphocytic leukemia.
在第一方面，本发明提供式I所示化合物在制备治疗白血病的药物中的用途，In a first aspect, the present invention provides the use of a compound of formula I for the manufacture of a medicament for the treatment of leukemia,
Figure PCTCN2018083596-appb-000001
Figure PCTCN2018083596-appb-000001
式中，In the formula,
R a选自：氢、C 1-C 3烷基、
Figure PCTCN2018083596-appb-000002
R a is selected from the group consisting of hydrogen, C 1 -C 3 alkyl,
Figure PCTCN2018083596-appb-000002
R b选自：H、C 1-C 6烷基、卤素取代的C 1-C 6烷基、C 1-C 3烷基羰基、任选取代的苯甲酰基、羧基、氨基羰基、C 1-C 6烷氧基羰基、羟基、C 1-C 6烷氧基、任选取代的C 6-C 10芳基或杂芳基、氨基、NR 6R 7； R b is selected from the group consisting of: H, C 1 -C 6 alkyl, halogen-substituted C 1 -C 6 alkyl, C 1 -C 3 alkylcarbonyl, optionally substituted benzoyl, carboxyl, aminocarbonyl, C 1 -C 6 alkoxycarbonyl, hydroxy, C 1 -C 6 alkoxy, optionally substituted C 6 -C 10 aryl or heteroaryl, amino, NR 6 R 7 ;
R 6和R 7各自独立选自：H、或任选取代的羰基C 1-C 3烷基(优选C 1-C 3烷基或C 3-C 6环烷基取代的羰基；最优选环丙基取代的羰基)； R 6 and R 7 are each independently selected from: H, or an optionally substituted carbonyl C 1 -C 3 alkyl group (preferably a C 1 -C 3 alkyl group or a C 3 -C 6 cycloalkyl substituted carbonyl group; most preferably a ring) Propyl substituted carbonyl);
R 2选自：H、C 1-C 10烷基或C 1-C 10卤代烷基、C 1-C 10烷氧基或C 1-C 10卤代烷氧基、或羟基C 1-C 6烷基或羟基C 1-C 6卤代烷基； R 2 is selected from the group consisting of: H, C 1 -C 10 alkyl or C 1 -C 10 haloalkyl, C 1 -C 10 alkoxy or C 1 -C 10 haloalkoxy, or hydroxy C 1 -C 6 alkyl Or a hydroxy C 1 -C 6 haloalkyl group;
R c选自：Ar或
Figure PCTCN2018083596-appb-000003
R c is selected from: Ar or
Figure PCTCN2018083596-appb-000003
R 3选自：H、C 1-C 6烷基或C 1-C 6卤代烷基、C 1-C 6烷氧基羰基、任选取代的苯基、C 1-C 4烷基羰基、任选取代的苯甲酰基、C 1-C 3烷基羧基、酰胺基、任选取代的苯胺甲酰基； R 3 is selected from the group consisting of: H, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, C 1 -C 6 alkoxycarbonyl, optionally substituted phenyl, C 1 -C 4 alkylcarbonyl, any a substituted benzoyl group, a C 1 -C 3 alkylcarboxy group, an amide group, an optionally substituted benzoyl group;
Ar选自：任选取代的C 6-C 14芳基、任选取代的C 6-C 14杂环基、任选取代的C 6-C 14芳基羰基、任选取代的C 6-C 14杂环基羰基、任选取代的C 6-C 14芳氧基烷基羰基； Ar is selected from the group consisting of: an optionally substituted C 6 -C 14 aryl group, an optionally substituted C 6 -C 14 heterocyclic group, an optionally substituted C 6 -C 14 arylcarbonyl group, an optionally substituted C 6 -C a 14 heterocyclylcarbonyl group, an optionally substituted C 6 -C 14 aryloxyalkylcarbonyl group;
R 1选自：H、卤素、C 1-C 6烷基或C 1-C 6卤代烷基； R 1 is selected from the group consisting of: H, halogen, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl;
R 5选自：H、卤素、OH、NR 8R 9、C 1-C 6烷氧基或C 1-C 6卤代烷氧基； R 5 is selected from the group consisting of: H, halogen, OH, NR 8 R 9 , C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy;
R 8和R 9各自独立选自：H、或C 1-C 3烷基、或C 1-C 3卤代烷基； R 8 and R 9 are each independently selected from: H, or C 1 -C 3 alkyl, or C 1 -C 3 haloalkyl;
R选自：醛基CHO，羧基COOH，C 1-C 6烷氧基羰基； R is selected from the group consisting of: aldehyde group CHO, carboxyl group COOH, C 1 -C 6 alkoxycarbonyl group;
A选自：C 1-C 6烷基(优选C 1-C 3烷基)。 A is selected from the group consisting of C 1 -C 6 alkyl groups (preferably C 1 -C 3 alkyl groups).
在具体的实施方式中，所述白血病包括但不限于：急性淋巴细胞白血病(ALL)、急性髓细胞白血病(AML，以往称为急性非淋巴细胞白血病)、慢性粒细胞白血病、慢性淋巴细胞白血病；优选急性髓细胞白血病。In a specific embodiment, the leukemia includes, but is not limited to, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML, formerly known as acute non-lymphocytic leukemia), chronic myeloid leukemia, chronic lymphocytic leukemia; Acute myeloid leukemia is preferred.
在具体的实施方式中，式I所示化合物具有式Ia所示结构：In a specific embodiment, the compound of Formula I has the structure of Formula Ia:
Figure PCTCN2018083596-appb-000004
Figure PCTCN2018083596-appb-000004
式中，In the formula,
R 3选自：C 1-C 6烷基、C 1-C 6烷氧基羰基、任选取代的苯基、C 1-C 4烷基羰基、任选取代的苯甲酰基、C 1-C 3烷基羧基、酰胺基、任选取代的苯胺甲酰基；和 R 3 is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxycarbonyl, optionally substituted phenyl, C 1 -C 4 alkylcarbonyl, optionally substituted benzoyl, C 1 - a C 3 alkylcarboxy group, an amide group, an optionally substituted benzoic acid group;
Ar、R b如上文所述。 Ar, R b are as described above.
在具体的实施方式中，Ar上具有0-5个取代基，所述取代基选自：C 1-C 10烷基、C 3-C 8环烷基、C 1-C 4烷氧基、任选取代的苯基、任选取代的苯氧基、苄氧基、CF 3、卤素。 In a specific embodiment, Ar has 0-5 substituents selected from the group consisting of: C 1 -C 10 alkyl, C 3 -C 8 cycloalkyl, C 1 -C 4 alkoxy, optionally substituted phenyl, optionally substituted phenoxy, benzyloxy, CF 3, halogen.
在具体的实施方式中，R b选自：C 1-C 6烷基、CF 3、苯基、乙酰基、苯甲酰基、羧基、氨基甲酰基、C 1-C 6烷氧基羰基、氨基；更优选甲基、CF 3或苯基。 In a specific embodiment, R b is selected from the group consisting of: C 1 -C 6 alkyl, CF 3 , phenyl, acetyl, benzoyl, carboxyl, carbamoyl, C 1 -C 6 alkoxycarbonyl, amino More preferred are methyl, CF 3 or phenyl.
在具体的实施方式中，R 3选自：C 1-C 6烷基、苯基、C 1-C 3烷基羰基、任选取代的苯甲酰基、羧基、C 1-C 6烷氧基羰基、酰胺基、任选取代的苯胺甲酰基；优选C 1-C 3烷基羰基，C 1-C 3烷氧基羰基。 In a specific embodiment, R 3 is selected from the group consisting of: C 1 -C 6 alkyl, phenyl, C 1 -C 3 alkylcarbonyl, optionally substituted benzoyl, carboxy, C 1 -C 6 alkoxy A carbonyl group, an amide group, an optionally substituted benzocarbamoyl group; preferably a C 1 -C 3 alkylcarbonyl group, a C 1 -C 3 alkoxycarbonyl group.
在具体的实施方式中，式I所示化合物选自化合物1-100。In a specific embodiment, the compound of formula I is selected from the group consisting of compounds 1-100.
在具体的实施方式中，式I所示化合物具有式Ib所示结构：In a specific embodiment, the compound of Formula I has the structure of Formula Ib:
Figure PCTCN2018083596-appb-000005
Figure PCTCN2018083596-appb-000005
式中，In the formula,
R 4选自：H、卤素、C 1-C 6烷基或C 1-C 6卤代烷基、或C 1-C 6烷氧基或C 1-C 6卤代烷氧基； R 4 is selected from the group consisting of: H, halogen, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, or C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy;
m＝0～3的整数；An integer of m=0 to 3;
R、R 1、R 2、R 3、R 5如上文所述。 R, R 1 , R 2 , R 3 , R 5 are as described above.
在具体的实施方式中，式I所示化合物具有式Ic所示结构：In a specific embodiment, the compound of Formula I has the structure of Formula Ic:
Figure PCTCN2018083596-appb-000006
Figure PCTCN2018083596-appb-000006
R 1选自H、F、Cl、Br、C 1-C 3烷基或C 1-C 3卤代烷基； R 1 is selected from H, F, Cl, Br, C 1 -C 3 alkyl or C 1 -C 3 haloalkyl;
R 2选自H、C 1-C 6烷基或C 1-C 6卤代烷基、C 1-C 6烷氧基或C 1-C 6卤代烷氧基、或羟基C 1-C 3烷基或羟基C 1-C 3卤代烷基； R 2 is selected from H, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy, or hydroxy C 1 -C 3 alkyl or a hydroxy C 1 -C 3 haloalkyl group;
R 3自H、C 1-C 3烷基或C 1-3卤代烷基； R 3 is from H, C 1 -C 3 alkyl or C 1-3 haloalkyl;
R 4选自H、F、Cl、Br、C 1-C 3烷基或C 1-C 3卤代烷基、C 1-C 3烷氧基或C 1-C 3卤代烷氧基； R 4 is selected from H, F, Cl, Br, C 1 -C 3 alkyl or C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy or C 1 -C 3 haloalkoxy;
R 5选自H、F、Cl、Br、OH、NH 2、OCH 3。 R 5 is selected from the group consisting of H, F, Cl, Br, OH, NH 2 , OCH 3 .
在具体的实施方式中，In a specific embodiment,
R 1选自H、C 1-C 3烷基； R 1 is selected from the group consisting of H, C 1 -C 3 alkyl;
R 2选自C 1-C 3烷基； R 2 is selected from C 1 -C 3 alkyl;
R 3选自H、C 1-C 3烷基 R 3 is selected from H, C 1 -C 3 alkyl
R 4选自H或Cl； R 4 is selected from H or Cl;
R 5选自H。 R 5 is selected from H.
在具体的实施方式中，式I所示化合物选自下组化合物：In a specific embodiment, the compound of Formula I is selected from the group consisting of:
Figure PCTCN2018083596-appb-000007
Figure PCTCN2018083596-appb-000007
Figure PCTCN2018083596-appb-000008
Figure PCTCN2018083596-appb-000008
Figure PCTCN2018083596-appb-000009
Figure PCTCN2018083596-appb-000009
在具体的实施方式中，式I所示化合物选自下组化合物：In a specific embodiment, the compound of Formula I is selected from the group consisting of:
Figure PCTCN2018083596-appb-000010
Figure PCTCN2018083596-appb-000010
在第二方面，本发明提供一种非淋巴细胞性白血病的治疗方法，包括将治疗有效量的本发明第一方面所述的化合物给予需要治疗白血病的患者。In a second aspect, the invention provides a method of treating non-lymphocytic leukemia comprising administering a therapeutically effective amount of a compound of the first aspect of the invention to a patient in need of treatment for leukemia.
在优选的实施方式中，所述白血病包括但不限于：急性淋巴细胞白血病(ALL)、急性髓细胞白血病(AML)、慢性粒细胞白血病、慢性淋巴细胞白血病等；优选非淋巴细胞性白血病，包括但不限于：急性髓细胞性白血病、慢性粒细胞性白血病；更优选急性髓细胞性白血病。In a preferred embodiment, the leukemia includes, but is not limited to, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia, chronic lymphocytic leukemia, and the like; preferably non-lymphocytic leukemia, including However, it is not limited to: acute myeloid leukemia, chronic myeloid leukemia; more preferably acute myeloid leukemia.
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。限于篇幅，在此不再一一累述。It is to be understood that within the scope of the present invention, the various technical features of the present invention and the various technical features specifically described hereinafter (as in the embodiments) may be combined with each other to constitute a new or preferred technical solution. Due to space limitations, we will not repeat them here.
具体实施方式detailed description
发明人经过广泛而深入的研究，出乎意料地发现一系列噻唑衍生物，这些噻唑衍生物具备优异的抑制非淋巴细胞性白血病细胞系的活性，从而能够用于治疗非淋巴细胞性白血病的药物的开发。在此基础上完成了本发明。After extensive and intensive research, the inventors have unexpectedly discovered a series of thiazole derivatives which have excellent activity in inhibiting non-lymphocytic leukemia cell lines and can be used for the treatment of non-lymphocytic leukemia. Development. The present invention has been completed on this basis.
白血病leukemia
本文所述的“白血病”具有本领域技术人员通常理解的含义，包括急性淋巴细胞白血病(ALL)、急性髓细胞白血病(AML，以往称为急性非淋巴细胞白血病)、慢性粒细胞白血病、慢性淋巴细胞白血病等。"Leukemia" as used herein has the meaning commonly understood by those skilled in the art, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML, formerly known as acute non-lymphocytic leukemia), chronic myeloid leukemia, chronic lymphoid. Cellular leukemia, etc.
根据增生细胞的类型，白血病也可分类为粒细胞性、淋巴细胞性和单核细胞性三类。在具体的实施方式中，本文所述的白血病是非淋巴细胞性白血病，即，排除淋巴细胞性白血病以外的白血病。在优选的实施方式中，本文所述的非淋巴细胞性白血病是指急性髓细胞性白血病、慢性粒细胞性白血病；更优选急性髓细胞性白血病。According to the type of proliferating cells, leukemia can also be classified into three types: granulocyte, lymphocyte and monocyte. In a specific embodiment, the leukemia described herein is a non-lymphocytic leukemia, ie, leukemia other than lymphocytic leukemia is excluded. In a preferred embodiment, the non-lymphocytic leukemia described herein refers to acute myeloid leukemia, chronic myeloid leukemia; more preferably acute myeloid leukemia.
术语定义Definition of Terms
本文中涉及的基团具有本领域技术人员常规理解的含义；为清晰起见，对其中的一些基团定义如下：The groups referred to herein have the meanings conventionally understood by those skilled in the art; for clarity, some of the groups are defined as follows:
在本文中，“烷基”指碳链长度为1-10个碳原子的饱和的支链或直链烷基，优选的烷基 包括长2-8个碳原子、1-6个、1-4个碳原子、1-3个碳原子不等的烷基。烷基的例子包括但不限于甲基、乙基、正丙基、异丙基、正丁基、异丁基、庚基等。烷基可以被1个或多个取代基取代，例如被卤素或卤代烷基取代。例如，烷基可以是被1-4个氟原子取代的烷基，或者烷基可以是被氟代烷基取代的烷基。As used herein, "alkyl" refers to a saturated branched or straight-chain alkyl group having a carbon chain length of from 1 to 10 carbon atoms, and preferred alkyl groups include from 2 to 8 carbon atoms, from 1 to 6, and from 1 to An alkyl group having 4 carbon atoms and 1-3 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, heptyl, and the like. The alkyl group may be substituted by one or more substituents, for example by halogen or haloalkyl. For example, the alkyl group may be an alkyl group substituted with 1 to 4 fluorine atoms, or the alkyl group may be an alkyl group substituted with a fluoroalkyl group.
在本文中，“烷氧基”指被烷基取代的氧基。优选的烷氧基是长1-6个碳原子的烷氧基，更优选为长1-4个碳原子的烷氧基。烷氧基的例子包括但不限于甲氧基、乙氧基、丙氧基等。在具体的实施方式中，烷氧基可以是取代的烷氧基，例如，卤素取代的烷氧基。在具体的实施方式中，优选卤素取代的C1-C3烷氧基。As used herein, "alkoxy" refers to an oxy group substituted with an alkyl group. Preferred alkoxy groups are alkoxy groups having from 1 to 6 carbon atoms, more preferably alkoxy groups having from 1 to 4 carbon atoms. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, and the like. In a particular embodiment, the alkoxy group can be a substituted alkoxy group, for example, a halogen substituted alkoxy group. In a specific embodiment, a halogen-substituted C1-C3 alkoxy group is preferred.
在本文中，“卤素”指氟、氯、溴和碘。在优选的实施方式中，卤素是氯或氟；更优选氯。As used herein, "halogen" refers to fluoro, chloro, bromo and iodo. In a preferred embodiment, the halogen is chlorine or fluorine; more preferably chlorine.
在本文中，“氨基”指结构式为“NR xR y”的基团，其中，R x和R y可独立选自H或C 1-C 3烷基或C 1-C 3卤代烷基。在具体的实施方式中，本文所述的“氨基”是指NH 2。 As used herein, "amino" refers to a group of the formula "NR x R y ", wherein R x and R y may be independently selected from H or C 1 -C 3 alkyl or C 1 -C 3 haloalkyl. In specific embodiments herein described in the "amino" refers to NH 2.
在本文中，“羰基”是指RC(O)-所示的基团，其中R可以是低级烷基或低级烷氧基，例如C 1-C 6或C 1-C 3烷基或C 1-C 6或C 1-C 3烷氧基；本领域技术人员还知晓，当RC(O)-所示羰基中的R为烷氧基时，RC(O)-所示基团为酯基；例如当R为乙氧基时，RC(O)-为乙酯基。 As used herein, "carbonyl" refers to a group represented by RC(O)-, wherein R may be lower alkyl or lower alkoxy, such as C 1 -C 6 or C 1 -C 3 alkyl or C 1 -C 6 or C 1 -C 3 alkoxy; it is also known to those skilled in the art that when R in the carbonyl group represented by RC(O)- is an alkoxy group, the group represented by RC(O)- is an ester group. For example, when R is an ethoxy group, RC(O)- is an ethyl ester group.
本发明的优点：Advantages of the invention:
本发明发现了一系列噻唑衍生物具备优异的抑制非淋巴细胞性白血病细胞系的活性，这些噻唑衍生物对于非淋巴细胞性白血病细胞系的抑制作用甚至优于阳性对照药物，从而为治疗非淋巴细胞性白血病的药物的开发奠定了新的物质基础。The present inventors have found that a series of thiazole derivatives have excellent activity in inhibiting non-lymphocytic leukemia cell lines, and these thiazole derivatives have even better inhibitory effects on non-lymphocytic leukemia cell lines than positive control drugs, thereby treating non-lymphatic drugs. The development of drugs for cellular leukemia has laid a new material foundation.
以下结合具体实施案例对本发明的技术方案进一步描述，但以下实施案例不构成对本发明的限制，所有依据本发明的原理和技术手段采用的各种施用方法，均属于本发明范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件，或按照制造厂商所建议的条件。除非另外说明，否则百分比和份数按重量计算。The technical solutions of the present invention are further described below in conjunction with the specific embodiments, but the following embodiments are not intended to limit the present invention, and all the application methods according to the principles and technical means of the present invention are within the scope of the present invention. The experimental methods in the following examples which do not specify the specific conditions are usually in accordance with conventional conditions or according to the conditions recommended by the manufacturer. Percentages and parts are by weight unless otherwise stated.
合成部分Synthetic part
实施例1：化合物1-12的合成通法：Example 1: Synthesis of Compounds 1-12:
Figure PCTCN2018083596-appb-000011
Figure PCTCN2018083596-appb-000011
将氯代乙酰乙酸乙酯(9.52g，57.84mmol)溶解在100mL乙醇中，搅拌条件下加入硫代乙酰胺(4.8g，63.9mmol)，升温至回流温度，搅拌回流2h，待反应结束，将反应液减压除溶剂,得桔粉色固体9.80g，收率91.1％，直接用于下一步反应。Ethyl chloroacetate (9.52 g, 57.84 mmol) was dissolved in 100 mL of ethanol, and thioacetamide (4.8 g, 63.9 mmol) was added under stirring, the temperature was raised to reflux temperature, and the mixture was stirred under reflux for 2 h. The reaction solution was evaporated under reduced pressure to give EtOAc.
称取LiOH.H 2O(1.25g，29.7mmol)溶解在50mL水中，搅拌条件下加上一步反应合成的酯(2.5g，13.5mmol)，升温至90℃，随着反应进行，固体逐渐溶解，1h后停止反应，用稀盐酸调节反应液pH至中性偏酸性，有大量固体析出，抽滤，滤饼用水洗后，干燥，得淡 黄色固体2.05g，收率96.6％。 LiOH.H 2 O (1.25 g, 29.7 mmol) was weighed and dissolved in 50 mL of water, and the ester (2.5 g, 13.5 mmol) synthesized in one step was added under stirring, and the temperature was raised to 90 ° C. The solid gradually dissolved as the reaction proceeded. After 1 h, the reaction was stopped, the pH of the reaction solution was adjusted to neutral neutral acidity with dilute hydrochloric acid, a large amount of solid was precipitated, suction filtration, and the filter cake was washed with water and dried to give a pale yellow solid (2.05 g, yield 96.6%).
Figure PCTCN2018083596-appb-000012
Figure PCTCN2018083596-appb-000012
称取噻唑酸(1.1eq)和HATU(1.2eq)溶解于7mL DMF中，搅拌均匀后，滴加8滴DIPEA，搅拌5min后，再加入芳胺类化合物(1eq)，室温条件下搅拌过夜，TLC跟踪反应。The thiazole acid (1.1 eq) and HATU (1.2 eq) were weighed and dissolved in 7 mL of DMF. After stirring, 8 drops of DIPEA were added dropwise. After stirring for 5 min, an aromatic amine compound (1 eq) was added, and the mixture was stirred at room temperature overnight. TLC tracks the reaction.
后处理方法一:于反应液中滴加饱和氯化铵溶液，溶液逐渐变混浊出现大量固体，滴加饱和氯化铵溶液至不再出现固体，抽滤反应液，滤饼先用饱和氯化铵水溶液洗，再用饱和碳酸氢钠水溶液洗，干燥滤饼，即得目标化合物1-9，12。Post-treatment method 1: Add saturated ammonium chloride solution to the reaction solution, the solution gradually becomes turbid and a large amount of solid appears. Add saturated ammonium chloride solution until no more solids appear. Filter the reaction solution. The filter cake is first saturated with chlorination. The ammonium aqueous solution is washed, washed with a saturated aqueous solution of sodium hydrogencarbonate, and the cake is dried to give the object compound 1-9, 12.
后处理方法二:于反应液中滴加饱和氯化铵溶液，溶液逐渐变混浊出现大量固体，滴加饱和氯化铵溶液至不再出现固体，抽滤反应液，滤饼先用饱和氯化铵水溶液洗，再用饱和碳酸氢钠水溶液洗，干燥滤饼，干燥后得到的粗品再用硅胶柱层析分离，得到化合物10。Post-treatment method 2: Saturate ammonium chloride solution is added dropwise to the reaction solution, and the solution gradually becomes turbid and a large amount of solid appears. The saturated ammonium chloride solution is added dropwise until solids no longer appear. The reaction solution is filtered, and the filter cake is first saturated with chlorination. The ammonium aqueous solution was washed with a saturated aqueous solution of sodium hydrogencarbonate, and the cake was dried.
后处理方法三:减压除去反应液的大量溶剂，用乙酸乙酯/饱和氯化铵对其进行萃取，收集得到的有机相用无水硫酸钠干燥后减压除溶剂，得到的固体再进一步硅胶柱层析纯化，得到化合物11。Post-treatment method 3: a large amount of the solvent of the reaction liquid is removed under reduced pressure, and the mixture is extracted with ethyl acetate / saturated ammonium chloride. The obtained organic phase is dried over anhydrous sodium sulfate and then evaporated. Purification by silica gel column chromatography gave Compound 11.
目标化合物谱图数据Target compound spectrum data
N-(4-氯苯基)-2，4-二甲基噻唑-5-甲酰胺(化合物1)N-(4-chlorophenyl)-2,4-dimethylthiazole-5-carboxamide (Compound 1)
Figure PCTCN2018083596-appb-000013
Figure PCTCN2018083596-appb-000013
1H NMR(400MHz,CDCl 3):δ10.24(s,1H),7.70(d,J＝8.8Hz,2H),7.40(d,J＝8.8Hz,2H),2.66(s,3H),2.54(s,3H). 13C NMR(100MHz,CDCl 3):δ166.52,160.16,156.11,136.05,129.88,129.04,125.16,121.77,19.34,17.24.HRMS(ESI)calcd for C 12H 11ClN 2OS[M+H] +267.0359,found 267.0355。 1 H NMR (400MHz, CDCl 3 ): δ10.24 (s, 1H), 7.70 (d, J = 8.8Hz, 2H), 7.40 (d, J = 8.8Hz, 2H), 2.66 (s, 3H), 2.54(s,3H). 13 C NMR (100MHz, CDCl 3 ): δ166.52,160.16,156.11,136.05,129.88,129.04,125.16,121.77,19.34,17.24.HRMS(ESI)calcd for C 12 H 11 ClN 2 OS [M+H] + 267.0359, found 267.0355.
N-[4-(三氟甲基)苯基]-2，4-二甲基-噻唑-5-甲酰胺(化合物2)N-[4-(Trifluoromethyl)phenyl]-2,4-dimethyl-thiazole-5-carboxamide (Compound 2)
Figure PCTCN2018083596-appb-000014
Figure PCTCN2018083596-appb-000014
1H NMR(400MHz,CDCl 3):δ7.69(d,J＝8.4Hz,2H),7.62(d,J＝8.8Hz,2H),7.51(s,1H),2.73(s,3H),2.72(s,3H). 13C NMR(100MHz,CDCl 3):δ166.91,160.25,156.50,140.58,126.30,126.26,126.22,124.97,119.97,19.28,17.22.HRMS(ESI)calcd for C 13H 11F 3N 2OS[M-H] +299.0466,found 299.0464。 1 H NMR (400MHz, CDCl 3 ): δ7.69 (d, J = 8.4Hz, 2H), 7.62 (d, J = 8.8Hz, 2H), 7.51 (s, 1H), 2.73 (s, 3H), 2.72(s,3H). 13 C NMR (100MHz, CDCl 3 ): δ166.91,160.25,156.50,140.58,126.30,126.26,126.22,124.97,119.97,19.28,17.22.HRMS(ESI)calcd for C 13 H 11 F 3 N 2 OS[MH] + 299.0466, found 299.0464.
N-(3-氟-4-甲基苯基)-2，4-二甲基噻唑-5-甲酰胺(化合物3)N-(3-Fluoro-4-methylphenyl)-2,4-dimethylthiazole-5-carboxamide (Compound 3)
Figure PCTCN2018083596-appb-000015
Figure PCTCN2018083596-appb-000015
1H NMR(400MHz,CDCl 3):δ7.46(dd,J 1＝2.0Hz,J 2＝11.2Hz,1H),7.41(s,1H),7.15(t, J＝8.0Hz,1H),7.10(dd,J 1＝2.0Hz,J 2＝8.4Hz,1H),2.72(s,6H),2.26(d,J＝1.6Hz,3H). 13C NMR(100MHz,CDCl 3):δ166.43,162.25,160.09,159.83,155.99,136.54,136.43,131.40,131.33,125.25,121.26,121.08,115.62,115.59,107.93,107.66,19.31,17.20,14.13,14.10.HRMS(ESI)calcd for:C 13H 13FN 2OS[M+H] +265.0811,found 265.0805。 1 H NMR (400MHz, CDCl 3 ): δ7.46 (dd, J 1 = 2.0Hz, J 2 = 11.2Hz, 1H), 7.41 (s, 1H), 7.15 (t, J = 8.0Hz, 1H), 7.10 (dd, J 1 = 2.0 Hz, J 2 = 8.4 Hz, 1H), 2.72 (s, 6H), 2.26 (d, J = 1.6 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 166. 43,162.25,160.09,159.83,155.99,136.54,136.43,131.40,131.33,125.25,121.26,121.08,115.62,115.59,107.93,107.66,19.31,17.20,14.13,14.10.HRMS(ESI)calcd for:C 13 H 13 FN 2 OS[M+H] + 265.0811, found 265.0805.
N-(4-溴-2-甲基苯基)-2,4-二甲基噻唑-5-甲酰胺(化合物4)N-(4-bromo-2-methylphenyl)-2,4-dimethylthiazole-5-carboxamide (Compound 4)
Figure PCTCN2018083596-appb-000016
Figure PCTCN2018083596-appb-000016
1H NMR(400MHz,CDCl 3):δ7.80(d,J＝9.2Hz,1H),7.37-7.35(m,2H),7.21(s,1H),2.73(s,3H),2.71(s,3H),2.28(s,3H). 13C NMR(100MHz,CDCl 3):δ166.56,159.90,156.01,134.5133.28,131.12,129.88,125.44,124.47,118.40,19.45,17.68,17.41.HRMS(ESI)calcd for:C 13H 13BrN 2OS[M+H] +325.0010,found 325.0009。 1 H NMR (400MHz, CDCl 3 ): δ7.80 (d, J = 9.2Hz, 1H), 7.37-7.35 (m, 2H), 7.21 (s, 1H), 2.73 (s, 3H), 2.71 (s , 3H), 2.28 (s, 3H). 13 C NMR (100MHz, CDCl 3 ): δ 166.56, 159.90, 156.01, 134.5133.28, 131.12, 129.88, 125.44, 124.47, 118.40, 19.45, 17.68, 17.41.HRMS(ESI)calcd For: C 13 H 13 BrN 2 OS [M+H] + 325.0010, found 325.0009.
N-(9-乙基-9H-咔唑-3-基)-2,4-二甲基噻唑-5-甲酰胺(化合物5)N-(9-ethyl-9H-carbazol-3-yl)-2,4-dimethylthiazole-5-carboxamide (Compound 5)
Figure PCTCN2018083596-appb-000017
Figure PCTCN2018083596-appb-000017
1H NMR(400MHz,CDCl 3):δ8.36(s,1H),8.10(d,J＝7.6Hz,1H),7.57-7.55(m,2H),7.52-7.49(m,1H),7.44-7.39(m,2H),7.25(t,J＝7.2Hz,1H),4.41-4.36(m,2H),2.78(s,3H),2.74(s,3H),1.45(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ166.02,160.33,155.50,140.45,137.52,129.10,125.98,123.03,122.70,120.69,120.07,118.87,113.59,108.61,108.52,37.59,19.35,17.32,13.82.HRMS(ESI)calcd for:C 20H 19N 3OS[M+H] +350.1327,found 350.1332。 1 H NMR (400MHz, CDCl 3 ): δ8.36 (s, 1H), 8.10 (d, J = 7.6Hz, 1H), 7.57-7.55 (m, 2H), 7.52-7.49 (m, 1H), 7.44 -7.39 (m, 2H), 7.25 (t, J = 7.2 Hz, 1H), 4.41-4.36 (m, 2H), 2.78 (s, 3H), 2.74 (s, 3H), 1.45 (t, J = 7.2) Hz,3H). 13 C NMR (100MHz, CDCl 3 ): δ166.02,160.33,155.50,140.45,137.52,129.10,125.98,123.03,122.70,120.69,120.07,118.87,113.59,108.61,108.52,37.59,19.35,17.32 , 13.82. HRMS (ESI) calcd for: C 20 H 19 N 3 OS [M+H] + 350.1327, found 350.1332.
N-(蒽-2-基)-2,4-二甲基噻唑-5-甲酰胺(化合物6)N-(indol-2-yl)-2,4-dimethylthiazole-5-carboxamide (compound 6)
Figure PCTCN2018083596-appb-000018
Figure PCTCN2018083596-appb-000018
1H NMR(400MHz,DMSO-d 6):δ8.52(s,2H),8.48(s,1H),8.08-8.04(m,3H),7.70(dd,J 1＝1.6Hz,J 2＝9.2Hz,1H),7.50-7.47(m,2H),2.68(s,3H),2.59(s,3H). 13C NMR(100MHz,DMSO-d 6):δ166.37,160.84,155.11,136.26,132.16,131.90,131.09,129.20,129.15,128.55,128.23,126.34,126.14,126.09,125.74,125.58,122.13,116.04,19.35,17.42.HRMS(ESI)calcd for:C 20H 16N 2OS[M-H] +331.0905,found 331.0907。 1 H NMR (400MHz, DMSO- d 6): δ8.52 (s, 2H), 8.48 (s, 1H), 8.08-8.04 (m, 3H), 7.70 (dd, J 1 = 1.6Hz, J 2 = 9.2 Hz, 1H), 7.50-7.47 (m, 2H), 2.68 (s, 3H), 2.59 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6 ): δ 166.37, 160.84, 155.11, 136.26, 132.16 , 131.90, 131.09, 129.20, 129.15, 128.55, 128.23, 126.34, 126.14, 126.09, 125.74, 125.58, 122.13, 116.04, 19.35, 17.42. HRMS (ESI) calcd for: C 20 H 16 N 2 OS[MH] + 331.0905 , found 331.0907.
N-(4-溴-3-(三氟甲基)苯基)-2,4-二甲基噻唑-5-甲酰胺(化合物7)N-(4-bromo-3-(trifluoromethyl)phenyl)-2,4-dimethylthiazole-5-carboxamide (compound 7)
Figure PCTCN2018083596-appb-000019
Figure PCTCN2018083596-appb-000019
1H NMR(400MHz,CDCl 3):δ8.76(d,J＝4.4Hz,1H),8.47(d,J＝8.4Hz,1H),7.50-7.47(m,1H),2.82(s,3H),2.80(s,3H). 13C NMR(100MHz,CDCl 3):δ166.88,160.13,157.10,136.91,135.53,130.84,130.53,124.45,124.36,123.89,121.17,119.65,119.60,119.54,119.48,114.59,19.44,17.37.HRMS(ESI)calcd for:C 13H 10BrF 3N 2OS[M-H] +376.9571,found 376.9572。 1 H NMR (400MHz, CDCl 3 ): δ8.76 (d, J = 4.4Hz, 1H), 8.47 (d, J = 8.4Hz, 1H), 7.50-7.47 (m, 1H), 2.82 (s, 3H ), 2.80 (s, 3H). 13 C NMR (100MHz, CDCl 3 ): δ 166.88, 160.13, 157.10, 136.91, 135.53, 130.84, 130.53, 124.45, 124.36, 123.89, 121.17, 119.65, 119.60, 119.54, 119.48, 114.59 , 19.44, 17.37. HRMS (ESI) calcd for: C 13 H 10 BrF 3 N 2 OS [MH] + 376.9571, found 376.9572.
N-(3,5-二氯苯基)-2,4-二甲基噻唑-5-甲酰胺(化合物8)N-(3,5-dichlorophenyl)-2,4-dimethylthiazole-5-carboxamide (compound 8)
Figure PCTCN2018083596-appb-000020
Figure PCTCN2018083596-appb-000020
1H NMR(400MHz,CDCl 3):δ8.77(dd,J 1＝1.2Hz,J 2＝4.4Hz,1H),8.48(dd,J 1＝1.2Hz,J 2＝8.0Hz,1H),7.51-7.48(m,1H),2.83(s,3H),2.81(s,3H)。HRMS(ESI)calcd for:C 12H 10C l2N 2OS[M-H] +298.9813，found 298.9806。 1 H NMR (400 MHz, CDCl 3 ): δ 8.77 (dd, J 1 = 1.2 Hz, J 2 = 4.4 Hz, 1H), 8.48 (dd, J 1 = 1.2 Hz, J 2 = 8.0 Hz, 1H), 7.51-7.48 (m, 1H), 2.83 (s, 3H), 2.81 (s, 3H). HRMS (ESI) calcd for: C 12 H 10 C l 2 N 2 OS [MH] + 298.9813, found 298.9806.
2,4-二甲基-N-(4-吗啉苯基)噻唑-5-甲酰胺(化合物9)2,4-Dimethyl-N-(4-morpholinylphenyl)thiazole-5-carboxamide (Compound 9)
Figure PCTCN2018083596-appb-000021
Figure PCTCN2018083596-appb-000021
1H NMR(400MHz CDCl 3):δ9.86(s 1H)7.50(d J＝8.4Hz 2H)6.92(d J＝8.8Hz 2H)3.73(t,J＝4.4Hz,4H),3.06(t,J＝4.4Hz,4H),2.65(s,3H),2.52(s,3H). 13C NMR(100MHz,CDCl 3):δ166.02,160.33,155.50,140.45,137.52,129.10,125.98,123.03,122.70,120.69,120.07,118.87,113.59,108.61,108.52,37.59,19.35,17.32,13.82.HRMS(ESI)calcd for:C 16H 19N 3O 2S[M+H] +318.1276,found 318.1276。 1 H NMR (400 MHz CDCl 3 ): δ 9.86 (s 1H) 7.50 (d J = 8.4 Hz 2H) 6.92 (d J = 8.8 Hz 2H) 3.73 (t, J = 4.4 Hz, 4H), 3.06 (t, J = 4.4 Hz, 4H), 2.65 (s, 3H), 2.52 (s, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 166.02, 160.33, 155.50, 140.45, 137.52, 129.10, 125.98, 123.03, 122.70, 120.69, 120.07, 118.87, 113.59, 108.61, 108.52, 37.59, 19.35, 17.32, 13.82. HRMS (ESI) calcd for: C 16 H 19 N 3 O 2 S [M+H] + 318.1276, found 318.1276.
2,4-二甲基-N–(萘-2-基)噻唑-5-甲酰胺(化合物10)2,4-Dimethyl-N-(naphthalen-2-yl)thiazole-5-carboxamide (Compound 10)
Figure PCTCN2018083596-appb-000022
Figure PCTCN2018083596-appb-000022
1H NMR(400MHz,CDCl 3):δ8.26(s,1H),7.86-7.82(m,3H),7.64(s,1H),7.57–7.42(m,3H),2.78(s,3H),2.74(s,3H). 13C NMR(100MHz,CDCl 3):δ166.39,160.06,156.08,134.86,133.79,130.90,128.95,127.73,127.62,126.70,125.35,120.01,117.24,19.44,17.34.HRMS(ESI)calcd for:C 16H 14N 2OS[M+H] +283.0905,found 283.0900。 1 H NMR (400MHz, CDCl 3 ): δ8.26 (s, 1H), 7.86-7.82 (m, 3H), 7.64 (s, 1H), 7.57-7.42 (m, 3H), 2.78 (s, 3H) , 2.74 (s, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 166.39, 160.06, 156.08, 134.86, 133.79, 130.90, 128.95, 127.73, 127.62, 126.70, 125.35, 120.01, 117.24, 19.44, 17.34. HRMS ( ESI)calcd for: C 16 H 14 N 2 OS [M+H] + 283.0905, found 283.0900.
2,4-二甲基-N-苯基噻唑-5-甲酰胺(化合物11)2,4-Dimethyl-N-phenylthiazole-5-carboxamide (Compound 11)
Figure PCTCN2018083596-appb-000023
Figure PCTCN2018083596-appb-000023
1H NMR(400MHz,CDCl 3):δ7.57(d,J＝7.6Hz,2H),7.43(s,1H),7.39(t,J＝7.6Hz,2H),7.18(t,J＝7.2Hz,1H),2.75(s,3H),2.74(s,3H). 13C NMR(100MHz,CDCl 3):δ166.27,160.23,155.67,137.50,129.03,125.60,124.86,120.55,19.31,17.20.HRMS(ESI)calcd for:C 12H 12N 2OS[M+H] +233.0749,found 233.0745。 1 H NMR (400MHz, CDCl 3 ): δ7.57 (d, J = 7.6Hz, 2H), 7.43 (s, 1H), 7.39 (t, J = 7.6Hz, 2H), 7.18 (t, J = 7.2 Hz, 1H), 2.75 (s, 3H), 2.74 (s, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 166.27, 160.23, 155.67, 137.50, 129.03, 125.60, 124.86, 120.55, 19.31, 17.20. (ESI) calcd for: C 12 H 12 N 2 OS [M+H] + 233.0749, found 233.0745.
N-(二苯并(b,d)噻吩-2-基)-2,4-二甲基噻唑-5-甲酰胺(化合物12)N-(dibenzo(b,d)thiophen-2-yl)-2,4-dimethylthiazole-5-carboxamide (Compound 12)
Figure PCTCN2018083596-appb-000024
Figure PCTCN2018083596-appb-000024
HRMS(ESI)calcd for:C 18H 14N 2OS 2[M+H] +339.0626,found 339.0620。 HRMS (ESI) calcd for: C 18 H 14 N 2 OS 2 [M+H] + 339.0626, found 339.0620.
实施例2：化合物13-18的合成通法：Example 2: Synthesis of Compound 13-18:
Figure PCTCN2018083596-appb-000025
Figure PCTCN2018083596-appb-000025
将甲酰胺(1eq)溶解于20mL甲苯中，搅拌条件下加入称量好得劳森试剂(0.25eq)，升温至100℃至劳森试剂全部溶解，TLC跟踪反应，待硫代反应结束，滴加氯代乙酰乙酸乙酯(0.6eq)，继续反应，TLC跟踪，反应结束后，减压除去大量甲苯溶剂，再用乙酸乙酯萃取，有机相用饱和食盐水洗，收集得到的有机相用无水硫酸钠干燥后减压除溶剂，得到黄色粗品，用硅胶柱层析进一步纯化(PE:EA＝8:1)。The formamide (1 eq) was dissolved in 20 mL of toluene, and the Lawson reagent (0.25 eq) was weighed under stirring, and the temperature was raised to 100 ° C until the Lawson reagent was completely dissolved. The TLC followed the reaction until the end of the thio reaction. Ethyl chloroacetate (0.6 eq) was added, and the reaction was continued. TLC was followed. After completion of the reaction, a large amount of toluene solvent was removed under reduced pressure, and then extracted with ethyl acetate. The organic phase was washed with saturated brine, and the obtained organic phase was collected. The organic layer was dried (MgSO4).
称取LiOH.H 2O(1.25g，29.7mmol)溶解在50mL水中，搅拌条件下加上一步反应合成的酯(2.5g，13.5mmol)，升温至90℃，随着反应进行，固体逐渐溶解，1h后停止反应，用稀盐酸调节反应液pH至中性偏酸性，有大量固体析出，抽滤，滤饼用水洗后，干燥，得淡黄色固体。 LiOH.H 2 O (1.25 g, 29.7 mmol) was weighed and dissolved in 50 mL of water, and the ester (2.5 g, 13.5 mmol) synthesized in one step was added under stirring, and the temperature was raised to 90 ° C. The solid gradually dissolved as the reaction proceeded. After 1 h, the reaction was stopped, and the pH of the reaction solution was adjusted to neutral neutrality with dilute hydrochloric acid. A large amount of solid was precipitated, suction filtered, and the filter cake was washed with water and dried to give a pale yellow solid.
Figure PCTCN2018083596-appb-000026
Figure PCTCN2018083596-appb-000026
合成方法采用实例1流程类似的方法制备得到化合物13-18。其中化合物13-15，18采用后处理方一，化合物16采用后处理方法二，化合物17采用后处理方法三。Synthetic Method Compound 13-18 was prepared in a similar manner to the procedure of Example 1. Among them, compounds 13-15, 18 are treated with post-treatment one, compound 16 is treated with post-treatment method 2, and compound 17 is treated with post-treatment method three.
目标化合物谱图数据Target compound spectrum data
N-(4-氯苯基)-4-甲基噻唑-5-甲酰胺(化合物13)N-(4-chlorophenyl)-4-methylthiazole-5-carboxamide (Compound 13)
Figure PCTCN2018083596-appb-000027
Figure PCTCN2018083596-appb-000027
1H NMR(400MHz,CDCl 3):δ8.81(s,1H),7.55(d,J＝8.8Hz,2H),7.52(s,1H),7.36(d,J＝8.8Hz,2H),2.83(s,3H). 13C NMR(100MHz,CDCl 3):δ159.93,156.74,152.86,135.85,130.16,129.20,121.73,17.33.HRMS(ESI)calcd for:C 11H 9ClN 2OS[M+H] +253.0202,found 253.0206。 1 H NMR (400MHz, CDCl 3 ): δ8.81 (s, 1H), 7.55 (d, J = 8.8Hz, 2H), 7.52 (s, 1H), 7.36 (d, J = 8.8Hz, 2H), 2.83(s,3H). 13 C NMR (100MHz, CDCl 3 ): δ159.93,156.74,152.86,135.85,130.16,129.20,121.73,17.33.HRMS(ESI)calcd for:C 11 H 9 ClN 2 OS[M+ H] + 253.0202, found 253.0206.
N-(9-乙基-9H-咔唑-3-基)-4-甲基噻唑-5-甲酰胺(化合物14)N-(9-ethyl-9H-indazol-3-yl)-4-methylthiazole-5-carboxamide (Compound 14)
Figure PCTCN2018083596-appb-000028
Figure PCTCN2018083596-appb-000028
1H NMR(400MHz,CDCl 3):δ8.70(s,1H),8.33(s,1H),8.05-7.99(m,2H),7.56–7.47(m,2H),7.40(d,J＝8.0Hz,1H),7.31(d,J＝8.4Hz,1H),7.22(t,J＝7.2Hz,1H),4.30(q,J＝7.2Hz,2H),2.81(s,3H),1.40(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ160.21,156.02,152.55,140.46,137.60,128.93,126.04,123.04,122.66,120.69,120.04,118.92,113.65,108.65,108.57,37.61,17.33,13.83.HRMS(ESI)calcd for:C 19H 17N 3OS[M+H] +336.1171,found 336.1176。 1 H NMR (400MHz, CDCl 3 ): δ8.70 (s, 1H), 8.33 (s, 1H), 8.05-7.99 (m, 2H), 7.56-7.47 (m, 2H), 7.40 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 7.22 (t, J = 7.2 Hz, 1H), 4.30 (q, J = 7.2 Hz, 2H), 2.81 (s, 3H), 1.40 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 160.21, 156.02, 152.55, 140.46, 137.60, 128.93, 126.04, 123.04, 122.66, 120.69, 120.04, 118.92, 113.65, 108.65, 108.57 , 37.61, 17.33, 13.83. HRMS (ESI) calcd for: C 19 H 17 N 3 OS [M+H] + 336.1171, found 336.1176.
N-(蒽-2-基)-4-甲基噻唑-5-甲酰胺(化合物15)N-(indol-2-yl)-4-methylthiazole-5-carboxamide (compound 15)
Figure PCTCN2018083596-appb-000029
Figure PCTCN2018083596-appb-000029
1H NMR(400MHz,DMSO-d 6):δ9.17(s,1H),8.53(d,J＝4.4Hz,2H),8.50(s,1H),8.09-8.05(m,3H),7.72(dd,J 1＝2.0Hz,J 2＝10.0Hz,1H),7.51-7.46(m,2H),2.68(s,3H). 13C  NMR(100MHz,DMSO-d 6):δ160.52,155.32,154.47,135.77,131.66,131.39,130.61,128.73128.66,128.05,127.74,126.29,125.86,125.65,125.28,125.10,121.63,115.62,79.23,16.95.HRMS(ESI)calcd for:C 19H 14N 2OS[M-H] +317.0749,found 317.0750。 1 H NMR (400MHz, DMSO- d 6): δ9.17 (s, 1H), 8.53 (d, J = 4.4Hz, 2H), 8.50 (s, 1H), 8.09-8.05 (m, 3H), 7.72 (dd, J 1 =2.0 Hz, J 2 = 10.0 Hz, 1H), 7.51 - 7.46 (m, 2H), 2.68 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6 ): δ 160.52, 155.32, 154.47,135.77,131.66,131.39,130.61,128.73128.66,128.05,127.74,126.29,125.86,125.65,125.28,125.10,121.63,115.62,79.23,16.95.HRMS(ESI)calcd for:C 19 H 14 N 2 OS[MH ] + 317.0749, found 317.0750.
4-甲基-N-(萘-2-基)噻唑-5-甲酰胺(化合物16)4-methyl-N-(naphthalen-2-yl)thiazole-5-carboxamide (Compound 16)
Figure PCTCN2018083596-appb-000030
Figure PCTCN2018083596-appb-000030
1H NMR(400MHz,CDCl 3):δ8.76(s,1H),8.25(s,1H),7.84–7.81(m,4H),7.56–7.44(m,3H),2.83(s,3H). 13C NMR(100MHz,CDCl 3):δ160.04,156.57,152.73,134.73,133.74,130.98,128.99,127.75,127.63,126.74,126.26,125.45,120.05,117.46,17.36.HRMS(ESI)calcd for:C 15H 12N 2OS[M-H] +267.0592,found 267.0590。 1 H NMR (400MHz, CDCl 3 ): δ8.76 (s, 1H), 8.25 (s, 1H), 7.84-7.81 (m, 4H), 7.56-7.44 (m, 3H), 2.83 (s, 3H) 13 C NMR (100 MHz, CDCl 3 ): δ 160.04, 156.57, 152.73, 134.73, 133.74, 130.98, 128.99, 127.75, 127.63, 126.74, 126.26, 125.45, 120.05, 117.46, 17.36. HRMS (ESI) calcd for: C 15 H 12 N 2 OS [MH] + 267.0592, found 267.0590.
4-甲基-N-苯基噻唑-5-甲酰胺(化合物17)4-methyl-N-phenylthiazole-5-carboxamide (Compound 17)
Figure PCTCN2018083596-appb-000031
Figure PCTCN2018083596-appb-000031
1H NMR(400MHz,CDCl 3):δ8.79(s,1H),7.59(d,J＝7.6Hz,2H),7.53(s,1H),7.40(t,J＝7.6Hz,2H),7.21(t,J＝7.6Hz,1H),2.83(s,3H). 13C NMR(100MHz,CDCl 3):δ159.99,156.31,152.76,137.28,129.17,126.34,125.12,120.52,17.27.HRMS(ESI)calcd for:C 11H 10N 2OS[M-H] +217.0436,found 217.0435。 1 H NMR (400MHz, CDCl 3 ): δ8.79 (s, 1H), 7.59 (d, J = 7.6Hz, 2H), 7.53 (s, 1H), 7.40 (t, J = 7.6Hz, 2H), 7.21 (t, J = 7.6 Hz, 1H), 2.83 (s, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 159.99, 156.31, 152.76, 137.28, 129.17, 126.34, 125.12, 120.52, 17.27. HRMS (ESI) Calcd for: C 11 H 10 N 2 OS [MH] + 217.0436, found 217.0435.
N-(二苯并(b,d)噻吩-2-基)-2-甲基噻唑-5-甲酰胺(化合物18)N-(dibenzo(b,d)thiophen-2-yl)-2-methylthiazole-5-carboxamide (Compound 18)
Figure PCTCN2018083596-appb-000032
Figure PCTCN2018083596-appb-000032
HRMS(ESI)calcd for:C 17H 12N 2OS 2[M+H] +325.0469,found 325.0468。 HRMS (ESI) calcd for: C 17 H 12 N 2 OS 2 [M+H] + 325.0469, found 325.0468.
实施例3：化合物19-55的合成通法：Example 3: Synthesis of Compound 19-55:
硫脲的合成Synthesis of thiourea
Figure PCTCN2018083596-appb-000033
Figure PCTCN2018083596-appb-000033
将芳胺(8mmol，1eq)溶解于24mL丙酮中，于搅拌条件下加入称好的三乙烯二胺(24mmol，3eq)，再滴加二硫化碳20mL，出现大量固体，继续室温搅拌24h，抽滤反应液，滤饼用石油醚洗，干燥后，将滤饼溶解于50mL氯仿中，称取BTC(2.7mmol，0.33eq)溶解于30mL氯仿中，1h内滴加至反应液中，室温下搅拌该溶液过夜。反应结束后，抽滤反应液，滤饼用二氯甲烷洗，得到的滤液直接加硅胶旋干后干法上样(PE洗脱)。The aromatic amine (8 mmol, 1 eq) was dissolved in 24 mL of acetone, and the weighed triethylenediamine (24 mmol, 3 eq) was added under stirring, and then 20 mL of carbon disulfide was added dropwise. A large amount of solid appeared, and the mixture was stirred at room temperature for 24 h. The solution and the filter cake were washed with petroleum ether. After drying, the cake was dissolved in 50 mL of chloroform, and BTC (2.7 mmol, 0.33 eq) was weighed and dissolved in 30 mL of chloroform, and added dropwise to the reaction solution over 1 h, and stirred at room temperature. The solution was overnight. After completion of the reaction, the reaction mixture was filtered under suction, and the filter cake was washed with dichloromethane, and the obtained filtrate was directly applied to silica gel and dried, and then dried (PE eluted).
将NCS溶解于少量二氯甲烷中，加大大过量的氨水，0℃下搅拌3h，抽滤反应液，滤饼用水洗，干燥滤饼，即得硫脲，直接用于下一步反应。The NCS was dissolved in a small amount of methylene chloride, a large excess of ammonia water was added, and the mixture was stirred at 0 ° C for 3 hours. The reaction mixture was filtered, the filter cake was washed with water, and the filter cake was dried to obtain thiourea, which was directly used for the next reaction.
目标化合物的合成Synthesis of target compound
Figure PCTCN2018083596-appb-000034
Figure PCTCN2018083596-appb-000034
将β-环糊精(590mg，0.52mmol)溶于10mL H 2O中，将该溶液升温至50℃至β-环糊精全部溶解形成一个无色透明的溶液，将相对应的乙酰乙酸乙酯用0.5mL丙酮稀释后滴加至β-环糊***溶液中，搅拌均匀后称取NBS(138.9mg，0.780mmol)加入该混合溶液，搅拌1h后，再加芳香硫脲(0.52mmol)，TLC跟踪反应，待反应进行完全，用乙酸乙酯/饱和食盐水萃取反应液，收集得到的有机相用无水硫酸钠干燥后减压除溶剂，得到的粗品用硅胶柱层析进一步纯化(PE:EA＝10:1)。 The β-cyclodextrin (590 mg, 0.52 mmol) was dissolved in 10 mL of H 2 O, and the solution was warmed to 50 ° C until the β-cyclodextrin was completely dissolved to form a colorless transparent solution, and the corresponding acetoacetate B was added. The ester was diluted with 0.5 mL of acetone and added dropwise to the β-cyclodextrin aqueous solution. After stirring, NBS (138.9 mg, 0.780 mmol) was added to the mixed solution, and after stirring for 1 h, aromatic thiourea (0.52 mmol) was added. The reaction was carried out by TLC, and the reaction was completed. The mixture was extracted with ethyl acetate / brine, and the obtained organic phase was dried over anhydrous sodium sulfate. :EA=10:1).
目标化合物谱图数据Target compound spectrum data
2-苯胺基-4-苯基-5-噻唑甲酸乙酯(化合物19)Ethyl 2-anilino-4-phenyl-5-thiazolecarboxylate (Compound 19)
Figure PCTCN2018083596-appb-000035
Figure PCTCN2018083596-appb-000035
1H NMR(400MHz,CDCl 3):δ7.74-7.72(m,2H),7.38(d,J＝3.6Hz,3H),7.38(t,J＝8.0Hz,2H),7.14(d,J＝6.8Hz,3H),4.26-4.21(m,2H),1.26(t,J＝6.8Hz,3H). 13C NMR(100MHz,CDCl 3):δ178.42,168.09,161.76,158.65,139.35,134.13,129.79,129.49,129.14,127.69,124.47,120.04,109.92,60.89,29.58,14.24.HRMS(ESI)calcd for:C 18H 16N 2O 2S[M+H] +325.1011,found 325.1009。 1 H NMR (400 MHz, CDCl 3 ): δ 7.74 - 7.72 (m, 2H), 7.38 (d, J = 3.6 Hz, 3H), 7.38 (t, J = 8.0 Hz, 2H), 7.14 (d, J) = 6.8 Hz, 3H), 4.26 - 4.21 (m, 2H), 1.26 (t, J = 6.8 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 178.42, 168.09, 161.76, 158.65, 139.35, 134.13, 129.79, 129.49, 129.14, 127.69, 124.47, 120.04, 109.92, 60.89, 29.58, 14.24. HRMS (ESI) calcd for: C 18 H 16 N 2 O 2 S [M+H] + 325.1011, found 325.1009.
2-(3,4-二甲基)苯胺基-4-苯基-5-噻唑甲酸乙酯(化合物20)Ethyl 2-(3,4-dimethyl)anilino-4-phenyl-5-thiazolecarboxylate (Compound 20)
Figure PCTCN2018083596-appb-000036
Figure PCTCN2018083596-appb-000036
1H NMR(400MHz,CDCl 3):δ7.74-7.72(m,2H),7.40-7.39(m,3H),7.12(d,J＝8.4Hz,1H),7.02(dd,J 1＝2.4Hz,J 2＝8.0Hz,1H),6.97(d,J＝2.0Hz,1H),4.25-4.20(m,2H),2.27(s,6H),1.26(t,J＝6.8Hz,3H). 13C NMR(100MHz,CDCl 3):δ161.67,158.13,138.06,136.90,133.83,133.63,130.54,129.73,129.12,127.67,122.08,122.02,117.95,117.90,60.85,19.93,19.26,14.24.HRMS(ESI)calcd for:C 20H 20N 2O 2S[M+H] +353.1324,found 353.1324。 1 H NMR (400MHz, CDCl 3 ): δ7.74-7.72 (m, 2H), 7.40-7.39 (m, 3H), 7.12 (d, J = 8.4Hz, 1H), 7.02 (dd, J 1 = 2.4 Hz, J 2 = 8.0 Hz, 1H), 6.97 (d, J = 2.0 Hz, 1H), 4.25 - 4.20 (m, 2H), 2.27 (s, 6H), 1.26 (t, J = 6.8 Hz, 3H) 13 C NMR (100 MHz, CDCl 3 ): δ 161.67, 158.13, 138.06, 136.90, 133.83, 133.63, 130.54, 129.73, 129.12, 127.67, 122.08, 122.02, 117.95, 117.90, 60.85, 19.93, 19.26, 14.24. HRMS (ESI) Calcd for: C 20 H 20 N 2 O 2 S[M+H] + 353.1324, found 353.1324.
2-(3-氯-4-甲基)-苯胺基-4-苯基-5-噻唑甲酸乙酯(化合物21)Ethyl 2-(3-chloro-4-methyl)-anilino-4-phenyl-5-thiazolecarboxylate (Compound 21)
Figure PCTCN2018083596-appb-000037
Figure PCTCN2018083596-appb-000037
1H NMR(400MHz,CDCl 3):δ7.74-7.72(m,2H),7.40-7.39(m,3H),7.23(d,J＝2.4Hz,1H),7.19(d,J＝7.6Hz,1H),7.03(dd,J 1＝2.4Hz,J 2＝8.0Hz,1H),4.24(q,J＝7.2Hz,2H),2.37(s,3H),1.27(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ167.73,161.59,158.47,138.11,134.93,133.93,132.44,131.48,129.66,129.12,127.69,120.97,118.66,110.54,60.92,19.46,14.21.HRMS(ESI)calcd for:C 19H 17ClN 2O 2S[M+H] +373.0778,found 373.0778。 1 H NMR (400 MHz, CDCl 3 ): δ 7.74-7.72 (m, 2H), 7.40-7.39 (m, 3H), 7.23 (d, J = 2.4 Hz, 1H), 7.19 (d, J = 7.6 Hz) , 1H), 7.03 (dd, J 1 = 2.4 Hz, J 2 = 8.0 Hz, 1H), 4.24 (q, J = 7.2 Hz, 2H), 2.37 (s, 3H), 1.27 (t, J = 7.2 Hz) , 3H). 13 C NMR (100MHz, CDCl 3 ): δ167.73, 161.59, 158.47, 138.11, 134.93, 133.93, 132.44, 131.48, 129.66, 129.12, 127.69, 120.97, 118.66, 110.54, 60.92, 19.46, 14.21.HRMS( ESI)calcd for: C 19 H 17 ClN 2 O 2 S [M+H] + 373.0778, found 373.0778.
2-(4-甲氧基)-苯胺基-4-苯基-5-噻唑甲酸乙酯(化合物22)Ethyl 2-(4-methoxy)-anilino-4-phenyl-5-thiazolecarboxylate (Compound 22)
Figure PCTCN2018083596-appb-000038
Figure PCTCN2018083596-appb-000038
1H NMR(400MHz,CDCl 3):δ8.54(s,1H),7.69(dd,J 1＝3.2Hz,J 2＝4.4Hz,2H),7.37-7.35(m,3H),7.14(d,J＝9.2Hz,2H),6.88(d,J＝8.8Hz,2H),4.20(q,J＝7.2Hz,2H),3.85(s,3H),1.24(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ170.58,161.75,159.06,157.30,134.33,132.62,129.64,128.87,127.54,123.84,114.71,109.40,60.65,55.51,14.21.HRMS(ESI)calcd for:C 19H 18N 2O 3S[M+H] +355.1116,found 355.1115。 1 H NMR (400MHz, CDCl 3 ): δ8.54 (s, 1H), 7.69 (dd, J 1 = 3.2Hz, J 2 = 4.4Hz, 2H), 7.37-7.35 (m, 3H), 7.14 (d , J = 9.2 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 4.20 (q, J = 7.2 Hz, 2H), 3.85 (s, 3H), 1.24 (t, J = 7.2 Hz, 3H) 13 C NMR (100 MHz, CDCl 3 ): δ 170.58, 161.75, 159.06, 157.30, 134.33, 132.62, 129.64, 128.87, 127.54, 123.84, 114.71, 109.40, 60.65, 55.51, 14.21.HRMS(ESI)calcd for:C 19 H 18 N 2 O 3 S[M+H] + 355.1116, found 355.1115.
2-(3-三氟甲基-4-溴)-苯胺基-4-苯基-5-噻唑甲酸乙酯(化合物23)Ethyl 2-(3-trifluoromethyl-4-bromo)-anilino-4-phenyl-5-thiazolecarboxylate (Compound 23)
Figure PCTCN2018083596-appb-000039
Figure PCTCN2018083596-appb-000039
1H NMR(400MHz,CDCl 3):δ7.69-7.67(m,2H),7.53(d,J＝8.8Hz,1H),7.47(d,J＝2.8Hz,1H),7.33-7.29(m,3H),7.10(dd,J1＝2.8Hz,J 2＝8.6Hz,1H),4.28-4.23(m,2H),1.28(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ166.75,161.45,158.13,138.81,135.82,133.48,129.68,129.37,127.74,123.77,119.19,119.13,113.92,111.25,61.22,14.15.HRMS(ESI)calcd for:C 19H 14BrF 3N 2O 2S[M+H] +470.9990,found 470.9986。 1 H NMR (400MHz, CDCl 3 ): δ7.69-7.67 (m, 2H), 7.53 (d, J = 8.8Hz, 1H), 7.47 (d, J = 2.8Hz, 1H), 7.33-7.29 (m , 3H), 7.10 (dd, J1 = 2.8 Hz, J 2 = 8.6 Hz, 1H), 4.28 - 4.23 (m, 2H), 1.28 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl) 3 ): δ166.75,161.45,158.13,138.81,135.82,133.48,129.68,129.37,127.74,123.77,119.19,119.13,113.92,111.25,61.22,14.15.HRMS(ESI)calcd for:C 19 H 14 BrF 3 N 2 O 2 S[M+H] + 470.9990, found 470.9986.
2-(3,4-二氯)-苯胺基-4-苯基-5-噻唑甲酸乙酯(化合物24)Ethyl 2-(3,4-dichloro)-anilino-4-phenyl-5-thiazolecarboxylate (Compound 24)
Figure PCTCN2018083596-appb-000040
Figure PCTCN2018083596-appb-000040
1H NMR(400MHz,CDCl 3):δ7.70-7.67(m,2H),7.35(dd,J 1＝2.0Hz,J 2＝5.4Hz,3H),7.26(d,J＝8.8Hz,1H),7.14(d,J＝2.4Hz,1H),6.88(dd,J 1＝2.8Hz,J 2＝8.6Hz,1H),4.27-4.22(m,2H),1.27(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ167.54,161.52,158.29,138.82,133.68,133.09,130.82,129.65,129.34,127.83,127.76,121.83,119.38,110.73,61.14,14.22.HRMS(ESI)calcd for:C 18H 14C l2N 2O 2S[M+H] +393.0231,found 393.0234。 1 H NMR (400MHz, CDCl 3 ): δ7.70-7.67 (m, 2H), 7.35 (dd, J 1 = 2.0Hz, J 2 = 5.4Hz, 3H), 7.26 (d, J = 8.8Hz, 1H ), 7.14 (d, J = 2.4 Hz, 1H), 6.88 (dd, J 1 = 2.8 Hz, J 2 = 8.6 Hz, 1H), 4.27-4.22 (m, 2H), 1.27 (t, J = 7.2 Hz) , 3H). 13 C NMR (100MHz, CDCl 3 ): δ 167.54, 161.52, 158.29, 138.82, 133.68, 133.09, 130.82, 129.65, 129.34, 127.83, 127.76, 121.83, 119.38, 110.73, 61.14, 14.22.HRMS (ESI) Calcd for: C 18 H 14 C l2 N 2 O 2 S[M+H] + 393.0231, found 393.0234.
2-(4-氯)-苯胺基-4-苯基-5-噻唑甲酸乙酯(化合物25)Ethyl 2-(4-chloro)-anilino-4-phenyl-5-thiazolecarboxylate (Compound 25)
Figure PCTCN2018083596-appb-000041
Figure PCTCN2018083596-appb-000041
1H NMR(400MHz,CDCl 3):δ10.59(s,1H),7.67(d,J＝6.4Hz,2H),7.36-7.28(m,3H),7.13(d,J＝8.4Hz,2H),6.85(d,J＝8.8Hz,2H),4.25-4.20(m,2H),1.25(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ168.23,161.60,158.519,137.94,134.03,129.76,129.59,129.41,129.23,127.74,121.57,110.14,60.98,14.22.HRMS(ESI)calcd for:C 18H 15ClN 2O 2S[M+H] +359.0621,found 359.0615。 1 H NMR (400MHz, CDCl 3 ): δ10.59 (s, 1H), 7.67 (d, J = 6.4Hz, 2H), 7.36-7.28 (m, 3H), 7.13 (d, J = 8.4Hz, 2H ), 6.85 (d, J = 8.8 Hz, 2H), 4.25 - 4.20 (m, 2H), 1.25 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 168.23, 161.60, 158. , 137.94, 134.03, 129.76, 129.59, 129.41, 129.23, 127.74, 121.57, 110.14, 60.98, 14.22. HRMS (ESI) calcd for: C 18 H 15 ClN 2 O 2 S [M+H] + 359.0621, found 359.0615.
2-(2-甲基-4-溴)-苯胺基-4-苯基-5-噻唑甲酸乙酯(化合物26)Ethyl 2-(2-methyl-4-bromo)-anilino-4-phenyl-5-thiazolecarboxylate (Compound 26)
Figure PCTCN2018083596-appb-000042
Figure PCTCN2018083596-appb-000042
1H NMR(400MHz,CDCl 3):δ7.52-7.50(m,2H),7.36(dd,J1＝2.4Hz,J 2＝8.4Hz,1H),7.29(d,J＝2.0Hz,1H),7.27-7.23(m,2H),7.15(t,J＝3.6Hz,2H),4.19-4.14(m,2H),2.08(s, 3H),1.21(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ170.40,161.54,158.93,137.12,135.76,134.12,133.79,130.28,129.26,128.90,127.39,126.33,126.29,120.14,110.18,60.80,29.73,17.45,14.19.HRMS(ESI)calcd for:C 19H 17BrN 2O 2S[M+H] +417.0272,found 417.0271。 1 H NMR (400 MHz, CDCl 3 ): δ 7.52-7.50 (m, 2H), 7.36 (dd, J1 = 2.4 Hz, J 2 = 8.4 Hz, 1H), 7.29 (d, J = 2.0 Hz, 1H) , 7.27-7.23 (m, 2H), 7.15 (t, J = 3.6 Hz, 2H), 4.19-4.14 (m, 2H), 2.08 (s, 3H), 1.21 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 170.40, 161.54, 158.93, 137.12, 135.76, 134.12, 133.79, 130.28, 129.26, 128.90, 127.39, 126.33, 126.29, 120.14, 110.18, 60.80, 29.73, 17.45, 14.19. HRMS ( ESI)calcd for: C 19 H 17 BrN 2 O 2 S [M+H] + 417.0272, found 417.0271.
2-蒽氨基-4-苯基-5-噻唑甲酸乙酯(化合物27)2-蒽Amino-4-phenyl-5-thiazolecarboxylic acid ethyl ester (Compound 27)
Figure PCTCN2018083596-appb-000043
Figure PCTCN2018083596-appb-000043
1H NMR(400MHz,CDCl 3):8.43(s,2H),8.03(d,J＝8.8Hz,3H),7.99(d,J＝2.0Hz,1H),7.83-7.81(m,2H),7.54-7.46(m,5H),7.27(d,J＝2.0Hz,1H),4.32-4.27(m,2H),1.31(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ165.74,161.57,135.64,133.72,132.47,131.68,131.33,130.35,129.81,129.39,128.98,128.27,127.88,127.82,126.44,126.00,125.45,125.32,120.37,113.57,111.20,61.11,14.27,HRMS(ESI)calcd for:C 26H 20N 2O 2S[M+H] +425.1324,found 425.1324。 1 H NMR (400MHz, CDCl 3 ): 8.43 (s, 2H), 8.03 (d, J = 8.8Hz, 3H), 7.99 (d, J = 2.0Hz, 1H), 7.83-7.81 (m, 2H), 7.54-7.46 (m, 5H), 7.27 (d, J = 2.0 Hz, 1H), 4.32-4.27 (m, 2H), 1.31 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ165.74,161.57,135.64,133.72,132.47,131.68,131.33,130.35,129.81,129.39,128.98,128.27,127.88,127.82,126.44,126.00,125.45,125.32,120.37,113.57,111.20,61.11,14.27,HRMS( ESI)calcd for: C 26 H 20 N 2 O 2 S[M+H] + 425.1324, found 425.1324.
2-(3-三氟甲基-4-氯)-苯胺基-4-苯基-5-噻唑甲酸乙酯(化合物28)Ethyl 2-(3-trifluoromethyl-4-chloro)-anilino-4-phenyl-5-thiazolecarboxylate (Compound 28)
Figure PCTCN2018083596-appb-000044
Figure PCTCN2018083596-appb-000044
1H NMR(400MHz,CDCl 3):δ7.70-7.67(m,2H),7.50(d,J＝2.8Hz,1H),7.38-7.32(m,4H),7.22(dd,J 1＝2.8Hz,J 2＝8.8Hz,1H),4.28-4.23(m,2H),1.27(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ166.90,161.48,158.24,138.21,133.55,132.36,129.68,129.36,127.74,126.95,123.85,120.96,119.02,118.97,111.14,61.22,14.18.HRMS(ESI)calcd for:C 19H 14ClF 3N 2O 2S[M+H] +427.0495,found 427.0493。 1 H NMR (400MHz, CDCl 3 ): δ7.70-7.67 (m, 2H), 7.50 (d, J = 2.8Hz, 1H), 7.38-7.32 (m, 4H), 7.22 (dd, J 1 = 2.8 Hz, J 2 = 8.8 Hz, 1H), 4.28-4.23 (m, 2H), 1.27 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 166.90, 161.48, 158.24, 138.21. 133.55,132.36,129.68,129.36,127.74,126.95,123.85,120.96,119.02,118.97,111.14,61.22,14.18.HRMS(ESI)calcd for:C 19 H 14 ClF 3 N 2 O 2 S[M+H] + 427.0495, found 427.0493.
2-(4-三氟甲基)-苯胺基-4-苯基-5-噻唑甲酸乙酯(化合物29)Ethyl 2-(4-trifluoromethyl)-anilino-4-phenyl-5-thiazolecarboxylate (Compound 29)
Figure PCTCN2018083596-appb-000045
Figure PCTCN2018083596-appb-000045
1H NMR(400MHz,CDCl 3):7.78-7.75(m,2H),7.59(d,J＝8.4Hz,2H),7.43-7.41(m,3H),7.34(d,J＝8.4Hz,2H),4.30-4.25(m,2H),1.29(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ166.39,161.50,158.21,142.18,133.82,129.81,129.43,127.79,126.62,126.59,118.66,111.10,61.17,14.21.HRMS(ESI)calcd for:C 19H 15F 3N 2O 2S[M+H] +393.0885,found 393.0884。 1 H NMR (400MHz, CDCl 3 ): 7.78-7.75 (m, 2H), 7.59 (d, J = 8.4Hz, 2H), 7.43-7.41 (m, 3H), 7.34 (d, J = 8.4Hz, 2H ), 4.30-4.25 (m, 2H), 1.29 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 166.39, 161.50, 158.21, 142.18, 133.82, 129.81, 129.43, 127.79, 126.62 , 126.59, 118.66, 111.10, 61.17, 14.21. HRMS (ESI) calcd for: C 19 H 15 F 3 N 2 O 2 S [M+H] + 393.0885, found 393.0884.
2-((3-氟-[1,1’-联苯]-4-基)氨基)-4-苯基-5-噻唑甲酸乙酯(化合物30)Ethyl 2-((3-fluoro-[1,1'-biphenyl]-4-yl)amino)-4-phenyl-5-thiazolecarboxylate (Compound 30)
Figure PCTCN2018083596-appb-000046
Figure PCTCN2018083596-appb-000046
1H NMR(400MHz,CDCl 3):7.98(t,J＝8.4Hz,1H),7.81-7.79(m,2H),7.61-7.59(m,2H),7.50-7.40(m,8H),4.30-4.25(m,2H),1.30(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):165.85,161.61,158.62,154.64,152.19,139.25,138.19,138.11,134.05,129.75,129.13,129.01,127.80,127.60,126.78,126.72,126.60,123.25,123.22,120.69,114.31,114.11,111.75,61.04,29.73,14.24.HRMS(ESI)calcd for:C 24H 19FN 2O 2S[M+H] +419.1230,found 419.1232。 1 H NMR (400 MHz, CDCl 3 ): 7.98 (t, J = 8.4 Hz, 1H), 7.81-7.79 (m, 2H), 7.61 - 7.59 (m, 2H), 7.50 - 7.40 (m, 8H), 4.30 -4.25 (m, 2H), 1.30 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): 165.85, 161.61, 158.62, 154.64, 152.19, 139.25, 138.19, 138.11, 134.05, 129.75, 129.13,129.01,127.80,127.60,126.78,126.72,126.60,123.25,123.22,120.69,114.31,114.11,111.75,61.04,29.73,14.24.HRMS(ESI)calcd for:C 24 H 19 FN 2 O 2 S[M +H] + 419.1230, found 419.1232.
2-(苯并[d][1,3]二氧戊环-5-基-氨基)-4-苯基-5-噻唑甲酸乙酯(化合物31)Ethyl 2-(benzo[d][1,3]dioxolan-5-yl-amino)-4-phenyl-5-thiazolecarboxylate (Compound 31)
Figure PCTCN2018083596-appb-000047
Figure PCTCN2018083596-appb-000047
1H NMR(400MHz,CDCl 3):δ7.68-7.66(m,2H),7.37-7.34(m,3H),6.75(d,J＝8.0Hz, 1H),6.65-6.68(m,2H),6.01(s,2H),4.23-4.18(m,2H),1.24(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ170.08,161.65,158.74,148.25,145.35,134.03,133.70,130.02,129.61,128.93,128.25,127.57,115.41,109.67,108.51,104.05,101.51,60.75,14.20.HRMS(ESI)calcd for:C 19H 16N 2O 4S[M+H] +369.0909,found 369.0902。 1 H NMR (400MHz, CDCl 3 ): δ7.68-7.66 (m, 2H), 7.37-7.34 (m, 3H), 6.75 (d, J = 8.0Hz, 1H), 6.65-6.68 (m, 2H) , 6.01 (s, 2H), 4.23-4.18 (m, 2H), 1.24 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 170.08, 161.65, 158.74, 148.25, 145.35, 134.03 , 133.70,130.02,129.61,128.93,128.25,127.57,115.41,109.67,108.51,104.05,101.51,60.75,14.20.HRMS(ESI)calcd for:C 19 H 16 N 2 O 4 S[M+H] + 369.0909 , found 369.0902.
2-((9-乙基-9H-咔唑-3-基)氨基)-4-苯基-5-噻唑甲酸乙酯(化合物32)Ethyl 2-((9-ethyl-9H-indazol-3-yl)amino)-4-phenyl-5-thiazolecarboxylate (Compound 32)
Figure PCTCN2018083596-appb-000048
Figure PCTCN2018083596-appb-000048
1H NMR(400MHz,CDCl 3):δ10.71(s,1H),8.36(d,J＝1.2Hz,1H),8.12(d,J＝7.6Hz,1H),7.79-7.76(m,2H),7.67-7.61(m,3H),7.49-7.44(m,4H),7.21(t,J＝7.2Hz,1H),4.48-4.43(m,2H),4.16-4.10(m,2H),1.33(t,J＝7.2Hz,3H),1.12(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ171.26,161.80,159.27,140.58,138.18,134.38,131.22,129.58,128.76,127.48,126.23,123.63 122.53,121.77,120.78,119.07,115.49,109.62,109.26,108.73,60.58,37.71,14.19,13.84.HRMS(ESI)calcd for:C 26H 23N 3O 2S[M+H] +442.1589,found 442.1582。 1 H NMR (400MHz, CDCl 3 ): δ10.71 (s, 1H), 8.36 (d, J = 1.2Hz, 1H), 8.12 (d, J = 7.6Hz, 1H), 7.79-7.76 (m, 2H ), 7.67-7.61 (m, 3H), 7.49-7.44 (m, 4H), 7.21 (t, J = 7.2 Hz, 1H), 4.48-4.43 (m, 2H), 4.16-4.10 (m, 2H), 1.33 (t, J = 7.2 Hz, 3H), 1.12 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 171.26, 161.80, 159.27, 140.58, 138.18, 134.38, 131.22, 129.58, 128.76,127.48,126.23,123.63 122.53,121.77,120.78,119.07,115.49,109.62,109.26,108.73,60.58,37.71,14.19,13.84.HRMS(ESI)calcd for:C 26 H 23 N 3 O 2 S[M+ H] + 442.1589, found 442.1582.
2-(3,5二氯)-苯胺基-4-苯基-5-噻唑甲酸乙酯(化合物33)Ethyl 2-(3,5-dichloro)-anilino-4-phenyl-5-thiazolecarboxylate (Compound 33)
Figure PCTCN2018083596-appb-000049
Figure PCTCN2018083596-appb-000049
1H NMR(400MHz,CDCl 3):δ7.74-7.72(m,2H),7.39-7.37(m,3H),7.06(d,J＝1.6Hz,1H),7.00(d,J＝1.6Hz,2H),4.30-4.24(m,2H),1.29(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ166.16,161.45,158.13,141.13,135.68,133.54,129.65,129.44,127.87,124.12,117.67,111.64,61.20,14.20.HRMS(ESI)calcd for:C 18H 14Cl 2N 2O 2S[M+H] +393.0231,found 393.0231。 1 H NMR (400MHz, CDCl 3 ): δ7.74-7.72 (m, 2H), 7.39-7.37 (m, 3H), 7.06 (d, J = 1.6Hz, 1H), 7.00 (d, J = 1.6Hz , 2H), 4.30-4.24 (m, 2H), 1.29 (t, J = 7.2 Hz, 3H). 13 C NMR (100MHz, CDCl 3 ): δ 166.16, 161.45, 158.13, 141.13, 135.68, 133.54, 129.65, 129.44 , 127.87, 124.12, 117.67, 111.64, 61.20, 14.20. HRMS (ESI) calcd for: C 18 H 14 Cl 2 N 2 O 2 S [M+H] + 393.0231, found 393.0231.
2-((5,6,7,8-四氢萘-2-基)氨基)-4-苯基-5-噻唑甲酸乙酯(化合物34)Ethyl 2-((5,6,7,8-tetrahydronaphthalen-2-yl)amino)-4-phenyl-5-thiazolecarboxylate (Compound 34)
Figure PCTCN2018083596-appb-000050
Figure PCTCN2018083596-appb-000050
1H NMR(400MHz,CDCl 3):δ7.76-7.73(m,2H),7.42-7.41(m,3H),7.72(d,J＝8.4Hz,1H),7.02(dd,J 1＝2.4Hz,J 2＝7.4Hz,1H),6.94(d,J＝2.0Hz,1H),4.27-4.21(m,2H),2.78(s,4H),1.85-1.81(m,4H),1.26(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ168.61,161.77,158.71,138.50,136.68,134.24,134.14,130.06,129.74,128.94,127.58,121.17,118.02,109.86,60.72,29.46,28.95,23.15,22.98,14.24.HRMS(ESI)calcd for:C 22H 22N 2O 2S[M+H] +379.1480,found 379.1481。 1 H NMR (400MHz, CDCl 3 ): δ7.76-7.73 (m, 2H), 7.42-7.41 (m, 3H), 7.72 (d, J = 8.4Hz, 1H), 7.02 (dd, J 1 = 2.4 Hz, J 2 = 7.4 Hz, 1H), 6.94 (d, J = 2.0 Hz, 1H), 4.27 - 4.21 (m, 2H), 2.78 (s, 4H), 1.85-1.81 (m, 4H), 1.26 ( t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 168.61, 161.77, 158.71, 138.50, 136.68, 134.24, 134.14, 130.06, 129.74, 128.94, 127.58, 121.17, 118.02, 109.86, 60.72, 29.46, 28.95, 23.15, 22.98, 14.24. HRMS (ESI) calcd for: C 22 H 22 N 2 O 2 S [M+H] + 379.1480, found 379.1481.
2-(4-叔丁基)-苯氨基-4-苯基-5-噻唑甲酸乙酯(化合物35)Ethyl 2-(4-tert-butyl)-phenylamino-4-phenyl-5-thiazolecarboxylate (Compound 35)
Figure PCTCN2018083596-appb-000051
Figure PCTCN2018083596-appb-000051
1H NMR(400MHz,CDCl 3):δ7.75-7.73(m,2H),7.40-7.38(m,5H),7.19(d,J＝8.4Hz,2H),4.26-4.21(m,2H),1.36(s,9H),1.27(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ168.40,161.72,158.73,147.77,136.66,134.20,129.73,129.01,127.56,126.35,120.19,109.85, 60.75,34.43,31.34,14.24.HRMS(ESI)calcd for:C 22H 24N 2O 2S[M+H] +381.1637,found 381.1635。 1 H NMR (400MHz, CDCl 3 ): δ7.75-7.73 (m, 2H), 7.40-7.38 (m, 5H), 7.19 (d, J = 8.4Hz, 2H), 4.26-4.21 (m, 2H) , 1.36 (s, 9H), 1.27 (t, J = 7.2 Hz, 3H). 13 C NMR (100MHz, CDCl 3 ): δ 168.40, 161.72, 158.73, 147.77, 136.66, 134.20, 129.73, 129.01, 127.56, 126.35, 120.19, 109.85, 60.75, 34.43, 31.34, 14.24. HRMS (ESI) calcd for: C 22 H 24 N 2 O 2 S [M+H] + 381.1637, found 381.1635.
2-(3-氟-4-甲基)-苯胺基-4-苯基-5-噻唑甲酸乙酯(化合物36)Ethyl 2-(3-fluoro-4-methyl)-anilino-4-phenyl-5-thiazolecarboxylate (Compound 36)
Figure PCTCN2018083596-appb-000052
Figure PCTCN2018083596-appb-000052
1H NMR(400MHz,CDCl 3):δ7.72-7.70(m,2H),7.38-7.37(m,3H),7.08(t,J＝7.6Hz,1H),6.84-6.78(m,2H),4.26-4.21(m,2H),2.25(s,3H),1.26(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ168.12,162.43,161.64,159.99,158.54,138.48,138.38,133.99,131.85,131.79,129.72,129.12,127.70,121.08,120.91,115.66,115.63,110.09,107.59,107.33,60.92,29.73,14.23,14.12,14.09.HRMS(ESI)calcd for:C 19H 17FN 2O 2S[M+H] +357.1073,found 357.1068。 1 H NMR (400MHz, CDCl 3 ): δ7.72-7.70 (m, 2H), 7.38-7.37 (m, 3H), 7.08 (t, J = 7.6Hz, 1H), 6.84-6.78 (m, 2H) , 4.26-4.21 (m, 2H), 2.25 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 168.12, 162.43, 161.64, 159.99, 158.54, 138.48 , 138.38, 133.99, 131.85, 131.79, 129.72, 129.12, 127.70, 121.08, 120.91, 115.66, 115.63, 110.09, 107.59, 107.33, 60.92, 29.73, 14.23, 14.12, 14.09. HRMS (ESI) calcd for: C 19 H 17 FN 2 O 2 S[M+H] + 357.1073, found 357.1068.
2-([1,1’-联苯]-4-基-氨基)-4-苯基-5-噻唑甲酸乙酯(化合物37)Ethyl 2-([1,1'-biphenyl]-4-yl-amino)-4-phenyl-5-thiazolecarboxylate (Compound 37)
Figure PCTCN2018083596-appb-000053
Figure PCTCN2018083596-appb-000053
1H NMR(400MHz,CDCl 3):δ8.11-8.09(m,1H),7.75(dd,J1＝2.4Hz,J 2＝6.6Hz,2H),7.64-7.61(m,4H),7.48-7.44(m,5H),7.38(d,J＝8.0Hz,2H),4.29-4.23(m,2H),1.29(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ171.13,167.18,161.59,158.19,140.25,138.41,137.30,133.68,133.22,130.09,129.82,129.28,128.89,128.32,128.22,127.71,127.31,126.85,119.73,110.30,60.98,14.25.HRMS(ESI)calcd for:C 24H 20N 2O 2S[M+H] +401.1324,found 401.1318。 1 H NMR (400 MHz, CDCl 3 ): δ 8.11 - 8.09 (m, 1H), 7.75 (dd, J1 = 2.4 Hz, J 2 = 6.6 Hz, 2H), 7.64 - 7.61 (m, 4H), 7.48- 7.44 (m, 5H), 7.38 (d, J = 8.0 Hz, 2H), 4.29 - 4.23 (m, 2H), 1.29 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ171.13,167.18,161.59,158.19,140.25,138.41,137.30,133.68,133.22,130.09,129.82,129.28,128.89,128.32,128.22,127.71,127.31,126.85,119.73,110.30,60.98,14.25.HRMS(ESI)calcd for : C 24 H 20 N 2 O 2 S[M+H] + 401.1324, found 401.1318.
2-((3’-甲氧基-[1,1’-联苯]-4-基)氨基)-4-苯基-5-噻唑甲酸乙酯(化合物38)Ethyl 2-((3'-methoxy-[1,1'-biphenyl]-4-yl)amino)-4-phenyl-5-thiazolecarboxylate (Compound 38)
Figure PCTCN2018083596-appb-000054
Figure PCTCN2018083596-appb-000054
1H NMR(400MHz,CDCl 3):δ7.76-7.74(m,2H),7.51(d,J＝8.4Hz,2H),7.41-7.37(m,4H),7.17(d,J＝8.4Hz,3H),7.12(d,J＝2.0Hz,1H),6.93(dd,J1＝2.4Hz,J 2＝8.0Hz,1H),4.28-4.22(q,J＝7.2Hz,2H),3.91(s,3H),1.28(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ167.62,161.69,160.01,158.63,141.82,138.61,137.09,134.15,129.88,129.83,129.16,128.12,127.71,120.10,119.35,112.71,112.52,110.25,60.91,55.35,14.26.HRMS(ESI)calcd for:C 25H 22N 2O 3S[M+H] +431.1429,found 431.1432。 1 H NMR (400MHz, CDCl 3 ): δ7.76-7.74 (m, 2H), 7.51 (d, J = 8.4Hz, 2H), 7.41-7.37 (m, 4H), 7.17 (d, J = 8.4Hz , 3H), 7.12 (d, J = 2.0 Hz, 1H), 6.93 (dd, J1 = 2.4 Hz, J 2 = 8.0 Hz, 1H), 4.28 - 4.22 (q, J = 7.2 Hz, 2H), 3.91 ( s, 3H), 1.28 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 167.62, 161.69, 160.01, 158.63, 141.82, 138.61, 137.09, 134.15, 129.88, 129.83, 129.16, 128.12 , 127.71, 120.10, 119.35, 112.71, 112.52, 110.25, 60.91, 55.35, 14.26. HRMS (ESI) calcd for: C 25 H 22 N 2 O 3 S [M+H] + 431.1429, found 431.1432.
2-((3-氟-3’-甲氧基-[1,1’-联苯]-4-基)氨基)-4-苯基-5-噻唑甲酸乙酯(化合物39)Ethyl 2-((3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)amino)-4-phenyl-5-thiazolecarboxylate (Compound 39)
Figure PCTCN2018083596-appb-000055
Figure PCTCN2018083596-appb-000055
1H NMR(400MHz,CDCl 3):δ8.00(t,J＝8.4Hz,1H),7.82-7.79(m,2H),7.48-7.38(m,6H),7.18(d,J＝7.6Hz,1H),7.12(s,1H),6.94(dd,J1＝2.4Hz,J 2＝8.4Hz,1H),4.30-4.25(m,2H),3.90(s,3H),1.30(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ165.55,161.57,160.12,158.54,154.44,152.00,140.75,137.92,137.85,134.05,130.01,129.77,129.13,127.60,126.84,126.73,123.29,123.26,120.42,119.25,114.32,114.12,113.09,112.6f4,111.92,61.03,55.36,14.21.HRMS(ESI)calcd for:C 25H 21FN 2O 3S[M+H] +449.1335,found 449.1331。 1 H NMR (400 MHz, CDCl 3 ): δ 8.00 (t, J = 8.4 Hz, 1H), 7.82-7.79 (m, 2H), 7.48-7.38 (m, 6H), 7.18 (d, J = 7.6 Hz) , 1H), 7.12 (s, 1H), 6.94 (dd, J1 = 2.4 Hz, J 2 = 8.4 Hz, 1H), 4.30-4.25 (m, 2H), 3.90 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 165.55, 161.57, 160.12, 158.54, 154.44, 152.00, 140.75, 137.92, 137.85, 134.05, 130.01, 129.77, 129.13, 127.60, 126.84, 126.73, 123.29 , 123.26, 120.42, 119.25, 114.32, 114.12, 113.09, 112.6f4, 111.92, 61.03, 55.36, 14.21.HRMS(ESI)calcd for: C 25 H 21 FN 2 O 3 S[M+H] + 449.1335,found 449.1331 .
2-((3,5-二氟-3’-甲氧基-[1,1’-联苯]-4-基)氨基)-4-苯基-5-噻唑甲酸乙酯(化合物40)Ethyl 2-((3,5-difluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)amino)-4-phenyl-5-thiazolecarboxylate (Compound 40)
Figure PCTCN2018083596-appb-000056
Figure PCTCN2018083596-appb-000056
1H NMR(400MHz,CDCl 3):δ7.66(d,J＝7.6Hz,2H),7.43(t,J＝8.0Hz,1H),7.26(d,J＝7.0Hz,3H),7.19-7.16(m,3H),7.10(s,1H),7.01(d,J＝8.0Hz,1H),4.22-4.17(m,2H),3.92(s,3H),1.22(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ170.93,161.38,160.18,159.47,159.43,158.14,156.97,156.92,141.94,139.74,133.57,133.37,130.25,130.12,129.49,128.93,128.36,127.38,119.30,115.41,113.95,112.76,111.48,110.96,110.72,60.89,55.43,29.72,14.18.HRMS(ESI)calcd for:C 25H 20F 2N 2O 3S[M+H] +467.1241,found 467.1235。 1 H NMR (400MHz, CDCl 3 ): δ7.66 (d, J = 7.6Hz, 2H), 7.43 (t, J = 8.0Hz, 1H), 7.26 (d, J = 7.0Hz, 3H), 7.19- 7.16(m,3H),7.10(s,1H),7.01(d,J=8.0Hz,1H),4.22-4.17(m,2H),3.92(s,3H),1.22(t,J=7.2Hz , 3H). 13 C NMR (100MHz, CDCl 3 ): δ170.93,161.38,160.18,159.47,159.43,158.14,156.97,156.92,141.94,139.74,133.57,133.37,130.25,130.12,129.49,128.93,128.36,127.38, 119.30,115.41,113.95,112.76,111.48,110.96,110.72,60.89,55.43,29.72,14.18.HRMS(ESI)calcd for:C 25 H 20 F 2 N 2 O 3 S[M+H] + 467.1241,found 467.1235 .
2-((3-氯-4-苯氧基苯基)氨基)-4-苯基-5-噻唑甲酸乙酯(化合物41)Ethyl 2-((3-chloro-4-phenoxyphenyl)amino)-4-phenyl-5-thiazolecarboxylate (Compound 41)
Figure PCTCN2018083596-appb-000057
Figure PCTCN2018083596-appb-000057
1H NMR(400MHz,CDCl 3):δ7.72(s,2H),7.40-7.31(m,6H),7.15(t,J＝7.2Hz,1H),7.07-7.05(m,1H),6.99(d,J＝7.6Hz,2H),6.93(d,J＝8.8Hz,1H),4.27-4.22(m,2H),1.27(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ168.09,161.52,158.51,157.03,149.29,135.91,133.93,129.81,129.66,129.19,127.70,126.70,123.41,123.07,121.57,120.40,117.68,110.70,60.96,14.19.HRMS(ESI)calcd for:C 24H 19ClN 2O 3S[M+H] +451.0883,found 451.0882。 1 H NMR (400MHz, CDCl 3 ): δ7.72 (s, 2H), 7.40-7.31 (m, 6H), 7.15 (t, J = 7.2Hz, 1H), 7.07-7.05 (m, 1H), 6.99 (d, J = 7.6 Hz, 2H), 6.93 (d, J = 8.8 Hz, 1H), 4.27 - 4.22 (m, 2H), 1.27 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ168.09,161.52,158.51,157.03,149.29,135.91,133.93,129.81,129.66,129.19,127.70,126.70,123.41,123.07,121.57,120.40,117.68,110.70,60.96,14.19.HRMS(ESI)calcd for : C 24 H 19 ClN 2 O 3 S[M+H] + 451.0883, found 451.0882.
2-((4-(苄氧基)-3-氯苯基)氨基)-4-苯基-5-噻唑甲酸乙酯(化合物42)Ethyl 2-((4-(benzyloxy)-3-chlorophenyl)amino)-4-phenyl-5-thiazolecarboxylate (Compound 42)
Figure PCTCN2018083596-appb-000058
Figure PCTCN2018083596-appb-000058
1H NMR(400MHz,CDCl 3):δ7.70(d,J＝3.2Hz,2H),7.50(d,J＝7.6Hz,2H),7.44(t,J＝8.8Hz,2H),7.39-7.36(m,4H),7.30(d,J＝2.4Hz,1H),7.09(dd,J 1＝2.4Hz,J 2＝8.8Hz,1H),6.93(d,J＝8.8Hz,1H),5.20(s,2H),4.25-4.20(m,2H),1.26(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ169.48,161.58,158.70,151.90,136.39,133.97,133.30,129.52,129.03,128.68,128.15,127.59,127.12,124.33,124.00,121.36,114.76,110.10,77.35,60.82,14.19.HRMS(ESI)calcd for:C 25H 21ClN 2O 3S[M+H] +465.1040,found 465.1032。 1 H NMR (400MHz, CDCl 3 ): δ7.70 (d, J = 3.2Hz, 2H), 7.50 (d, J = 7.6Hz, 2H), 7.44 (t, J = 8.8Hz, 2H), 7.39- 7.36 (m, 4H), 7.30 (d, J = 2.4 Hz, 1H), 7.09 (dd, J 1 = 2.4 Hz, J 2 = 8.8 Hz, 1H), 6.93 (d, J = 8.8 Hz, 1H), 5.20(s, 2H), 4.25-4.20 (m, 2H), 1.26 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 169.48, 161.58, 158.70, 151.90, 136.39, 133.97, 133.30,129.52,129.03,128.68,128.15,127.59,127.12,124.33,124.00,121.36,114.76,110.10,77.35,60.82,14.19.HRMS(ESI)calcd for:C 25 H 21 ClN 2 O 3 S[M+H ] + 465.1040, found 465.1032.
2-((3-氯-4-((2-氯-6-氟苯基)苯氧基)氨基)-4-苯基-5-噻唑甲酸乙酯(化合物43)Ethyl 2-((3-chloro-4-((2-chloro-6-fluorophenyl)phenoxy)amino)-4-phenyl-5-thiazolecarboxylate (Compound 43)
Figure PCTCN2018083596-appb-000059
Figure PCTCN2018083596-appb-000059
1H NMR(400MHz,CDCl 3):δ7.63-7.61(m,2H),7.37-7.32(m,2H),7.30-7.26(m,3H),7.10(t,J＝8.0Hz,1H),7.01(d,J＝2.4Hz,1H),6.96(d,J＝8.8Hz,1H),6.90(dd,J 1＝2.4Hz,J 2＝8.8Hz,1H),5.25(s,2H),4.21(q,J＝7.2Hz,2H),1.24(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ169.36,163.32,161.62,160.81,158.77,151.79,136.72,136.68,133.91,133.82,131.07,130.97,129.53,129.10,127.63,125.70,125.67,124.61,124.14,121.98,121.81,121.20,115.65,114.51,114.28,109.99,62.96,62.92,60.86,14.22.HRMS(ESI)calcd for:C 25H19C l2FN 2O 3S[M+H] +517.0556,found 517.0562。 1 H NMR (400MHz, CDCl 3 ): δ7.63-7.61 (m, 2H), 7.37-7.32 (m, 2H), 7.30-7.26 (m, 3H), 7.10 (t, J = 8.0Hz, 1H) , 7.01 (d, J = 2.4 Hz, 1H), 6.96 (d, J = 8.8 Hz, 1H), 6.90 (dd, J 1 = 2.4 Hz, J 2 = 8.8 Hz, 1H), 5.25 (s, 2H) , 4.21 (q, J = 7.2 Hz, 2H), 1.24 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 169.36, 163.32, 161.62, 160.81, 158.77, 151.79, 136.72, 136.68 ,133.91,133.82,131.07,130.97,129.53,129.10,127.63,125.70,125.67,124.61,124.14,121.98,121.81,121.20,115.65,114.51,114.28,109.99,62.96,62.92,60.86,14.22.HRMS(ESI)calcd For: C 25 H19C l2 FN 2 O 3 S[M+H] + 517.0556, found 517.0562.
2-((2,3-二氢-1H-茚-5-基)氨基)-4-苯基-5-噻唑甲酸乙酯(化合物44)Ethyl 2-((2,3-dihydro-1H-indol-5-yl)amino)-4-phenyl-5-thiazolecarboxylate (Compound 44)
Figure PCTCN2018083596-appb-000060
Figure PCTCN2018083596-appb-000060
1H NMR(400MHz,CDCl 3):δ7.74-7.73(m,2H),7.39-7.38(m,3H),7.19(d,J＝8.0Hz,1H),7.07-6.99(m,2H),4.25-4.20(m,2H),2.91(t,J＝7.6Hz,4H),2.14-2.07(m,2H),1.26(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):161.78,158.78,145.92,141.21,137.52,134.27,129.73,128.96,127.62,125.07,118.72,117.07,117.03,60.75,33.01,32.38,25.63,14.25.HRMS(ESI)calcd for:C 21H 20N 2O 2S[M+H] +365.1324,found 365.1326。 1 H NMR (400 MHz, CDCl 3 ): δ 7.74-7.73 (m, 2H), 7.39-7.38 (m, 3H), 7.19 (d, J = 8.0 Hz, 1H), 7.07-6.99 (m, 2H) , 4.25-4.20 (m, 2H), 2.91 (t, J = 7.6 Hz, 4H), 2.14 - 2.07 (m, 2H), 1.26 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl) 3 ): 161.78,158.78,145.92,141.21,137.52,134.27,129.73,128.96,127.62,125.07,118.72,117.07,117.03,60.75,33.01,32.38,25.63,14.25.HRMS(ESI)calcd for:C 21 H 20 N 2 O 2 S[M+H] + 365.1324, found 365.1326.
2-萘氨基-4-苯基-5-噻唑甲酸乙酯(化合物45)Ethyl 2-naphthylamino-4-phenyl-5-thiazolecarboxylate (Compound 45)
Figure PCTCN2018083596-appb-000061
Figure PCTCN2018083596-appb-000061
1H NMR(400MHz,DMSO-d 6):δ10.90(s,1H),8.23(s,1H),7.92-7.63(m,6H),7.52-7.34(m,5H),4.27(q,J＝7.2Hz,2H),1.30(t,J＝7.2Hz,3H)。ESI[M+H] +found 375.3。 1 H NMR (400MHz, DMSO- d 6): δ10.90 (s, 1H), 8.23 (s, 1H), 7.92-7.63 (m, 6H), 7.52-7.34 (m, 5H), 4.27 (q, J = 7.2 Hz, 2H), 1.30 (t, J = 7.2 Hz, 3H). ESI [M+H] + found 375.3.
2-(3,4-二甲基)苯胺基-4-环丙基-5-噻唑甲酸乙酯(化合物46)Ethyl 2-(3,4-dimethyl)anilino-4-cyclopropyl-5-thiazolecarboxylate (Compound 46)
Figure PCTCN2018083596-appb-000062
Figure PCTCN2018083596-appb-000062
1H NMR(400MHz,CDCl 3):δ7.52(s,1H),7.14(d,J＝8.8Hz,1H),7.07(d,J＝6.0Hz,2H),4.32(q,J＝7.2Hz,2H),3.06–2.99(m,1H),2.28(s,3H),2.26(s,3H),1.36(t,J＝7.2Hz,3H),1.10-1.09(m,2H),1.04-1.02(m,2H). 13C NMR(100MHz,CDCl 3):δ167.42,164.91,163.14,137.98,137.06,132.92,130.55,121.13,117.14,108.84,60.46,19.95,19.15,14.50,11.65,9.75.HRMS(ESI)calcd for:C 17H 20N 2O 2S[M+H] +317.1324,found 317.1175。 1 H NMR (400MHz, CDCl 3 ): δ7.52 (s, 1H), 7.14 (d, J = 8.8Hz, 1H), 7.07 (d, J = 6.0Hz, 2H), 4.32 (q, J = 7.2 Hz, 2H), 3.06–2.99 (m, 1H), 2.28 (s, 3H), 2.26 (s, 3H), 1.36 (t, J = 7.2 Hz, 3H), 1.10.10.09 (m, 2H), 1.04 -1.02 (m, 2H). 13 C NMR (100MHz, CDCl 3 ): δ 167.42, 164.91, 163.14, 137.98, 137.06, 132.92, 130.55, 121.13, 117.14, 108.84, 60.46, 19.95, 19.15, 14.50, 11.65, 9.75. HRMS (ESI) calcd for: C 17 H 20 N 2 O 2 S [M+H] + 317.1324, found 317.1175.
2-(3-氟-4-甲基)-苯胺基-4-环丙基-5-噻唑甲酸乙酯(化合物47)Ethyl 2-(3-fluoro-4-methyl)-anilino-4-cyclopropyl-5-thiazolecarboxylate (Compound 47)
Figure PCTCN2018083596-appb-000063
Figure PCTCN2018083596-appb-000063
1H NMR(400MHz,CDCl 3):δ7.19-7.11(m,2H),6.96(dd,J 1＝2.0Hz,J 2＝8.0Hz,1H),4.33(q,J＝7.2Hz,2H),3.05-2.99(m,1H),2.27(s,3H),1.37(t,J＝7.2Hz,3H),1.11-1.09(m,2H),1.07-1.04(m,2H). 13C NMR(100MHz,CDCl 3):δ165.88,164.58,162.87,162.65,160.21,138.35,138.25,132.04,131.97,120.46,120.28,114.35,109.56,106.36,106.10,60.61,14.45,14.03,14.00,11.63,9.85.HRMS(ESI)calcd for:C 16H 17FN 2O 2S[M-H] +319.0917,found 319.0916。 1 H NMR (400MHz, CDCl 3 ): δ7.19-7.11 (m, 2H), 6.96 (dd, J 1 = 2.0Hz, J 2 = 8.0Hz, 1H), 4.33 (q, J = 7.2Hz, 2H ), 3.05-2.99 (m, 1H), 2.27 (s, 3H), 1.37 (t, J = 7.2 Hz, 3H), 1.11-1.09 (m, 2H), 1.07-1.04 (m, 2H). 13 C NMR (100 MHz, CDCl 3 ): δ 165.88, 164.58, 162.87, 162.65, 160.21, 138.35, 138.25, 132.04, 131.97, 120.46, 120.28, 114.35, 109.56, 106.36, 106.10, 60.61, 14.45, 14.03, 14.00, 11.63, 9.85. HRMS (ESI) calcd for: C 16 H 17 FN 2 O 2 S [MH] + 319.0917, found 319.0916.
2-(3-氯-4-甲基)-苯胺基-4-环丙基-5-噻唑甲酸乙酯(化合物48)Ethyl 2-(3-chloro-4-methyl)-anilino-4-cyclopropyl-5-thiazolecarboxylate (Compound 48)
Figure PCTCN2018083596-appb-000064
Figure PCTCN2018083596-appb-000064
1H NMR(400MHz,CDCl 3):δ7.40(d,J＝2.4Hz,1H),7.22(d,J＝8.4Hz,1H),7.13(dd,J 1＝2.4Hz,J 2＝8.0Hz,1H),4.33(q,J＝7.2Hz,2H),3.05–2.99(m,1H),2.37(s,3H),1.37(t,J＝7.2Hz,3H),1.13-1.09(m,2H),1.07-1.03(m,2H). 13C NMR(100MHz,CDCl 3):δ165.96,164.67,162.87,138.04,135.04,131.76,131.55,119.73,117.39,60.60,29.69,19.39,14.47,11.63,9.84.HRMS(ESI)calcd for:C 16H 17ClN 2O 2S[M+H] +337.0778,found 337.0770。 1 H NMR (400 MHz, CDCl 3 ): δ 7.40 (d, J = 2.4 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 7.13 (dd, J 1 = 2.4 Hz, J 2 = 8.0 Hz, 1H), 4.33 (q, J = 7.2 Hz, 2H), 3.05 - 2.99 (m, 1H), 2.37 (s, 3H), 1.37 (t, J = 7.2 Hz, 3H), 1.13-1.09 (m , 2H), 1.07-1.03 (m, 2H). 13 C NMR (100MHz, CDCl 3 ): δ 165.96, 164.67, 162.87, 138.04, 135.04, 131.76, 131.55, 119.73, 117.39, 60.60, 29.69, 19.39, 14.47, 11.63 , 9.84. HRMS (ESI) calcd for: C 16 H 17 ClN 2 O 2 S [M+H] + 337.0778, found 337.0770.
2-((5,6,7,8-四氢萘-2-基)氨基)-4-环丙基-5-噻唑甲酸乙酯(化合物49)Ethyl 2-((5,6,7,8-tetrahydronaphthalen-2-yl)amino)-4-cyclopropyl-5-thiazolecarboxylate (Compound 49)
Figure PCTCN2018083596-appb-000065
Figure PCTCN2018083596-appb-000065
1H NMR(400MHz,CDCl 3):δ7.56(s,1H),7.09-7.03(m,2H),7.01(s,1H),4.32(q,J＝7.2Hz,2H),3.06-3.00(m,1H),2.78-2.76(m,4H),1.81-1.80(m,4H),1.36(t,J＝7.2Hz,3H),1.11–1.08(m,2H),1.05-1.00(m,2H). 13C NMR(100MHz,CDCl 3):δ167.37,164.81,163.10,138.55,136.64,133.65,130.13,120.13,117.24,108.83,60.46,29.55,28.88,23.16,22.99,14.51,11.62,9.75.HRMS(ESI)calcd for:C 19H 22N 2O 2S[M+H] +343.1480,found 343.1477。 1 H NMR (400MHz, CDCl 3 ): δ7.56 (s, 1H), 7.09-7.03 (m, 2H), 7.01 (s, 1H), 4.32 (q, J = 7.2Hz, 2H), 3.06-3.00 (m, 1H), 2.78-2.76 (m, 4H), 1.81-1.80 (m, 4H), 1.36 (t, J = 7.2 Hz, 3H), 1.11 - 1.08 (m, 2H), 1.05-1.00 (m , 2H). 13 C NMR (100MHz, CDCl 3 ): δ 167.37, 164.81, 163.10, 138.55, 136.64, 133.65, 130.13, 120.13, 117.24, 108.83, 60.46, 29.55, 28.88, 23.16, 22.99, 14.51, 11.62, 9.75. HRMS (ESI) calcd for: C 19 H 22 N 2 O 2 S [M+H] + 343.1480, found 343.1477.
2-((2,3-二氢-1H-茚-5-基)氨基)-4-环丙基-5-噻唑甲酸乙酯(化合物50)Ethyl 2-((2,3-dihydro-1H-indol-5-yl)amino)-4-cyclopropyl-5-thiazolecarboxylate (Compound 50)
Figure PCTCN2018083596-appb-000066
Figure PCTCN2018083596-appb-000066
1H NMR(400MHz,CDCl 3):δ7.73(s,1H),7.22(s,1H),7.20(d,J＝8.00Hz,1H),7.07(d,J＝8.0Hz,1H),4.32(q,J＝7.2Hz,2H),3.06-3.00(m,1H),2.95–2.88(m,4H),2.15-2.08(m,2H),1.36(t,J＝7.2Hz,3H),1.11-1.08(m,2H),1.04–1.00(m,2H). 13C NMR(100MHz,CDCl 3):167.67,164.97,163.15,145.93,140.71,137.57,125.11,118.12,116.16,108.80,60.46,33.05,32.35,25.62,14.51,11.66,9.75.HRMS(ESI)calcd for:C 18H 20N 2O 2S[M-H] +327.1167,found 327.1169。 1 H NMR (400MHz, CDCl 3 ): δ7.73 (s, 1H), 7.22 (s, 1H), 7.20 (d, J = 8.00Hz, 1H), 7.07 (d, J = 8.0Hz, 1H), 4.32 (q, J = 7.2 Hz, 2H), 3.06-3.00 (m, 1H), 2.95 - 2.88 (m, 4H), 2.15 - 2.08 (m, 2H), 1.36 (t, J = 7.2 Hz, 3H) , 1.11-1.08 (m, 2H), 1.04 - 1.00 (m, 2H). 13 C NMR (100MHz, CDCl 3 ): 167.67, 164.97, 163.15, 145.93, 140.71, 137.57, 125.11, 118.12, 116.16, 108.80, 60.46 , 33.05, 32.35, 25.62, 14.51, 11.66, 9.75. HRMS (ESI) calcd for: C 18 H 20 N 2 O 2 S [MH] + 327.1167, found 327.1169.
2-(3,4-二甲基)苯胺基-4-叔丁基-5-噻唑甲酸乙酯(化合物51)Ethyl 2-(3,4-dimethyl)anilino-4-tert-butyl-5-thiazolecarboxylate (Compound 51)
Figure PCTCN2018083596-appb-000067
Figure PCTCN2018083596-appb-000067
1H NMR(400MHz,CDCl 3):δ7.16(d,J＝8.8Hz,1H),7.10(s,2H),4.28(q,J＝7.2Hz,2H),2.30(s,3H),2.27(s,3H),1.49(s,9H),1.35(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ170.04,165.38,161.71,138.05,137.17,132.74,130.59,120.84,116.74,109.63,60.70,36.39,29.27,20.02,19.92,19.20,14.41.HRMS(ESI)calcd for:C 18H 24N 2O 2S[M+H] +333.1637,found 333.1633。 1 H NMR (400MHz, CDCl 3 ): δ7.16 (d, J = 8.8Hz, 1H), 7.10 (s, 2H), 4.28 (q, J = 7.2Hz, 2H), 2.30 (s, 3H), 2.27(s,3H), 1.49(s,9H), 1.35(t,J=7.2Hz,3H). 13 C NMR (100MHz, CDCl 3 ): δ170.04, 165.38,161.71,138.05,137.17,132.74,130.59, 120.84, 116.74, 109.63, 60.70, 36.39, 29.27, 20.02, 19.92, 19.20, 14.41. HRMS (ESI) calcd for: C 18 H 24 N 2 O 2 S [M+H] + 333.1637, found 333.1633.
2-(3-氟-4-甲基)-苯胺基-4-叔丁基-5-噻唑甲酸乙酯(化合物52)Ethyl 2-(3-fluoro-4-methyl)-anilino-4-tert-butyl-5-thiazolecarboxylate (Compound 52)
Figure PCTCN2018083596-appb-000068
Figure PCTCN2018083596-appb-000068
1H NMR(400MHz,CDCl 3):δ7.20-7.15(m,2H),6.99(dd,J 1＝2.0Hz,J 2＝8.0Hz,1H),4.29(q,J＝7.2Hz,2H),2.28(s,3H),1.50(s,9H),1.37(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ169.59,163.87,162.69,161.51,160.25,138.49,138.38,132.08,132.01,120.23,120.05,114.06,114.03,110.43,106.05,105.78,60.90,36.44,29.26,14.37.HRMS(ESI)calcd for:C 17H 21FN 2O 2S[M-H] +335.1230,found 335.1223。 1 H NMR (400MHz, CDCl 3 ): δ7.20-7.15 (m, 2H), 6.99 (dd, J 1 = 2.0Hz, J 2 = 8.0Hz, 1H), 4.29 (q, J = 7.2Hz, 2H ), 2.28 (s, 3H), 1.50 (s, 9H), 1.37 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 169.59, 163.87, 162.69, 161.51, 160.25, 138.49, 138.38,132.08,132.01,120.23,120.05,114.06,114.03,110.43,106.05,105.78,60.90,36.44,29.26,14.37.HRMS(ESI)calcd for:C 17 H 21 FN 2 O 2 S[MH] + 335.1230, Found 335.1223.
2-(3-氯-4-甲基)-苯胺基-4-叔丁基-5-噻唑甲酸乙酯(化合物53)Ethyl 2-(3-chloro-4-methyl)-anilino-4-tert-butyl-5-thiazolecarboxylate (Compound 53)
Figure PCTCN2018083596-appb-000069
Figure PCTCN2018083596-appb-000069
1H NMR(400MHz,CDCl 3):δ7.47(d,J＝2.0Hz,1H),7.23(d,J＝8.4Hz,1H),7.16(dd,J 1＝2.4Hz,J 2＝8.4Hz,1H),4.29(q,J＝7.2Hz,2H),2.37(s,3H),1.49(s,9H),1.36(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ169.80,163.94,161.58,138.29,135.03,131.53,131.40,119.43,117.06,110.58,60.87,36.48,29.29,19.39,14.36.HRMS(ESI)calcd for:C 17H 21ClN 2O 2S[M-H] +351.0934,found 351.0937。 1 H NMR (400 MHz, CDCl 3 ): δ 7.47 (d, J = 2.0 Hz, 1H), 7.23 (d, J = 8.4 Hz, 1H), 7.16 (dd, J 1 = 2.4 Hz, J 2 = 8.4 Hz, 1H), 4.29 (q, J = 7.2 Hz, 2H), 2.37 (s, 3H), 1.49 (s, 9H), 1.36 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl) 3 ): δ169.80,163.94,161.58,138.29,135.03,131.53,131.40,119.43,117.06,110.58,60.87,36.48,29.29,19.39,14.36.HRMS(ESI)calcd for:C 17 H 21 ClN 2 O 2 S[ MH] + 351.0934, found 351.0937.
2-((5,6,7,8-四氢萘-2-基)氨基)-4-叔丁基-5-噻唑甲酸乙酯(化合物54)Ethyl 2-((5,6,7,8-tetrahydronaphthalen-2-yl)amino)-4-tert-butyl-5-thiazolecarboxylate (Compound 54)
Figure PCTCN2018083596-appb-000070
Figure PCTCN2018083596-appb-000070
1H NMR(400MHz,CDCl 3):δ7.11-7.07(m,2H),7.05(s,1H),4.28(q,J＝7.2Hz,2H),2.80-2.77(m,4H),1.83(s,4H),1.49(s,9H),1.35(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ169.81,165.27,161.64,138.62,136.68,133.51,130.20,119.82,116.88,109.62,60.71,36.35,29.25,26.64,23.16,22.99,14.40.HRMS(ESI)calcd for:C 20H 26N 2O 2S[M+H] +359.1793,found 359.1782。 1 H NMR (400MHz, CDCl 3 ): δ7.11-7.07 (m, 2H), 7.05 (s, 1H), 4.28 (q, J = 7.2Hz, 2H), 2.80-2.77 (m, 4H), 1.83 (s, 4H), 1.49 (s, 9H), 1.35 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 169.81, 165.27, 161.64, 138.62, 136.68, 133.51, 130.20, 119.82 , 116.88, 109.62, 60.71, 36.35, 29.25, 26.64, 23.16, 22.99, 14.40. HRMS (ESI) calcd for: C 20 H 26 N 2 O 2 S [M+H] + 359.1793, found 359.1782.
2-((2,3-二氢-1H-茚-5-基)氨基)-4-叔丁基-5-噻唑甲酸乙酯(化合物55)Ethyl 2-((2,3-dihydro-1H-indol-5-yl)amino)-4-tert-butyl-5-thiazolecarboxylate (Compound 55)
Figure PCTCN2018083596-appb-000071
Figure PCTCN2018083596-appb-000071
1H NMR(400MHz,CDCl 3):δ7.45(s,1H),7.25-7.21(m,2H),7.09(dd,J 1＝2.0Hz,J 2＝8.0Hz,1H),4.27(q,J＝7.2Hz,2H),2.97-2.90(m,4H),2.17-2.09(m,2H),1.49(s,9H),1.35(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):169.96,165.58,161.68,146.03,140.59,137.61,125.17,117.73,115.82,109.57,60.69,36.36,33.07,32.36,29.26,25.63,14.41.HRMS(ESI)calcd for:C 19H 24N 2O 2S[M-H] +343.1480,found 343.1482。 1 H NMR (400 MHz, CDCl 3 ): δ 7.45 (s, 1H), 7.25-7.21 (m, 2H), 7.09 (dd, J 1 = 2.0 Hz, J 2 = 8.0 Hz, 1H), 4.27 (q) , J=7.2 Hz, 2H), 2.97-2.90 (m, 4H), 2.17-2.09 (m, 2H), 1.49 (s, 9H), 1.35 (t, J = 7.2 Hz, 3H). 13 C NMR ( 100 MHz, CDCl 3 ): 169.96, 165.58, 161.68, 146.03, 140.59, 137.61, 125.17, 117.73, 115.82, 109.57, 60.69, 36.36, 33.07, 32.36, 29.26, 25.63, 14.41. HRMS (ESI) calcd for: C 19 H 24 N 2 O 2 S[MH] + 343.1480, found 343.1482.
实施例4：化合物56-75的合成Example 4: Synthesis of Compound 56-75
Figure PCTCN2018083596-appb-000072
Figure PCTCN2018083596-appb-000072
芳基硫脲的合成采用实例3流程中硫脲合成的方法。The synthesis of aryl thiourea was carried out by the method of thiourea synthesis in the procedure of Example 3.
取1mmol的取代苯基硫脲和1mmol的2-氯乙酰丙酮(2-氯乙酰乙酸乙酯)溶于20mL甲醇，回流过夜，旋干甲醇，加入少量稀碳酸钾水溶液中和，饱和食盐水洗涤，乙酸乙酯萃取，有机层浓缩干燥柱层析得产品。1 mmol of substituted phenylthiourea and 1 mmol of 2-chloroacetylacetone (2-chloroacetoacetate) were dissolved in 20 mL of methanol, refluxed overnight, and the methanol was spun dry, neutralized by adding a small amount of diluted potassium carbonate aqueous solution, and washed with saturated brine. The product was extracted with ethyl acetate, and the organic layer was concentrated and dried to give a product.
目标化合物谱图数据Target compound spectrum data
2-(3,4-甲基苯胺基)-4-甲基-5-乙酰基噻唑(化合物56)2-(3,4-methylanilino)-4-methyl-5-acetylthiazole (Compound 56)
Figure PCTCN2018083596-appb-000073
Figure PCTCN2018083596-appb-000073
1H NMR(400MHz,DMSO-d 6):δ10.58(s,1H),7.32(d,J＝8.0Hz,1H),7.28(s,1H),7.11(d,J＝8.4Hz,1H),2.53(s,3H),2.40(s,3H),2.21(s,3H),2.18(s,3H). 13C NMR(100MHz,DMSO-d 6):δ189.37,166.12,157.29,138.21,137.41,131.42,130.50,122.25,120.15,116.41, 56.50,30.12,20.16,19.22,18.94.HRMS(ESI)calcd for:C 14H 16N 2OS[M+H] +261.1062,found 261.1065。 1 H NMR (400MHz, DMSO- d 6): δ10.58 (s, 1H), 7.32 (d, J = 8.0Hz, 1H), 7.28 (s, 1H), 7.11 (d, J = 8.4Hz, 1H ), 2.53 (s, 3H), 2.40 (s, 3H), 2.21 (s, 3H), 2.18 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6 ): δ 189.37, 166.12, 157.29, 138.21. 137.41, 131.42, 130.50, 122.25, 120.15, 116.41, 56.50, 30.12, 20.16, 19.22, 18.94. HRMS (ESI) calcd for: C 14 H 16 N 2 OS [M+H] + 261.1062, found 261.1065.
2-(4-甲基-3-氯苯胺基)-4-甲基-5-乙酰基噻唑(化合物57)2-(4-Methyl-3-chloroanilino)-4-methyl-5-acetylthiazole (Compound 57)
Figure PCTCN2018083596-appb-000074
Figure PCTCN2018083596-appb-000074
1H NMR(400MHz,DMSO-d 6):δ10.79(s,1H),7.80(d,J＝2.0Hz,1H),7.75(dd,J 1＝2.4Hz,J 2＝8.4Hz,1H),7.30(d,J＝8.0Hz,1H),2.55(s,3H),2.42(s,3H),2.27(s,3H). 13C NMR(100MHz,DMSO-d 6):δ189.70,165.12,156.91,139.58,133.81,131.93,129.60,123.15,118.37,117.12,56.51,30.17,19.33,19.00,18.94.HRMS(ESI)calcd for:C 13H 13ClN 2OS[M+H] +281.0515,found 281.0515。 1 H NMR (400MHz, DMSO- d 6): δ10.79 (s, 1H), 7.80 (d, J = 2.0Hz, 1H), 7.75 (dd, J 1 = 2.4Hz, J 2 = 8.4Hz, 1H ), 7.30 (d, J = 8.0 Hz, 1H), 2.55 (s, 3H), 2.42 (s, 3H), 2.27 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6 ): δ 189.70, 165.12 ,156.91,139.58,133.81,131.93,129.60,123.15,118.37,117.12,56.51,30.17,19.33,19.00,18.94.HRMS(ESI)calcd for:C 13 H 13 ClN 2 OS[M+H] + 281.0515,found 281.0515.
2-(2-萘胺基)-4-甲基-5-乙酰基噻唑)(化合物58)2-(2-naphthylamino)-4-methyl-5-acetylthiazole) (Compound 58)
Figure PCTCN2018083596-appb-000075
Figure PCTCN2018083596-appb-000075
1H NMR(400MHz,DMSO-d 6):δ 1H NMR(400MHz,DMSO-d 6):δ11.02(s,1H),8.25(d,J＝2.0Hz,1H),7.91(d,J＝8.8Hz,1H),7.85(d,J＝8.8Hz,2H),7.61(dd,J 1＝2.4Hz,J 2＝8.8Hz,1H),7.51–7.47(m,1H),7.43–7.39(m,1H),2.62(s,3H),2.46(s,3H). 13C NMR(100MHz,DMSO-d 6):189.71,165.44,157.06,138.10,134.08,129.86,129.37,128.02,127.62,127.15,124.97,123.03,119.93,113.72,30.23,19.01.HRMS(ESI)calcd for:C 16H 14N 2OS[M+H] +283.0905,found 283.0903。 1 H NMR (400MHz, DMSO- d 6): δ 1 H NMR (400MHz, DMSO-d 6): δ11.02 (s, 1H), 8.25 (d, J = 2.0Hz, 1H), 7.91 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 8.8 Hz, 2H), 7.61 (dd, J 1 = 2.4 Hz, J 2 = 8.8 Hz, 1H), 7.51 - 7.47 (m, 1H), 7.43 - 7.39 (m, 1H), 2.62 (s, 3H), 2.46 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6 ): 189.71, 165.44, 157.06, 138.10, 134.08, 129.86, 129.37, 128.02, 127.62 , 127.15, 124.97, 123.03, 119.93, 113.72, 30.23, 19.01. HRMS (ESI) calcd for: C 16 H 14 N 2 OS [M+H] + 283.0905, found 283.0903.
2-(4-溴-3-三氟甲基苯胺基)-4-甲基-5-乙酰基噻唑(化合物59)2-(4-Bromo-3-trifluoromethylanilino)-4-methyl-5-acetylthiazole (Compound 59)
Figure PCTCN2018083596-appb-000076
Figure PCTCN2018083596-appb-000076
1H NMR(400MHz,DMSO-d 6):δ11.12(s,1H),8.25(s,1H),7.82(s,2H),2.57(s,3H),2.45(s,3H). 13C NMR(100MHz,DMSO-d 6):189.95,164.44,156.51,140.27,136.01,129.32,129.01,124.60,124.00,122.80,121.88,117.20,117.14,110.48,56.51,30.16,18.88.HRMS(ESI)calcd for:C 13H 10BrF 3N 2OS[M+H] +378.9728,found 378.9724。 1 H NMR (400MHz, DMSO- d 6):. Δ11.12 (s, 1H), 8.25 (s, 1H), 7.82 (s, 2H), 2.57 (s, 3H), 2.45 (s, 3H) 13 C NMR (100 MHz, DMSO-d 6 ): 189.95, 164.44, 156.51, 140.27, 136.01, 129.32, 129.01, 124.60, 124.00, 122.80, 121.88, 117.20, 117.14, 110.48, 56.51, 30.16, 18.88.HRMS(ESI)calcd For: C 13 H 10 BrF 3 N 2 OS [M+H] + 378.9728, found 378.9724.
2-(4-溴苯胺基)-4-甲基-5-乙酰基噻唑(化合物60)2-(4-bromoanilino)-4-methyl-5-acetylthiazole (Compound 60)
Figure PCTCN2018083596-appb-000077
Figure PCTCN2018083596-appb-000077
1H NMR(400MHz,DMSO-d 6):δ10.87(s,1H),7.61(d,J＝8.8Hz,2H),7.53(d,J＝8.8Hz,2H),2.56(s,3H),2.44(s,3H). 13C NMR(100MHz,DMSO-d 6):189.26,164.55,156.38,139.30,131.78,122.76,119.81,113.93,56.01,29.68,18.41.HRMS(ESI)calcd for:C 12H 11BrN 2OS[M+H] +310.9854,found 310.9854。 1 H NMR (400MHz, DMSO- d 6): δ10.87 (s, 1H), 7.61 (d, J = 8.8Hz, 2H), 7.53 (d, J = 8.8Hz, 2H), 2.56 (s, 3H ), 2.44(s,3H). 13 C NMR (100MHz, DMSO-d 6 ): 189.26, 164.55, 156.38, 139.30, 131.78, 122.76, 119.81, 113.93, 56.01, 29.68, 18.41. HRMS (ESI)calcd for: C 12 H 11 BrN 2 OS [M+H] + 310.9854, found 310.9854.
2-(苯胺基)-4-甲基-5-乙酰基噻唑(化合物61)2-(anilino)-4-methyl-5-acetylthiazole (Compound 61)
Figure PCTCN2018083596-appb-000078
Figure PCTCN2018083596-appb-000078
1H NMR(400MHz,DMSO-d 6):δ10.74(s,1H),7.60(d,J＝8.0Hz,2H),7.37(t,J＝8.0Hz,2H),7.05(t,J＝7.2Hz,1H),2.56(s,3H),2.43(s,3H). 13C NMR(100MHz,DMSO-d 6):189.67,165.69,157.17,140.41,129.62,123.28,122.71,118.62,56.54,30.12,18.90.HRMS(ESI)calcd for:C 12H 12N 2OS[M+H] +233.0749,found 233.0746。 1 H NMR (400MHz, DMSO- d 6): δ10.74 (s, 1H), 7.60 (d, J = 8.0Hz, 2H), 7.37 (t, J = 8.0Hz, 2H), 7.05 (t, J = 7.2 Hz, 1H), 2.56 (s, 3H), 2.43 (s, 3H). 13 C NMR (100MHz, DMSO-d 6 ): 189.67, 165.69, 157.17, 140.41, 129.62, 123.28, 122.71, 118.62, 56.54 , 30.12, 18.90. HRMS (ESI) calcd for: C 12 H 12 N 2 OS [M+H] + 233.0749, found 233.0746.
2-(2-蒽胺基)-4-甲基-5-乙酰基噻唑(化合物62)2-(2-Amidino)-4-methyl-5-acetylthiazole (Compound 62)
Figure PCTCN2018083596-appb-000079
Figure PCTCN2018083596-appb-000079
1H NMR(400MHz,DMSO-d 6):δ11.06(s,1H),8.51–8.47(m,3H),8.10–8.04(m,3H),7.57–7.45(m,3H),2.65(s,3H),2.48(s,3H). 13C NMR(100MHz,DMSO-d 6):189.86,165.15,157.07,137.37,132.38,132.18,130.81,129.86,128.66,128.56,128.10,126.45,126.25,125.40,125.21,123.30,121.03,112.01,30.22,18.98.HRMS(ESI)calcd for:C 20H 16N 2OS[M+H] +333.1062,found 333.1057。 1 H NMR (400MHz, DMSO- d 6): δ11.06 (s, 1H), 8.51-8.47 (m, 3H), 8.10-8.04 (m, 3H), 7.57-7.45 (m, 3H), 2.65 ( s, 3H), 2.48 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6 ): 189.86, 165.15, 157.07, 137.37, 132.38, 132.18, 130.81, 129.86, 128.66, 128.56, 128.10, 126.45, 126.25, 125.40, 125.21, 123.30, 121.03, 112.01, 30.22, 18.98. HRMS (ESI) calcd for: C 20 H 16 N 2 OS [M+H] + 333.1062, found 333.1057.
2-(9-乙基-9H-咔唑-3-氨基)-4-甲基-5-乙酰基噻唑(化合物63)2-(9-ethyl-9H-carbazole-3-amino)-4-methyl-5-acetylthiazole (compound 63)
Figure PCTCN2018083596-appb-000080
Figure PCTCN2018083596-appb-000080
1H NMR(400MHz,DMSO-d 6):δ10.68(s,1H),8.33(s,1H),8.13(d,J＝8.0Hz,1H),7.65-7.55(m,3H),7.47(t,J＝7.2Hz,1H),7.20(t,J＝7.2Hz,1H),4.47-4.42(m,2H)，2.57(s,3H),2.40(s,3H),1.32(t,J＝6.0Hz,3H).HRMS(ESI)calcd for C 20H 19N 3OS[M+H] +350.1327,found 350.1319。 1 H NMR (400MHz, DMSO- d 6): δ10.68 (s, 1H), 8.33 (s, 1H), 8.13 (d, J = 8.0Hz, 1H), 7.65-7.55 (m, 3H), 7.47 (t, J = 7.2 Hz, 1H), 7.20 (t, J = 7.2 Hz, 1H), 4.47 - 4.42 (m, 2H), 2.57 (s, 3H), 2.40 (s, 3H), 1.32 (t, J = 6.0 Hz, 3H). HRMS (ESI) calcd for C 20 H 19 N 3 OS [M+H] + 350.1327, found 350.1319.
2-(4-乙氧基苯胺基)-4-甲基-5-乙酰基噻唑(化合物64)2-(4-ethoxyanilino)-4-methyl-5-acetylthiazole (compound 64)
Figure PCTCN2018083596-appb-000081
Figure PCTCN2018083596-appb-000081
1H NMR(400MHz,DMSO-d 6):δ7.40(d,J＝8.4Hz,2H),7.91(d,J＝8.8Hz,2H),4.02-3.97(m,2H),2.50(s,3H),2.36(s,3H),1.32(t,J＝6.8Hz,3H).HRMS(ESI)calcd for C 14H 16N 2O 2S[M+H] +277.1011,found 277.1009。 1 H NMR (400MHz, DMSO- d 6): δ7.40 (d, J = 8.4Hz, 2H), 7.91 (d, J = 8.8Hz, 2H), 4.02-3.97 (m, 2H), 2.50 (s , 3H), 2.36 (s, 3H), 1.32 (t, J = 6.8 Hz, 3H). HRMS (ESI) calcd for C 14 H 16 N 2 O 2 S [M+H] + 277.1011, found 277.1009.
2-(4-叔丁基苯胺基)-4-甲基-5-乙酰基噻唑(化合物65)2-(4-tert-butylanilino)-4-methyl-5-acetylthiazole (Compound 65)
Figure PCTCN2018083596-appb-000082
Figure PCTCN2018083596-appb-000082
1H NMR(400MHz,DMSO-d 6):δ7.49(d,J＝8.4Hz,2H),7.38(d,J＝8.8Hz,2H),2.54(s,3H),2.42(s,3H),1.28(s,9H).HRMS(ESI)calcd for:C 16H 20N 2OS[M+H] +289.1375,found 289.1374。 1 H NMR (400MHz, DMSO- d 6): δ7.49 (d, J = 8.4Hz, 2H), 7.38 (d, J = 8.8Hz, 2H), 2.54 (s, 3H), 2.42 (s, 3H ), 1.28 (s, 9H). HRMS (ESI) calcd for: C 16 H 20 N 2 OS [M+H] + 289.1375, found 289.1374.
2-(4-氯-3-三氟甲基苯胺基)-4-甲基-5-乙酰基噻唑(化合物66)2-(4-Chloro-3-trifluoromethylanilino)-4-methyl-5-acetylthiazole (Compound 66)
Figure PCTCN2018083596-appb-000083
Figure PCTCN2018083596-appb-000083
1H NMR(400MHz,DMSO-d 6):δ11.13(s,1H),8.26(d,J＝2.4Hz,1H),7.91(dd,J 1＝2.4Hz,J 2＝8.8Hz,1H),7.69(d,J＝8.8Hz,1H),2.58(s,3H),2.46(s,3H). 13C NMR(100MHz,DMSO-d 6):189.92,164.46,156.50,139.80,132.61,127.51,127.20,124.49,123.95,123.03,122.66,121.77,116.80,116.74,56.51,30.11,18.85.HRMS(ESI)calcd for:C 13H 10ClF 3N 2OS[M+H] +335.0233,found 335.0231。 1 H NMR (400 MHz, DMSO-d 6 ): δ 11.13 (s, 1H), 8.26 (d, J = 2.4 Hz, 1H), 7.91 (dd, J 1 = 2.4 Hz, J 2 = 8.8 Hz, 1H ), 7.69 (d, J = 8.8 Hz, 1H), 2.58 (s, 3H), 2.46 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6 ): 189.92, 164.46, 156.50, 139.80, 132.61, 127.51, 127.20, 124.49, 123.95, 123.03, 122.66, 121.77, 116.80, 116.74, 56.51, 30.11, 18.85. HRMS (ESI) calcd for: C 13 H 10 ClF 3 N 2 OS[M+H] + 335.0233, found 335.0231 .
2-(4-乙氧基苯胺基)-4-甲基-5-甲酸乙酯噻唑(化合物67)2-(4-ethoxyanilino)-4-methyl-5-carboxylic acid ethyl ester thiazole (compound 67)
Figure PCTCN2018083596-appb-000084
Figure PCTCN2018083596-appb-000084
1H NMR(400MHz,DMSO-d 6):δ7.45(d,J＝9.2Hz,2H),6.92(d,J＝8.8Hz,2H),4.21-4.16(m,2H),4.02-3.97(m,2H),2.46(s,3H),1.32(t,J＝6.8Hz,3H),1.25(t,J＝7.2Hz,3H)。HRMS(ESI)calcd for:C 15H 18N 2O 3S[M+H] +307.1116,found 307.1114。 1 H NMR (400MHz, DMSO- d 6): δ7.45 (d, J = 9.2Hz, 2H), 6.92 (d, J = 8.8Hz, 2H), 4.21-4.16 (m, 2H), 4.02-3.97 (m, 2H), 2.46 (s, 3H), 1.32 (t, J = 6.8 Hz, 3H), 1.25 (t, J = 7.2 Hz, 3H). HRMS (ESI) calcd for: C 15 H 18 N 2 O 3 S [M+H] + 307.1116, found 307.1114.
2-(3,4-甲基苯胺基)-4-甲基-5-甲酸乙酯噻唑(化合物68)2-(3,4-methylanilino)-4-methyl-5-carboxylic acid ethyl ester thiazole (compound 68)
Figure PCTCN2018083596-appb-000085
Figure PCTCN2018083596-appb-000085
1H NMR(400MHz,CDCl 3):δ7.20-7.13(m,1H),7.07(d,J＝2.0Hz,2H),4.27(q,J＝7.2Hz,2H),2.55(s,3H),2.30(s,3H),2.26(s,3H),1.32(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ169.59,162.67,158.71,138.14,137.23,133.86,130.69,122.80,118.80,60.47,19.91,19.26,17.42,14.44.HRMS(ESI)calcd for:C 15H 18N 2O 2S[M+H] +291.1167,found 291.1164。 1 H NMR (400 MHz, CDCl 3 ): δ 7.20-7.13 (m, 1H), 7.07 (d, J = 2.0 Hz, 2H), 4.27 (q, J = 7.2 Hz, 2H), 2.55 (s, 3H) ), 2.30 (s, 3H), 2.26 (s, 3H), 1.32 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 169.59, 162.67, 158.71, 138.14, 137.23, 133.86, 130.69, 122.80, 118.80, 60.47, 19.91, 19.26, 17.42, 14.44. HRMS (ESI) calcd for: C 15 H 18 N 2 O 2 S [M+H] + 291.1167, found 291.1164.
2-((9-乙基-9H-咔唑-3-氨基)-4-甲基-5-甲酸乙酯噻唑(化合物69)2-((9-Ethyl-9H-carbazol-3-amino)-4-methyl-5-carboxylic acid ethyl ester thiazole (Compound 69)
Figure PCTCN2018083596-appb-000086
Figure PCTCN2018083596-appb-000086
1H NMR(400MHz,DMSO-d 6):δ10.57(s,1H),8.32(d,J＝1.6Hz,1H),8.13(d,J＝7.6Hz,1H),7.65-7.55(m,3H),7.47(d,J＝7.6Hz,1H),7.20(d,J＝7.6Hz,1H),4.47-4.42(m,2H),4.22-4.16(m,2H),2.54(s,3H),1.33(t,J＝7.2Hz,3H),1.25(t,J＝7.2Hz,3H).HRMS(ESI)calcd for:C 21H 21N 3O 2S[M+H] +380.1433,found 380.1436。 1 H NMR (400MHz, DMSO- d 6): δ10.57 (s, 1H), 8.32 (d, J = 1.6Hz, 1H), 8.13 (d, J = 7.6Hz, 1H), 7.65-7.55 (m , 3H), 7.47 (d, J = 7.6 Hz, 1H), 7.20 (d, J = 7.6 Hz, 1H), 4.47 - 4.42 (m, 2H), 4.22-4.16 (m, 2H), 2.54 (s, 3H), 1.33 (t, J = 7.2 Hz, 3H), 1.25 (t, J = 7.2 Hz, 3H). HRMS (ESI) calcd for: C 21 H 21 N 3 O 2 S[M+H] + 380.1433 , found 380.1436.
2-(4-甲基3-氯苯胺基)-4-甲基-5-甲酸乙酯噻唑(化合物70)2-(4-methyl 3-chloroanilino)-4-methyl-5-carboxylic acid ethyl ester thiazole (compound 70)
Figure PCTCN2018083596-appb-000087
Figure PCTCN2018083596-appb-000087
1H NMR(400MHz,DMSO-d 6):δ7.82(d,J＝2.0Hz,1H),7.40(dd,J 1＝2.0Hz,J 2＝8.4Hz,1H),7.31(d,J＝8.4Hz,1H),4.22(q,J＝7.2Hz,2H),2.53(s,3H),2.28(s,3H),1.27(t,J＝7.2Hz,3H). 13C NMR(100MHz,DMSO-d 6):164.97,162.26,158.85,139.71,133.77,131.93,129.41,118.29,117.05,109.86,60.79,19.33,17.83,14.74.HRMS(ESI)calcd for:C 14H 15ClN 2O 2S[M+H] +311.0621,found 311.0620。 1 H NMR (400MHz, DMSO- d 6): δ7.82 (d, J = 2.0Hz, 1H), 7.40 (dd, J 1 = 2.0Hz, J 2 = 8.4Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 4.22 (q, J = 7.2 Hz, 2H), 2.53 (s, 3H), 2.28 (s, 3H), 1.27 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz , DMSO-d 6 ): 164.97, 162.26, 158.85, 139.71, 133.77, 131.93, 129.41, 118.29, 117.05, 109.86, 60.79, 19.33, 17.83, 14.74. HRMS (ESI) calcd for: C 14 H 15 ClN 2 O 2 S[M+H] + 311.0621, found 311.0620.
2-(4-溴苯胺基)-4-甲基-5-甲酸乙酯噻唑(化合物71)2-(4-bromoanilino)-4-methyl-5-carboxylic acid ethyl ester thiazole (compound 71)
Figure PCTCN2018083596-appb-000088
Figure PCTCN2018083596-appb-000088
1H NMR(400MHz,DMSO-d 6):δ7.62(d,J＝8.8Hz,2H),7.52(d,J＝8.8Hz,2H),4.22(q,J＝7.2Hz,2H),2.53(s,3H),1.27(t,J＝7.2Hz,3H). 13C NMR(100MHz,DMSO-d 6):164.89, 162.26,158.70,139.96,132.23,120.23,114.20,109.97,60.78,17.78,14.73.HRMS(ESI)calcd for:C 13H 13BrN 2O 2S[M+H] +340.9959,found 340.9951。 1 H NMR (400MHz, DMSO- d 6): δ7.62 (d, J = 8.8Hz, 2H), 7.52 (d, J = 8.8Hz, 2H), 4.22 (q, J = 7.2Hz, 2H), 2.53 (s, 3H), 1.27 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, DMSO-d 6 ): 164.89, 162.26, 158.70, 139.96, 132.23, 120.23, 114.20, 109.97, 60.78, 17.78 , 14.73. HRMS (ESI) calcd for: C 13 H 13 BrN 2 O 2 S [M+H] + 340.9959, found 340.9951.
2-(2-蒽胺基)-4-甲基-5-甲酸乙酯噻唑(化合物72)2-(2-guanidino)-4-methyl-5-carboxylic acid ethyl ester thiazole (compound 72)
Figure PCTCN2018083596-appb-000089
Figure PCTCN2018083596-appb-000089
1H NMR(400MHz,DMSO-d 6):δ8.51–8.46(m,3H),8.10–8.05(m,3H),7.56–7.46(m,3H),4.25(q,J＝7.2Hz,2H),2.62(s,3H),1.30(t,J＝7.2Hz,3H). 13C NMR(100MHz,DMSO-d 6):δ189.86,165.15,157.07,137.37,132.38,132.18,130.81,129.86,128.66,128.56,128.10,126.45,126.25,125.40,125.21,123.30,121.03,112.01,18.98.HRMS(ESI)calcd for:C 21H 18N 2O 2S[M+H] +363.1167,found 363.1172。 1 H NMR (400MHz, DMSO- d 6): δ8.51-8.46 (m, 3H), 8.10-8.05 (m, 3H), 7.56-7.46 (m, 3H), 4.25 (q, J = 7.2Hz, 2H), 2.62 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, DMSO-d 6 ): δ 189.86, 165.15, 157.07, 137.37, 132.38, 132.18, 130.81, 129.86, 128.66, 128.56, 128.10, 126.45, 126.25, 125.40, 125.21, 123.30, 121.03, 112.01, 18.98. HRMS (ESI) calcd for: C 21 H 18 N 2 O 2 S [M+H] + 363.1167, found 363.1172.
2-((2,3-二氢-1H-茚-5-基)氨基)-4-甲基-5-噻唑甲酸乙酯(化合物73)Ethyl 2-((2,3-dihydro-1H-indol-5-yl)amino)-4-methyl-5-thiazolecarboxylate (Compound 73)
Figure PCTCN2018083596-appb-000090
Figure PCTCN2018083596-appb-000090
1H NMR(400MHz,CDCl 3):δ7.25(d,J＝8.0Hz,1H),7.21(s,1H),7.09(dd,J 1＝2.0Hz,J 2＝8.0Hz,1H),4.29(q,J＝7.2Hz,2H),2.97-2.91(m,4H),2.57(s,3H),2.17-2.10(m,2H),1.35(t,J＝6.8Hz,3H). 13C NMR(100MHz,CDCl 3):δ169.47,162.67,158.77,146.06,141.57,137.66,125.23,119.50,117.59,60.47,33.01,32.42,25.59,17.41,14.45.HRMS(ESI)calcd for:C 16H 18N 2O 2S[M+H] +303.1167,found 303.1163。 1 H NMR (400MHz, CDCl 3 ): δ7.25 (d, J = 8.0Hz, 1H), 7.21 (s, 1H), 7.09 (dd, J 1 = 2.0Hz, J 2 = 8.0Hz, 1H), 4.29 (q, J = 7.2 Hz, 2H), 2.97-2.91 (m, 4H), 2.57 (s, 3H), 2.17-2.10 (m, 2H), 1.35 (t, J = 6.8 Hz, 3H). 13 C NMR (100MHz, CDCl 3 ): δ 169.47, 162.67, 158.77, 146.06, 141.57, 137.66, 125.23, 119.50, 117.59, 60.47, 33.01, 32.42, 25.59, 17.41, 14.45. HRMS (ESI) calcd for: C 16 H 18 N 2 O 2 S[M+H] + 303.1167, found 303.1163.
2-(3-氟-4-甲基)-苯胺基-4-甲基-5-噻唑甲酸乙酯(化合物74)Ethyl 2-(3-fluoro-4-methyl)-anilino-4-methyl-5-thiazolecarboxylate (Compound 74)
Figure PCTCN2018083596-appb-000091
Figure PCTCN2018083596-appb-000091
1H NMR(400MHz,DMSO-d 6):δ10.73(s,1H),7.60(dd,J 1＝1.6Hz,J 2＝12.2Hz,1H),7.24(t,J＝8.4Hz,1H),7.19(dd,J 1＝2.0Hz,J 2＝8.4Hz,1H),4.21(q,J＝7.2Hz,2H),2.53(s,3H),2.18(q,J＝1.2Hz,3H),1.27(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ167.80,162.71,162.49,160.27,158.48,138.54,138.43,132.20,132.14,121.37,121.20,115.87,115.83,110.09,107.73,107.48,60.68,17.36,14.41,14.12,14.09.HRMS(ESI)calcd for:C 14H 15FN 2O 2S[M+H] +295.0917,found 295.0916。 1 H NMR (400MHz, DMSO- d 6): δ10.73 (s, 1H), 7.60 (dd, J 1 = 1.6Hz, J 2 = 12.2Hz, 1H), 7.24 (t, J = 8.4Hz, 1H ), 7.19 (dd, J 1 = 2.0 Hz, J 2 = 8.4 Hz, 1H), 4.21 (q, J = 7.2 Hz, 2H), 2.53 (s, 3H), 2.18 (q, J = 1.2 Hz, 3H) ), 1.27 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 167.80, 162.71, 162.49, 160.27, 158.48, 138.54, 138.43, 132.20, 132.14, 121.37, 121.20, 115.87, 115.83, 110.09, 107.73, 107.48, 60.68, 17.36, 14.41, 14.12, 14.09. HRMS (ESI) calcd for: C 14 H 15 FN 2 O 2 S [M+H] + 295.0917, found 295.0916.
2-((3,5-二氟-3’-甲氧基-[1,1’-联苯]-4-基)氨基)-4-甲基-5-噻唑甲酸乙酯(化合物75)Ethyl 2-((3,5-difluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)amino)-4-methyl-5-thiazolecarboxylate (Compound 75)
Figure PCTCN2018083596-appb-000092
Figure PCTCN2018083596-appb-000092
1H NMR(400MHz,CDCl 3):δ7.42(t,J＝8.0Hz,1H),7.27(s,3H),7.17(d,J＝7.6Hz,1H),6.99(dd,J 1＝2.0Hz,J 2＝8.0Hz,1H),4.28(q,J＝7.2Hz,2H),3.91(s,3H),2.59(s,3H),1.33(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ170.60,162.34,160.17,159.45,157.94,156.95,141.95,139.59,130.20,119.32,115.70,114.10,112.66,111.08,111.02,110.84,60.64,55.41,16.85,14.383.HRMS(ESI)calcd for:C 20H 18F 2N 2O 3S[M+H] +405.1084,found 405.1083。 1 H NMR (400 MHz, CDCl 3 ): δ 7.42 (t, J = 8.0 Hz, 1H), 7.27 (s, 3H), 7.17 (d, J = 7.6 Hz, 1H), 6.99 (dd, J 1 = 2.0 Hz, J 2 = 8.0 Hz, 1H), 4.28 (q, J = 7.2 Hz, 2H), 3.91 (s, 3H), 2.59 (s, 3H), 1.33 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 170.60, 162.34, 160.17, 159.45, 157.94, 156.95, 141.95, 139.59, 130.20, 119.32, 115.70, 114.10, 112.66, 111.08, 111.02, 110.84, 60.64, 55.41, 16.85, 14.383. HRMS (ESI) calcd for: C 20 H 18 F 2 N 2 O 3 S [M+H] + 405.1084, found 405.1083.
实施例5：化合物88-92的合成通法：Example 5: Synthesis of Compound 88-92:
Figure PCTCN2018083596-appb-000093
Figure PCTCN2018083596-appb-000093
芳基取代的异硫氰酸酯的合成采用实例3流程中NCS合成的方法。The synthesis of aryl-substituted isothiocyanates was carried out by the method of NCS synthesis in the procedure of Example 3.
将甲醇钠或者乙醇钠(41mmol)溶解在40mL甲醇或者乙醇中，冰浴条件下，将此溶液缓慢滴加至溶解有氰胺(41mmol)和取代异硫氰酸酯(41mmol)的乙醇(25mL)混合溶液中，搅拌过夜后，于反应液中滴加氯乙酸乙酯(41mmol)，继续搅拌过夜。待反应结束后，减压除去大量乙醇溶剂，粗品用乙酸乙酯和饱和食盐水萃取，收集到的有机相用无水硫酸钠干燥，旋蒸除去溶剂之后进一步用硅胶柱层析(PE/EA＝2/1，v/v)，得到白色纯品。Sodium methoxide or sodium ethoxide (41 mmol) was dissolved in 40 mL of methanol or ethanol, and the solution was slowly added dropwise to ethanol (25 mL) in which cyanamide (41 mmol) and substituted isothiocyanate (41 mmol) were dissolved in an ice bath. After the mixture was stirred overnight, ethyl chloroacetate (41 mmol) was added dropwise and the mixture was stirred overnight. After the reaction was completed, a large amount of ethanol solvent was removed under reduced pressure, and the crude product was extracted with ethyl acetate and brine, and the organic phase was dried over anhydrous sodium sulfate. =2/1, v/v), get white pure.
目标化合物谱图数据Target compound spectrum data
2-(3-氯-4-三氟甲基)-苯胺基-4-氨基-5-噻唑甲酸甲酯(化合物88)Methyl 2-(3-chloro-4-trifluoromethyl)-anilino-4-amino-5-thiazolecarboxylate (Compound 88)
Figure PCTCN2018083596-appb-000094
Figure PCTCN2018083596-appb-000094
1H NMR(400MHz,DMSO-d 6):δ11.00(s,1H),8.20(d,J＝2.4Hz,1H),7.91(dd,J 1＝2.4Hz,J  2＝8.8Hz,1H),7.67(d,J＝8.4Hz,1H),7.01(s,2H),3.32(s,3H). 13C NMR(100MHz,DMSO-d 6):δ164.75,164.17,139.79,132.67,127.59,127.29,124.52,123.25,123.07,121.80,117.25,117.20,117.14,51.17.HRMS(ESI)calcd for:C 12H 9ClF 3N 3O 2S[M+H] +352.0134,found 352.0130。 1 H NMR (400 MHz, DMSO-d 6 ): δ 11.00 (s, 1H), 8.20 (d, J = 2.4 Hz, 1H), 7.91 (dd, J 1 = 2.4 Hz, J 2 = 8.8 Hz, 1H ), 7.67 (d, J = 8.4 Hz, 1H), 7.01 (s, 2H), 3.32 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6 ): δ 164.75, 164.17, 139.79, 132.67, 127.59, 127.29, 124.52, 123.25, 123.07, 121.80, 117.25, 117.20, 117.14, 51.17. HRMS (ESI) calcd for: C 12 H 9 ClF 3 N 3 O 2 S [M+H] + 352.0134, found 352.0130.
2-(3-三氟甲基-4-氯)-苯胺基-4-氨基-5-噻唑甲酸乙酯(化合物89)Ethyl 2-(3-trifluoromethyl-4-chloro)-anilino-4-amino-5-thiazolecarboxylate (Compound 89)
Figure PCTCN2018083596-appb-000095
Figure PCTCN2018083596-appb-000095
1H NMR(400MHz,DMSO-d 6):δ10.98(s,1H),8.17(d,J＝2.4Hz,1H),7.92(dd,J 1＝2.4Hz,J  2＝8.8Hz,1H),7.67(d,J＝8.8Hz,1H),6.98(s,2H),4.15(q,J＝7.2Hz,2H),1.23(t,J＝7.2Hz,3H). 13C NMR(100MHz,DMSO-d 6):δ164.71,163.86,139.80,132.68,127.60,127.29,124.52,123.22,123.05,121.80,117.27,117.22,117.16,117.10,59.60,15.09.HRMS(ESI)calcd for:C 13H 11ClF 3N 3O 2S[M+H] +366.0291,found 366.0292。 1 H NMR (400MHz, DMSO- d 6): δ10.98 (s, 1H), 8.17 (d, J = 2.4Hz, 1H), 7.92 (dd, J 1 = 2.4Hz, J 2 = 8.8Hz, 1H ), 7.67 (d, J = 8.8 Hz, 1H), 6.98 (s, 2H), 4.15 (q, J = 7.2 Hz, 2H), 1.23 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz , DMSO-d 6 ): δ 164.71, 163.86, 139.80, 132.68, 127.60, 127.29, 124.52, 123.22, 123.05, 121.80, 117.27, 117.22, 117.16, 117.10, 59.60, 15.09. HRMS (ESI) calcd for: C 13 H 11 ClF 3 N 3 O 2 S[M+H] + 366.0291, found 366.0292.
2-(3,4-二甲基)-苯胺基-4-氨基-5-噻唑甲酸乙酯(化合物90)Ethyl 2-(3,4-dimethyl)-anilino-4-amino-5-thiazolecarboxylate (Compound 90)
Figure PCTCN2018083596-appb-000096
Figure PCTCN2018083596-appb-000096
1H NMR(400MHz,DMSO-d 6):δ10.40(s,1H),7.34(d,J＝9.6Hz,1H),7.31(s,1H),7.09(d,J＝8.4Hz,1H),6.89(s,2H),4.12(q,J＝7.2Hz,2H),2.21(s,3H),2.18(s,3H),1.21(t,J＝7.2Hz,3H). 13C NMR(100MHz,DMSO-d 6):δ166.06,163.90,138.14,137.29,131.40,130.37,120.46,116.76,59.30,20.14,19.22,15.14.HRMS(ESI)calcd for:C 14H 17N 3O 2S[M+H] +292.1120,found 292.1117。 1 H NMR (400MHz, DMSO- d 6): δ10.40 (s, 1H), 7.34 (d, J = 9.6Hz, 1H), 7.31 (s, 1H), 7.09 (d, J = 8.4Hz, 1H ), 6.89 (s, 2H), 4.12 (q, J = 7.2 Hz, 2H), 2.21 (s, 3H), 2.18 (s, 3H), 1.21 (t, J = 7.2 Hz, 3H). 13 C NMR (100MHz, DMSO-d 6 ): δ166.06, 163.90, 138.14, 137.29, 131.40, 130.37, 120.46, 116.76, 59.30, 20.14, 19.22, 15.14. HRMS (ESI) calcd for: C 14 H 17 N 3 O 2 S[ M+H] + 292.1120, found 292.1117.
2-(3,4-二氯)-苯胺基-4-氨基-5-噻唑甲酸乙酯(化合物91)Ethyl 2-(3,4-dichloro)-anilino-4-amino-5-thiazolecarboxylate (Compound 91)
Figure PCTCN2018083596-appb-000097
Figure PCTCN2018083596-appb-000097
1H NMR(400MHz,DMSO-d 6):δ10.87(s,1H),8.11(d,J＝2.4Hz,1H),7.73(d,J＝8.8Hz,1H),7.47(dd,J 1＝2.4Hz,J  2＝9.0Hz,1H),7.02(s,2H),4.14(q,J＝7.2Hz,2H),1.23(t,J＝7.2Hz,3H). 13C NMR(100MHz,DMSO-d 6):δ164.72,163.88,140.43,131.77,131.20,124.16,119.58,118.57,59.57,15.10.HRMS(ESI)calcd for:C 12H 11Cl 2N 3O 2S[M+H] +332.0027,found 332.0025。 1 H NMR (400MHz, DMSO- d 6): δ10.87 (s, 1H), 8.11 (d, J = 2.4Hz, 1H), 7.73 (d, J = 8.8Hz, 1H), 7.47 (dd, J 1 = 2.4 Hz, J 2 = 9.0 Hz, 1H), 7.02 (s, 2H), 4.14 (q, J = 7.2 Hz, 2H), 1.23 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz , DMSO-d 6 ): δ 164.72, 163.88, 140.43, 131.77, 131.20, 124.16, 119.58, 118.57, 59.57, 15.10. HRMS (ESI) calcd for: C 12 H 11 Cl 2 N 3 O 2 S[M+H] + 332.0027, found 332.0025.
2-(3-氟-4-甲基)-苯胺基-4-氨基-5-噻唑甲酸乙酯(化合物92)Ethyl 2-(3-fluoro-4-methyl)-anilino-4-amino-5-thiazolecarboxylate (Compound 92)
Figure PCTCN2018083596-appb-000098
Figure PCTCN2018083596-appb-000098
1H NMR(400MHz,DMSO-d 6):δ10.68(s,1H),7.68(d,J＝8.4Hz,1H),7.23(t,J＝8.4Hz,1H),7.16(dd,J＝1.6,8.0Hz,1H),6.97(s,2H),4.13(q,J＝7.2Hz,2H),2.18(s,3H),1.22(t,J＝7.2Hz,3H). 13C NMR(100MHz,DMSO-d 6):δ165.17,163.93,162.18,159.79,139.82,139.71,132.07,132.00,118.27,118.09,114.29,105.68,105.40,59.44,15.09,14.03.HRMS(ESI)calcd for:C 13H 14FN 3O 2S[M+H] +296.0869,found 296.0865。 1 H NMR (400MHz, DMSO- d 6): δ10.68 (s, 1H), 7.68 (d, J = 8.4Hz, 1H), 7.23 (t, J = 8.4Hz, 1H), 7.16 (dd, J =1.6, 8.0 Hz, 1H), 6.97 (s, 2H), 4.13 (q, J = 7.2 Hz, 2H), 2.18 (s, 3H), 1.22 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, DMSO-d 6 ): δ 165.17, 163.93, 162.18, 159.79, 139.82, 139.71, 132.07, 132.00, 118.27, 118.09, 114.29, 105.68, 105.40, 59.44, 15.09, 14.03. HRMS (ESI) calcd for: C 13 H 14 FN 3 O 2 S[M+H] + 296.0869, found 296.0865.
实施例6：化合物88-92的合成通法：Example 6: Synthesis of Compound 88-92:
Figure PCTCN2018083596-appb-000099
Figure PCTCN2018083596-appb-000099
称取4-氨基-2-(取代苯胺基)噻唑-5-甲酸乙酯(304μmol)于25mL单口烧瓶中，加入5mL甲苯，滴加15滴三乙胺，待搅拌均匀后，于冰浴条件下缓慢滴加对应的酰氯(456μmol)，滴加完毕，冰浴搅拌10min后，升温至90℃，继续反应，TLC跟踪至原料完全转化。将反应液降至室温，减压除去过量溶剂，得到的粗品进一步用硅胶柱层析(PE/EA＝4/1，v/v)，得到的淡黄色固体再用PE/EA重结晶。Weigh 4-amino-2-(substituted anilino)thiazole-5-carboxylic acid ethyl ester (304 μmol) in a 25 mL single-necked flask, add 5 mL of toluene, and add 15 drops of triethylamine dropwise, after stirring evenly, in ice bath conditions. The corresponding acid chloride (456 μmol) was slowly added dropwise, and the addition was completed. After stirring for 10 min in an ice bath, the mixture was warmed to 90 ° C, and the reaction was continued, and TLC was followed until the starting material was completely converted. The reaction mixture was cooled to room temperature, and the solvent was evaporated to dryness.
目标化合物谱图数据Target compound spectrum data
4-环丙酰胺基-2-(3,4-二甲基)-苯胺基-5-噻唑甲酸乙酯(化合物93)Ethyl 4-cyclopropionamido-2-(3,4-dimethyl)-anilino-5-thiazolecarboxylate (Compound 93)
Figure PCTCN2018083596-appb-000100
Figure PCTCN2018083596-appb-000100
1H NMR(400MHz,CDCl 3):δ7.31(d,J＝7.6Hz,1H),7.13(s,1H),7.10(d,J＝8.0Hz,1H),5.62(s,1H),4.27(q,J＝7.2Hz,2H),2.36(s,3H),2.35(s,3H),1.43-1.40(m,1H),1.33(t,J＝7.2Hz,3H),1.20–1.18(m,2H),0.84-0.81(m,2H). 13C NMR(100MHz,CDCl 3):δ173.98,165.07, 162.69,159.21,138.58,138.17,136.47,130.99,129.84,126.20,59.82,19.93,19.67,14.53,13.63,10.62.HRMS(ESI)calcd for:C 18H 21N 3O 3S[M+H] +360.1382,found 360.1388。 1 H NMR (400MHz, CDCl 3 ): δ7.31 (d, J = 7.6Hz, 1H), 7.13 (s, 1H), 7.10 (d, J = 8.0Hz, 1H), 5.62 (s, 1H), 4.27 (q, J = 7.2 Hz, 2H), 2.36 (s, 3H), 2.35 (s, 3H), 1.43-1.40 (m, 1H), 1.33 (t, J = 7.2 Hz, 3H), 1.20–1.18 (m, 2H), 0.84-0.81 (m, 2H). 13 C NMR (100MHz, CDCl 3 ): δ 173.98, 165.07, 162.69, 159.21, 138.58, 138.17, 136.47, 130.99, 129.84, 126.20, 59.82, 19.93, 19.67 , 14.53, 13.63, 10.62. HRMS (ESI) calcd for: C 18 H 21 N 3 O 3 S [M+H] + 360.1382, found 360.1388.
4-环丙酰胺基-2-(3,4-二氯)-苯胺基-5-噻唑甲酸乙酯(化合物94)Ethyl 4-cyclopropionamido-2-(3,4-dichloro)-anilino-5-thiazolecarboxylate (Compound 94)
Figure PCTCN2018083596-appb-000101
Figure PCTCN2018083596-appb-000101
1H NMR(400MHz,CDCl 3):δ7.66(d,J＝8.4Hz,1H),7.53(d,J＝2.4Hz,1H),7.26(dd,J 1＝2.4Hz,J  2＝8.8Hz,1H),4.28(q,J＝7.2Hz,2H),1.43-1.37(m,1H),1.34(t,J＝7.2Hz,3H),1.26-1.23(m,2H),0.95-0.90(m,2H). 13C NMR(100MHz,CDCl 3):δ173.00,165.07,161.88,158.80,138.10,133.92,133.87,131.55,131.33,128.70,60.04,14.50,13.87,10.92.HRMS(ESI)calcd for:C 16H 15Cl 2N 3O 3S[M+H] +400.0289,found 400.0289。 1 H NMR (400 MHz, CDCl 3 ): δ 7.66 (d, J = 8.4 Hz, 1H), 7.53 (d, J = 2.4 Hz, 1H), 7.26 (dd, J 1 = 2.4 Hz, J 2 = 8.8 Hz, 1H), 4.28 (q, J = 7.2 Hz, 2H), 1.43-1.37 (m, 1H), 1.34 (t, J = 7.2 Hz, 3H), 1.26-1.23 (m, 2H), 0.95-0.90 (m, 2H). 13 C NMR (100MHz, CDCl 3 ): δ 173.00, 165.07, 161.88, 158.80, 138.10, 133.92, 133.87, 131.55, 131.33, 128.70, 60.04, 14.50, 13.87, 10.92.HRMS(ESI)calcd for : C 16 H 15 Cl 2 N 3 O 3 S[M+H] + 400.0289, found 400.0289.
4-环丙酰胺基-2-(-三氟甲基-4-氯)-苯胺基-5-噻唑甲酸乙酯(化合物95)Ethyl 4-cyclopropionamido-2-(-trifluoromethyl-4-chloro)-anilino-5-thiazolecarboxylate (Compound 95)
Figure PCTCN2018083596-appb-000102
Figure PCTCN2018083596-appb-000102
1H NMR(400MHz,CDCl 3):δ7.73-7.71(m,2H),7.53(dd,J 1＝2.0Hz,J  2＝8.4Hz,1H),4.28(q,J＝7.20Hz,2H),1.36-1.32(m,4H),1.28-1.26(m,2H),0.94-0.89(m,2H). 13C NMR(100MHz,CDCl 3):δ172.82,164.89,161.82,158.73,137.63,133.80,133.46,133.10,130.27,129.95,128.81,128.75,128.70,128.65,123.50,120.78,60.07,14.49,13.98,10.95.HRMS(ESI)calcd for:C 17H 15ClF 3N 3O 3S[M+H] +434.0553,found 434.0556。 1 H NMR (400 MHz, CDCl 3 ): δ 7.73 - 7.71 (m, 2H), 7.53 (dd, J 1 = 2.0 Hz, J 2 = 8.4 Hz, 1H), 4.28 (q, J = 7.20 Hz, 2H) ), 1.36-1.32 (m, 4H), 1.28-1.26 (m, 2H), 0.94-0.89 (m, 2H). 13 C NMR (100MHz, CDCl 3 ): δ172.82, 164.89, 161.82, 158.73, 137.63, 133.80 , 133.46, 133.10, 130.27, 129.95, 128.81, 128.75, 128.70, 128.65, 123.50, 120.78, 60.07, 14.49, 13.98, 10.95. HRMS (ESI) calcd for: C 17 H 15 ClF 3 N 3 O 3 S[M+ H] + 434.0553, found 434.0556.
4-苯甲酰胺基-2-(3-三氟甲基-4-氯)-苯胺基-5-噻唑甲酸乙酯(化合物96)Ethyl 4-benzamide-2-(3-trifluoromethyl-4-chloro)-anilino-5-thiazolecarboxylate (Compound 96)
Figure PCTCN2018083596-appb-000103
Figure PCTCN2018083596-appb-000103
1H NMR(400MHz,CDCl 3):δ7.55(d,J＝2.4Hz,1H),7.48(d,J＝8.8Hz,1H),7.40-7.27(m,6H),5.63(s,2H),4.32(q,J＝7.2Hz,2H),1.38(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ169.13,164.83,161.83,158.70,138.11,133.95,133.26,132.59,132.23,131.17,129.39,129.12,129.07,129.01,128.96,128.43,128.34,123.38,120.66,60.25,14.55.HRMS(ESI)calcd for:C 20H 15ClF 3N 3O 3S[M+H] +470.0553,found 470.0554。 1 H NMR (400MHz, CDCl 3 ): δ7.55 (d, J = 2.4Hz, 1H), 7.48 (d, J = 8.8Hz, 1H), 7.40-7.27 (m, 6H), 5.63 (s, 2H ), 4.32 (q, J = 7.2 Hz, 2H), 1.38 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 169.13, 164.83, 161.83, 158.70, 138.11, 133.95, 133.26, 132.59,132.23,131.17,129.39,129.12,129.07,129.01,128.96,128.43,128.34,123.38,120.66,60.25,14.55.HRMS(ESI)calcd for:C 20 H 15 ClF 3 N 3 O 3 S[M+H ] + 470.0553, found 470.0554.
4-苯甲酰胺基-2-苯胺基-5-噻唑甲酸乙酯(化合物97)Ethyl 4-benzamide-2-anilino-5-thiazolecarboxylate (Compound 97)
Figure PCTCN2018083596-appb-000104
Figure PCTCN2018083596-appb-000104
1H NMR(400MHz,CDCl 3):δ7.40-7.30(m,6H),7.26-7.20(m,4H),5.64(s,2H),4.32(q,J＝7.2Hz,2H),1.38(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ169.64,165.02,162.63,159.07,139.38,134.03,130.60,129.68,129.17,128.78,128.59,127.89,60.06,14.60.HRMS(ESI)calcd for:C 19H 17N 3O 3S[M+H] +368.1069,found 368.1072。 1 H NMR (400MHz, CDCl 3 ): δ7.40-7.30 (m, 6H), 7.26-7.20 (m, 4H), 5.64 (s, 2H), 4.32 (q, J = 7.2Hz, 2H), 1.38 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 169.64, 165.02, 162.63, 159.07, 139.38, 134.03, 130.60, 129.68, 129.17, 128.78, 128.59, 127.89, 60.06, 14.60.HRMS (ESI) calcd for: C 19 H 17 N 3 O 3 S[M+H] + 368.1069, found 368.1072.
4-苯甲酰胺基-2-(3,4-二甲基)-苯胺基-5-噻唑甲酸乙酯(化合物98)Ethyl 4-benzamide-2-(3,4-dimethyl)-anilino-5-thiazolecarboxylate (Compound 98)
Figure PCTCN2018083596-appb-000105
Figure PCTCN2018083596-appb-000105
1H NMR(400MHz,CDCl 3):δ7.31(d,J＝8.0Hz,3H),7.21(t,J＝8.0Hz,2H),7.09(d,J＝8.0Hz,1H),6.99(s,1H),6.95(d,J＝8.0Hz,1H),5.67(s,2H),4.31(q,J＝7.2Hz,2H),2.25(s,3H),2.20(s,3H),1.37(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ169.77,165.03,162.97,159.19,137.68,137.43,136.88.HRMS(ESI)calcd for:C 21H 21N 3O 3S[M+H] +396.1382,found396.1381。 1 H NMR (400MHz, CDCl 3 ): δ7.31 (d, J = 8.0Hz, 3H), 7.21 (t, J = 8.0Hz, 2H), 7.09 (d, J = 8.0Hz, 1H), 6.99 ( s, 1H), 6.95 (d, J = 8.0 Hz, 1H), 5.67 (s, 2H), 4.31 (q, J = 7.2 Hz, 2H), 2.25 (s, 3H), 2.20 (s, 3H), 1.37 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 169.77, 165.03, 162.97, 159.19, 137.68, 137.43, 136.88. HRMS (ESI) calcd for: C 21 H 21 N 3 O 3 S[M+H] + 396.1382, found396.1381.
实施例7：化合物99-100的合成通法：Example 7: Synthesis of Compound 99-100:
Figure PCTCN2018083596-appb-000106
Figure PCTCN2018083596-appb-000106
称取4-苯基-2-(芳香胺基)噻唑-5-甲酸乙酯(617μmol)于25mL烧瓶中，加入3mL DMF，于氩气保护下加入NaH(1mmol)，待搅拌均匀后，将溶解于2mL DMF中的EtI(617μmol)滴加至反应液中，滴加完毕继续室温搅拌反应2h。待反应结束后，用饱和NH 4Cl水溶液淬灭反应，再用乙酸乙酯/饱和食盐水萃取反应液，得到的有机相用无水Na 2SO 4干燥，减压除去溶剂，得到的粗品进一步用硅胶柱层析(PE:EA＝15:1)，得到白色纯品。 Weigh 4-phenyl-2-(aromatic amino)thiazole-5-carboxylic acid ethyl ester (617 μmol) in a 25 mL flask, add 3 mL DMF, add NaH (1 mmol) under argon atmosphere, and after stirring evenly, EtI (617 μmol) dissolved in 2 mL of DMF was added dropwise to the reaction solution, and the reaction was stirred at room temperature for 2 h after the dropwise addition. After completion of the reaction, quenched with saturated aqueous NH 4 Cl the reaction quenched with ethyl acetate / aqueous reaction solution was extracted with saturated brine, dried Na 2 SO 4 resulting organic phase was dried over anhydrous, the solvent was removed under reduced pressure to give further crude product Chromatography on silica gel (PE: EA = 15:1) gave white solid.
目标化合物谱图数据Target compound spectrum data
2-(乙基(苯胺基))-4-苯基-5-噻唑甲酸乙酯(化合物99)Ethyl 2-(ethyl(anilino))-4-phenyl-5-thiazolecarboxylate (Compound 99)
Figure PCTCN2018083596-appb-000107
Figure PCTCN2018083596-appb-000107
1H NMR(400MHz,CDCl 3):δ7.80(dd,J 1＝2.4Hz,J  2＝8.0Hz,2H),7.55–7.51(m,2H),7.45–7.39(m,6H),4.19–4.08(m,4H),1.30(t,J＝7.2Hz,3H),1.21(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ170.44,161.95,159.51,143.88,134.93,130.30,129.87,128.86,128.19,127.52,127.36,110.41,60.47,47.44,14.23,13.15.HRMS(ESI)calcd for:C 20H 20N 2O 2S[M+H] +353.1324,found 353.1328。 1 H NMR (400 MHz, CDCl 3 ): δ 7.80 (dd, J 1 = 2.4 Hz, J 2 = 8.0 Hz, 2H), 7.55 - 7.51 (m, 2H), 7.45 - 7.39 (m, 6H), 4.19 -4.08 (m, 4H), 1.30 (t, J = 7.2 Hz, 3H), 1.21 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 170.44, 161.95, 159.51, 143.88, 134.93,130.30,129.87,128.86,128.19,127.52,127.36,110.41,60.47,47.44,14.23,13.15.HRMS(ESI)calcd for:C 20 H 20 N 2 O 2 S[M+H] + 353.1324,found 353.1328 .
2-(甲基(5,6,7,8-四氢萘-2-基)氨基)-4-苯基-5-噻唑甲酸乙酯(化合物100)Ethyl 2-(methyl(5,6,7,8-tetrahydronaphthalen-2-yl)amino)-4-phenyl-5-thiazolecarboxylate (Compound 100)
Figure PCTCN2018083596-appb-000108
Figure PCTCN2018083596-appb-000108
1H NMR(400MHz,CDCl 3):δ7.79(dd,J 1＝2.4Hz,J 2＝7.6Hz,2H),7.45-7.42(m,3H),7.18-7.13(m,3H),4.17(q,J＝7.2Hz,2H),3.58(s,3H),2.83(s,4H),1.86(s,4H),1.22(t,J＝7.2Hz,3H). 13C NMR(100MHz,CDCl 3):δ170.81,162.00,159.55,142.90,139.22,137.04,134.92,130.76,129.83,128.87,127.56,125.99,122.62,110.52,60.50,40.13,29.44,29.12,23.01,22.87,14.27.HRMS(ESI)calcd for:C 23H 24N 2O 2S[M+H] +393.1642,found 393.1637。 1 H NMR (400MHz, CDCl 3 ): δ7.79 (dd, J 1 = 2.4Hz, J 2 = 7.6Hz, 2H), 7.45-7.42 (m, 3H), 7.18-7.13 (m, 3H), 4.17 (q, J = 7.2 Hz, 2H), 3.58 (s, 3H), 2.83 (s, 4H), 1.86 (s, 4H), 1.22 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): δ 170.81, 162.00, 159.55, 142.90, 139.22, 137.04, 134.92, 130.76, 129.83, 128.87, 127.56, 125.99, 122.62, 110.52, 60.50, 40.13, 29.44, 29.12, 23.01, 22.87, 14.27. HRMS (ESI) Calcd for: C 23 H 24 N 2 O 2 S[M+H] + 393.1642, found 393.1637.
实施例8.目标化合物S1-S25的合成方法Example 8. Synthesis method of target compound S1-S25
1-(2-丙叉基)氨基硫脲1a1-(2-propionyl)thiosemicarbazide 1a
Figure PCTCN2018083596-appb-000109
Figure PCTCN2018083596-appb-000109
称取氨基硫脲(3.81g，41.8mmol)于100mL两口瓶，加入乙醇60mL，搅拌下加入丙酮(3.1mL，41.8mmol)，醋酸0.5mL，加热回流，TLC跟踪反应至原料转化完全。反应液降至室温，析出白色晶体，抽滤得粗品，用水重结晶，得纯品4.5g，产率82％。Aminothiourea (3.81 g, 41.8 mmol) was weighed into a 100 mL two-necked flask, 60 mL of ethanol was added, acetone (3.1 mL, 41.8 mmol), acetic acid 0.5 mL was added with stirring, and the mixture was heated under reflux, and the reaction was traced by TLC until the starting material was completely converted. The reaction solution was cooled to room temperature, white crystals were precipitated, and the crude product was obtained by suction filtration, and recrystallized from water to give a pure product of 4.5 g, yield 82%.
4-苯基-2-(2-丙叉基肼基)噻唑1c4-phenyl-2-(2-propionylfluorenyl)thiazole 1c
Figure PCTCN2018083596-appb-000110
Figure PCTCN2018083596-appb-000110
将得到的中间体1a(4.5g，34.3mmol)投入250mL圆底烧瓶，加入2-溴苯乙酮(7.5g，37.7mmol)，加75mL乙醇，磁力搅拌，加热回流，TLC跟踪反应，待原料转化完全，静置至室温，抽滤，得黄色粉末固体，干燥，得黄色粉末状固体，产率85％。The obtained intermediate 1a (4.5 g, 34.3 mmol) was placed in a 250 mL round bottom flask, 2-bromoacetophenone (7.5 g, 37.7 mmol) was added, 75 mL of ethanol was added, magnetic stirring was carried out, and the mixture was heated to reflux, and the reaction was followed by TLC. The conversion was complete, allowed to stand at room temperature and suction filtered to give a yellow powdery solid which was dried to give a yellow powdery solid.
4-苯基-2-肼基噻唑1d4-phenyl-2-mercaptothiazole 1d
Figure PCTCN2018083596-appb-000111
Figure PCTCN2018083596-appb-000111
称取原料1c(1.0g，4.3mmol)于50mL两口瓶，加乙醇30mL，加80％水合肼(0.6mL，12.3mmol)，氩气保护下加热回流，24h后停止反应，静置一夜，抽滤，得黄色晶体，所得粗品用乙醇重结晶，得浅黄色针状晶体300mg，产率36％。Weigh 1c (1.0g, 4.3mmol) of raw material in a 50mL two-necked flask, add 30mL of ethanol, add 80% hydrazine hydrate (0.6mL, 12.3mmol), heat under reflux with argon gas, stop the reaction after 24h, let stand overnight, pump Filtration gave yellow crystals, and the obtained crude material was recrystallized from ethanol to give crystals of pale yellow needle crystals (yield: 36%).
1H NMR(400MHz,DMSO-d 6,ppm):δ8.52(s,1H),7.79(d,J＝7.6Hz,2H),7.35(t,J＝7.6Hz,2H),7.24(t,J＝7.2Hz,1H),7.09(s,1H),4.82(s,2H). 1 H NMR (400MHz, DMSO- d 6, ppm): δ8.52 (s, 1H), 7.79 (d, J = 7.6Hz, 2H), 7.35 (t, J = 7.6Hz, 2H), 7.24 (t , J = 7.2 Hz, 1H), 7.09 (s, 1H), 4.82 (s, 2H).
(E)-4-苯基-2-(2-羧基苄叉肼基)噻唑S1(E)-4-phenyl-2-(2-carboxybenzylidene)thiazole S1
Figure PCTCN2018083596-appb-000112
Figure PCTCN2018083596-appb-000112
称取邻羧基苯甲醛(66mg，0.44mmol)于25mL茄形瓶，加入肼解产物1d(70mg，0.37mmol)，加入乙醇15mL，滴入两滴醋酸作催化剂，氩气保护下常温搅拌，TLC跟踪反应至原料转化完全，快速抽滤，滤饼用冰乙醇洗，得亮黄色粉末状固体100mg，产率85％。Mp 196.8-197.5℃.The o-carboxybenzaldehyde (66 mg, 0.44 mmol) was weighed into a 25 mL eggplant-shaped flask, and the decomposed product 1d (70 mg, 0.37 mmol) was added, 15 mL of ethanol was added, two drops of acetic acid were added as a catalyst, and the mixture was stirred at room temperature under argon atmosphere, TLC The reaction was traced until the conversion of the starting material was complete, and the mixture was filtered rapidly. The filter cake was washed with iced ethanol to give a bright yellow powdery solid 100 mg, yield 85%. Mp 196.8-197.5 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.45(br,1H),12.49(br,1H),8.81(s,1H),7.99(d,J＝7.6Hz,1H),7.87(m,3H),7.63(t,J＝7.4Hz,1H),7.47(t,J＝7.2Hz,1H),7.41(t,J＝7.6Hz,2H),7.33(s,1H),7.30(t,J＝7.4Hz,1H). 13C NMR(125MHz,DMSO-d 6,ppm):δ168.53,168.53,150.97,140.58,135.02,134.99,132.31,130.74,130.15,129.15,128.96,128.96,127.90,126.34,125.90,125.90,104.20.HRMS(ESI)calcd for C 18H 16N 3O 2S[M-H] -322.0650,found 322.0656. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.45 (br, 1H), 12.49 (br, 1H), 8.81 (s, 1H), 7.99 (d, J = 7.6Hz, 1H), 7.87 (m, 3H), 7.63 (t, J = 7.4 Hz, 1H), 7.47 (t, J = 7.2 Hz, 1H), 7.41 (t, J = 7.6 Hz, 2H), 7.33 (s, 1H), 7.30 (t, J = 7.4 Hz, 1H). 13 C NMR (125 MHz, DMSO-d 6, ppm): δ 168.53, 168.53, 150.97, 140.58, 135.02, 134.99, 132.31, 130.74, 130.15, 129.15, 128.96, 128.96, 127.90 , 126.34, 125.90, 125.90, 104.20. HRMS (ESI) calcd for C 18 H 16 N 3 O 2 S [MH] - 322.0650, found 322.0656.
(E)-4-苯基-2-(2-甲酰基苄叉肼基)噻唑S2(E)-4-phenyl-2-(2-formylbenzylidene)thiazole S2
Figure PCTCN2018083596-appb-000113
Figure PCTCN2018083596-appb-000113
称取邻苯二甲醛(105mg，0.78mmol)于50mL两口瓶中，加入15mL乙醇溶解，向溶液中加入1d(75mg，0.39mmol)，氩气保护下常温搅拌，约10min后出现亮黄色沉淀，TLC跟踪反应至原料转化完全，抽滤，滤饼用乙醇洗，干燥，得25mg产物，产率21％。O-phthalaldehyde (105 mg, 0.78 mmol) was weighed into a 50 mL two-necked flask, dissolved in 15 mL of ethanol, and 1 d (75 mg, 0.39 mmol) was added to the solution. The mixture was stirred at room temperature under argon atmosphere, and a bright yellow precipitate appeared after about 10 min. TLC followed the reaction until the starting material was completely converted, suction filtered, and the filter cake was washed with ethanol and dried to give 25 mg of product.
1H NMR(400MHz,DMSO-d 6,ppm):δ12.51(s,1H),10.26(s,1H),8.80(s,1H),7.97(d,J＝8Hz,1H),7.91(d,J＝7.6Hz,1H),7.87(d,J＝7.6Hz,1H),7.31(t,J＝7Hz,1H),7.61(t,J＝7.2Hz,1H),7.44-7.38(m,3H),7.31(t,J＝7.2Hz,1H). 13C NMR(125MHz,DMSO-d 6,ppm):δ193.96,168.45,151.18,139.07,135.35,135.04,134.08,133.74,132.82,129.60,129.10,129.10,128.07,127.43,126.01,126.01,104.63.2.5.HRMS(ESI)calcd for C 17H 14N 3O 2S[M+H] +308.0858,found 308.0853. 1 H NMR (400MHz, DMSO- d 6, ppm): δ12.51 (s, 1H), 10.26 (s, 1H), 8.80 (s, 1H), 7.97 (d, J = 8Hz, 1H), 7.91 ( d, J = 7.6 Hz, 1H), 7.87 (d, J = 7.6 Hz, 1H), 7.31 (t, J = 7 Hz, 1H), 7.61 (t, J = 7.2 Hz, 1H), 7.44 - 7.38 (m , 3H), 7.31 (t, J = 7.2 Hz, 1H). 13 C NMR (125 MHz, DMSO-d 6, ppm): δ 193.96, 168.45, 151.18, 139.07, 135.35, 135.04, 134.08, 133.74, 132.82, 129.60, 129.10,129.10,128.07,127.43,126.01,126.01,104.63.2.5.HRMS(ESI)calcd for C 17 H 14 N 3 O 2 S[M+H] + 308.0858,found 308.0853.
4-(2-氯苯基)-2-(2-丙叉基肼基)噻唑3c4-(2-chlorophenyl)-2-(2-propionylfluorenyl)thiazole 3c
Figure PCTCN2018083596-appb-000114
Figure PCTCN2018083596-appb-000114
合成方法同1c，得到乳黄色粉末状固体，产率80％。Synthetic method was the same as 1c to give a milky yellow powdery solid, yield 80%.
1H NMR(400MHz,CDCl 3,ppm):δ7.71(d,J＝7.4Hz,1H),7.52(d,J＝7.4Hz,1H),7.42(m,2H),7.00(s,1H),2.22(s,3H),2.13(s,3H). 1 H NMR (400MHz, CDCl 3 , ppm): δ7.71 (d, J = 7.4Hz, 1H), 7.52 (d, J = 7.4Hz, 1H), 7.42 (m, 2H), 7.00 (s, 1H ), 2.22 (s, 3H), 2.13 (s, 3H).
4-(2-氯苯基)-2-肼基噻唑3d4-(2-chlorophenyl)-2-mercaptothiazole 3d
Figure PCTCN2018083596-appb-000115
Figure PCTCN2018083596-appb-000115
合成方法同1d，得乳黄色针状晶体1.3g，产率48％。The synthesis method was the same as 1d, and the yellow needle-like crystals were obtained in an amount of 1.3 g, and the yield was 48%.
1H NMR(400MHz,DMSO-d 6,ppm):δ8.56(s,1H),7.84(dd,J 1＝7.6Hz,J 2＝2.0Hz,1H),7.48(dd,J 1＝7.6Hz,J 2＝1.6Hz,1H),7.36(td,J 1＝7.6Hz,J 2＝1.6Hz,1H),7.29(td,J 1＝7.6Hz,J 2＝2.0Hz,1H),7.14(s,1H),4.87(s,2H). 1 H NMR (400MHz, DMSO- d 6, ppm): δ8.56 (s, 1H), 7.84 (dd, J 1 = 7.6Hz, J 2 = 2.0Hz, 1H), 7.48 (dd, J 1 = 7.6 Hz, J 2 = 1.6 Hz, 1H), 7.36 (td, J 1 = 7.6 Hz, J 2 = 1.6 Hz, 1H), 7.29 (td, J 1 = 7.6 Hz, J 2 = 2.0 Hz, 1H), 7.14 (s, 1H), 4.87 (s, 2H).
(E)-4-(2-氯苯基)-2-(2-羧基苄叉肼基)噻唑S3(E)-4-(2-chlorophenyl)-2-(2-carboxybenzylidene)thiazole S3
Figure PCTCN2018083596-appb-000116
Figure PCTCN2018083596-appb-000116
合成路线同S1，得亮黄色粉末状固体3.6g，产率81％。Mp 195.2-195.2℃.The synthesis route was the same as that of S1, and 3.6 g of a bright yellow powdery solid was obtained with a yield of 81%. Mp 195.2-195.2 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.2(br,1H),12.4(br,1H),8.82(s,1H),8.00(d,J＝7.6Hz,1H),7.88(t,J＝7.0Hz,2H),7.64(t,J＝7.4Hz,1H),7.6(d,J＝7.6Hz,1H),7.48(t,J＝7.6Hz,1H),7.42(t,J＝7.8Hz,1H),7.36(m,2H). 13C NMR(100MHz,DMSO-d 6,ppm):δ168.63,167.77,147.63,140.76,135.08,133.71,132.43,131.54,131.23,130.83,130.83,130.26,129.47,129.28,127.69,126.47,109.26.HRMS(ESI)calcd for C 17H 13N 3O 2SCl[M+H] +358.0417,found 358.0417. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.2 (br, 1H), 12.4 (br, 1H), 8.82 (s, 1H), 8.00 (d, J = 7.6Hz, 1H), 7.88 (t, J = 7.0 Hz, 2H), 7.64 (t, J = 7.4 Hz, 1H), 7.6 (d, J = 7.6 Hz, 1H), 7.48 (t, J = 7.6 Hz, 1H), 7.42 (t , J = 7.8 Hz, 1H), 7.36 (m, 2H). 13 C NMR (100 MHz, DMSO-d 6, ppm): δ 168.63, 167.77, 147.63, 140.76, 135.08, 133.71, 132.43, 131.54, 131.23, 130.83, 130.83, 130.26, 129.47, 129.28, 127.69, 126.47, 109.26. HRMS (ESI) calcd for C 17 H 13 N 3 O 2 SCl [M+H] + 358.0417, found 358.0417.
5-甲基-4-苯基-2-肼基噻唑4d5-methyl-4-phenyl-2-mercaptothiazole 4d
Figure PCTCN2018083596-appb-000117
Figure PCTCN2018083596-appb-000117
称取中间体1a(1.5g，11.4mmol)于50mL圆底烧瓶，加15mL乙醇作溶剂，搅拌下加入2-溴苯丙酮(1.74mL，11.4mmol)，加热至回流，TLC跟踪反应至原料转化完全，静置至室温，抽滤，干燥，得黄色粉末1.96g，未经纯化，直接用于下一步。称取上一步产物(1.0g，4.1mmol)于50mL两口瓶，加乙醇20mL，加入新的80％水合肼(0.6mL，12.3mmol)，氩气保护下加热回流24h后，停止反应，反应液静置一夜，抽滤，所得粗品乙醇重结晶，得黄色针状晶体200mg，产率26％。 1H NMR(400MHz,DMSO-d6,ppm)：δ8.25(s,1H),7.56(d,J＝7.2Hz,2H),7.38(t,J＝7.6Hz,2H),7.27(t,J＝7.2Hz,1H),4.74(s,2H),2.35(s,3H). Intermediate 1a (1.5 g, 11.4 mmol) was weighed into a 50 mL round bottom flask, 15 mL of ethanol was added as a solvent, 2-bromopropiophenone (1.74 mL, 11.4 mmol) was added with stirring, and the mixture was heated to reflux. After completion, it was allowed to stand at room temperature, suction filtered, and dried to give a white powder, 1.96 g, which was used in the next step without purification. The product of the previous step (1.0 g, 4.1 mmol) was weighed into a 50 mL two-necked flask, 20 mL of ethanol was added, and a new 80% hydrazine hydrate (0.6 mL, 12.3 mmol) was added. After heating under reflux for 24 h under argon atmosphere, the reaction was stopped. After standing overnight, suction filtration, and the obtained crude ethanol was recrystallized to obtain 200 mg of yellow needle crystals, yield 26%. 1 H NMR (400MHz, DMSO- d6, ppm): δ8.25 (s, 1H), 7.56 (d, J = 7.2Hz, 2H), 7.38 (t, J = 7.6Hz, 2H), 7.27 (t, J = 7.2 Hz, 1H), 4.74 (s, 2H), 2.35 (s, 3H).
(E)-5-甲基-4-苯基-2-(2-羧基苄叉肼基)噻唑S4(E)-5-methyl-4-phenyl-2-(2-carboxybenzylidene)thiazole S4
Figure PCTCN2018083596-appb-000118
Figure PCTCN2018083596-appb-000118
合成方法同S1，得土黄色粉末状固体100mg，产率76％。Mp 215.9-216.0℃.The synthesis method was the same as that of S1, and 100 mg of a yellowish powdery solid was obtained, yield 76%. Mp 215.9-216.0 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ12.7(br,2H),8.77(s,1H),7.99(d,J＝7.6Hz,1H),7.87(d,J＝8.0Hz,1H),7.63-7.59(m,3H),7.48-7.43(m,3H),7.33(t,J＝7.2Hz,1H),2.43(s,3H). 13C NMR(125MHz,DMSO-d 6,ppm):δ168.66,164.72,146.00,140.05,135.64,135.24,132.36,130.83,130.12,129.08,128.73,128.73,128.35,128.35,127.51,126.33,117.61,12.74.HRMS(ESI)calcd for C 18H 16N 3O 2S[M+H] +338.0963,found 338.0954. 1 H NMR (400MHz, DMSO- d 6, ppm): δ12.7 (br, 2H), 8.77 (s, 1H), 7.99 (d, J = 7.6Hz, 1H), 7.87 (d, J = 8.0Hz , 1H), 7.63-7.59 (m, 3H), 7.48-7.43 (m, 3H), 7.33 (t, J = 7.2 Hz, 1H), 2.43 (s, 3H). 13 C NMR (125 MHz, DMSO-d 6, ppm): δ168.66, 164.72, 146.00, 140.05, 135.64, 135.24, 132.36, 130.83, 130.12, 129.08, 128.73, 128.73, 128.35, 128.35, 127.71, 126.33, 117.61, 12.74. HRMS (ESI) calcd for C 18 H 16 N 3 O 2 S[M+H] + 338.0963,found 338.0954.
2’-氯-2-溴苯丙酮5b2'-chloro-2-bromopropiophenone 5b
Figure PCTCN2018083596-appb-000119
Figure PCTCN2018083596-appb-000119
称取2-氯苯丙酮(0.55g，3.3mmol)于50mL单口瓶，加入5mL***作溶剂，滴入2滴醋酸，将液溴(0.18mL，3.4mmol)溶于适量***，冰浴下滴加，滴完后撤去冰浴，室温搅拌过夜。反应完全后，反应液用饱和NaCO 3萃取三次，有机层加无水NaSO 4干燥，旋干溶剂，得淡黄色液体。硅胶柱层析(PE/DCM＝4/1，v/v)分离，得产物0.68g，产率84％。 Weigh 2-chloropropiophenone (0.55g, 3.3mmol) in a 50mL single-mouth bottle, add 5mL of diethyl ether as a solvent, add 2 drops of acetic acid, and dissolve the liquid bromine (0.18mL, 3.4mmol) in an appropriate amount of ether. Add, after the completion of the dropwise addition, remove the ice bath and stir at room temperature overnight. After completion of the reaction, the reaction solution was added anhydrous extracted three times with saturated NaCO 3, the organic layer was dried NaSO 4, rotary evaporation to give a pale yellow liquid. Silica gel column chromatography (PE/DCM=4/1, v/v) eluted
1H NMR(400MHz,DMSO-d 6,ppm):δ7.81(d,J＝7.6Hz,1H),7.60-7.42(m,3H),5.61(q,J＝6.4Hz,1H),1.79(d,J＝6.8Hz,1H).GC-MS(EI)calcd for C 9H 8BrClO[M] +2547.5,found 248.0. 1 H NMR (400MHz, DMSO- d 6, ppm): δ7.81 (d, J = 7.6Hz, 1H), 7.60-7.42 (m, 3H), 5.61 (q, J = 6.4Hz, 1H), 1.79 (d, J = 6.8 Hz, 1H). GC-MS (EI) calcd for C 9 H 8 BrClO [M] + 2547.5, found 248.0.
5-甲基-4-(2-氯苯基)-2-肼基噻唑5d5-methyl-4-(2-chlorophenyl)-2-mercaptothiazole 5d
Figure PCTCN2018083596-appb-000120
Figure PCTCN2018083596-appb-000120
合成方法同4d，粗品经薄层硅胶制备板分离得绿色针状固体65mg，产率46％。The synthesis method was the same as that of 4d, and the crude product was separated into a green needle-like solid by a thin layer of silica gel, and the yield was 46%.
1H NMR(400MHz,DMSO-d 6,ppm):δ8.22(s,1H),7.51-7.49(m,1H),7.37-7.34(m,3H),4.74(s,2H),2.05(s,3H). 1 H NMR (400MHz, DMSO- d 6, ppm): δ8.22 (s, 1H), 7.51-7.49 (m, 1H), 7.37-7.34 (m, 3H), 4.74 (s, 2H), 2.05 ( s, 3H).
(E)-5-甲基-4-(2-氯苯基)-2-(2-羧基苄叉肼基)噻唑S5(E)-5-Methyl-4-(2-chlorophenyl)-2-(2-carboxybenzylidene)thiazole S5
Figure PCTCN2018083596-appb-000121
Figure PCTCN2018083596-appb-000121
合成方法同S1，得淡黄色粉末状固体60mg，产率80％。Mp 220.0-220.3℃.The synthesis method was the same as that of S1 to obtain 60 mg of a pale yellow powdery solid, yield 80%. Mp 220.0-220.3 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ12.7(br,2H),8.77(s,1H),7.99(d,J＝7.6Hz,1H),7.87(d,J＝7.2Hz,1H),7.62(t,J＝7.4Hz,1H),7.562-7.543(m,1H),7.481-7.397(m,4H),2.14(s,3H). 13C NMR(125MHz,DMSO-d 6,ppm):δ168.65,165.18,144.49,140.16,135.25,134.56,133.21,132.46,130.83,130.14,130.03,129.11,127.45,126.37,119.49,12.15.HRMS(ESI)calcd for C 18H 15N 3O 2SCl[M+H] +372.0574,found 372.0569. 1 H NMR (400MHz, DMSO- d 6, ppm): δ12.7 (br, 2H), 8.77 (s, 1H), 7.99 (d, J = 7.6Hz, 1H), 7.87 (d, J = 7.2Hz , 1H), 7.62 (t, J = 7.4 Hz, 1H), 7.562-7.543 (m, 1H), 7.481-7.397 (m, 4H), 2.14 (s, 3H). 13 C NMR (125 MHz, DMSO-d 6, ppm): δ168.65, 165.18, 144.49, 140.16, 135.25, 134.56, 133.21, 132.46, 130.83, 130.14, 130.03, 129.11, 127.45, 126.37, 119.49, 12.15. HRMS (ESI) calcd for C 18 H 15 N 3 O 2 SCl[M+H] + 372.0574, found 372.0569.
2’-氯-2-溴苯丁酮6b2'-Chloro-2-bromopyridinone 6b
Figure PCTCN2018083596-appb-000122
Figure PCTCN2018083596-appb-000122
称取2-氯苯丁酮(1.0g，5.5mmol)于50mL单口瓶中，加入5mL***，搅拌下滴入2滴冰醋酸，冰浴下滴入液溴(0.88g，5.5mmol)的***溶液，室温搅拌过夜，TLC跟踪反应至原料转化完全，反应液用饱和NaHCO 3萃取三次，饱和NaCl萃取三次，无水NaSO 4干燥，旋干溶剂，得1.04g黄色液体，产率89％。 2-Chlorobenzophenone (1.0 g, 5.5 mmol) was weighed into a 50 mL single-mouth bottle, 5 mL of diethyl ether was added, 2 drops of glacial acetic acid were added dropwise with stirring, and liquid bromine (0.88 g, 5.5 mmol) of diethyl ether was added dropwise thereto under ice bath. solution was stirred at room temperature overnight, TLC the reaction was followed to complete conversion of starting material, the reaction solution was extracted 3 times with saturated NaHC03, extracted three times with saturated NaCl, dried over anhydrous NaSO 4, rotary evaporation to give 1.04g yellow liquid, yield 89%.
1H NMR(400MHz,DMSO-d 6,ppm):δ7.80(d,J＝7.6Hz,1H),7.61-7.55(m,2H),7.48(t,J＝7.6Hz,1H),5.45(t,J＝6.8Hz,1H),2.19-2.12(m,1H),1.99-1.88(m,1H),1.04(t,J＝7.2Hz,3H). 1 H NMR (400MHz, DMSO- d 6, ppm): δ7.80 (d, J = 7.6Hz, 1H), 7.61-7.55 (m, 2H), 7.48 (t, J = 7.6Hz, 1H), 5.45 (t, J = 6.8 Hz, 1H), 2.19-2.12 (m, 1H), 1.99-1.88 (m, 1H), 1.04 (t, J = 7.2 Hz, 3H).
5-乙基-4-(2-氯苯基)-2-(2-丙叉基肼基)噻唑6c5-ethyl-4-(2-chlorophenyl)-2-(2-propionylfluorenyl)thiazole 6c
Figure PCTCN2018083596-appb-000123
Figure PCTCN2018083596-appb-000123
合成方法同1c，得棕色粘稠液体0.6g，产率85％。The synthesis method was the same as 1c, and the brown viscous liquid was 0.6 g, and the yield was 85%.
1H NMR(400MHz,DMSO-d 6,ppm):δ10.43(br,1H),7.54-7.52(m,1H),7.41-7.37(m,3H),2.44(q,J＝7.6Hz,2H),1.94(s,3H),1.89(s,3H),1.10(t,J＝7.4Hz,3H). 1 H NMR (400MHz, DMSO- d 6, ppm): δ10.43 (br, 1H), 7.54-7.52 (m, 1H), 7.41-7.37 (m, 3H), 2.44 (q, J = 7.6Hz, 2H), 1.94 (s, 3H), 1.89 (s, 3H), 1.10 (t, J = 7.4 Hz, 3H).
5-乙基-4-(2-氯苯基)-2-肼基噻唑6d5-ethyl-4-(2-chlorophenyl)-2-mercaptothiazole 6d
Figure PCTCN2018083596-appb-000124
Figure PCTCN2018083596-appb-000124
称取6c(0.6g,2.0mmol)于25mL单口瓶中，加入12mL乙醇，搅拌下加入80％水合肼(0.3mL,6.0mmol)，氩气保护下回流，TLC跟踪反应至原料转化完全，旋干溶剂，粗品硅胶柱层析(PE:DCM:MeOH＝30:20:3,v/v/v)分离，得棕色固体190mg，产率37％。LC-MS(ESI)calcd for C 11H 13ClN 3S[M+H] +254.05,found 254.10. Weigh 6c (0.6g, 2.0mmol) in a 25mL single-mouth bottle, add 12mL of ethanol, add 80% hydrazine hydrate (0.3mL, 6.0mmol) under stirring, reflux under argon gas protection, follow the reaction by TLC until the conversion of the raw materials is complete, spin Dry solvent, crude silica gel column chromatography (EtOAc:EtOAc:EtOAc:EtOAc LC-MS (ESI) calcd for C 11 H 13 ClN 3 S [M+H] + 254.05, found 254.10.
(E)-5-乙基-4-(2-氯苯基)-2-(2-羧基苄叉肼基)噻唑S6(E)-5-ethyl-4-(2-chlorophenyl)-2-(2-carboxybenzylidene)thiazole S6
Figure PCTCN2018083596-appb-000125
Figure PCTCN2018083596-appb-000125
合成方法同S1，得亮黄色粉末状固体70mg，产率68％。Mp 223.9-223.9℃.The synthesis method was the same as that of S1 to obtain a bright yellow powdery solid of 70 mg, yield 68%. Mp 223.9-223.9 ° C.
1H NMR(500MHz,DMSO-d 6,ppm):δ12.57(br,2H),8.79(s,1H),8.01(d,J＝8.0Hz,1H),7.88(d,J＝8.0Hz,1H),7.62(t,J＝7.5Hz,1H),7.56–7.51(m,1H),7.46(t,J＝7.5Hz,1H),7.44-7.36(m,3H),2.49(q,J＝7.5Hz,1H),1.13(t,J＝7.5Hz,3H). 13C NMR(125MHz,DMSO-d 6,ppm):δ169.28,165.92,144.14,140.84,135.89,135.46,133.99,133.03,133.02,131.46,130.81,130.73,130.60,129.73,128.09,127.73,127.01,20.99,17.25.HRMS(ESI)calcd for C 19H 17N 3O 2SCl[M+H] +386.0730,found 386.0729. 1 H NMR (500MHz, DMSO- d 6, ppm): δ12.57 (br, 2H), 8.79 (s, 1H), 8.01 (d, J = 8.0Hz, 1H), 7.88 (d, J = 8.0Hz , 1H), 7.62 (t, J = 7.5 Hz, 1H), 7.56 - 7.51 (m, 1H), 7.46 (t, J = 7.5 Hz, 1H), 7.44 - 7.36 (m, 3H), 2.49 (q, J = 7.5 Hz, 1H), 1.13 (t, J = 7.5 Hz, 3H). 13 C NMR (125 MHz, DMSO-d 6, ppm): δ 169.28, 165.92, 144.14, 140.84, 135.89, 135.46, 133.99, 133.03, 133.02, 131.46, 130.81, 130.73, 130.60, 129.73, 128.09, 127.73, 127.01, 20.99, 17.25. HRMS (ESI) calcd for C 19 H 17 N 3 O 2 SCl [M+H] + 386.0730, found 386.0729.
(E)-4-(2-氯苯基)-2-[2-(2-羧基-4-氟苄叉基)肼基]噻唑S24(E)-4-(2-chlorophenyl)-2-[2-(2-carboxy-4-fluorobenzylidene)indolyl]thiazole S24
Figure PCTCN2018083596-appb-000126
Figure PCTCN2018083596-appb-000126
合成方法同S1，得土黄色粉末状固体75mg，产率70％。Mp 211.6-212.8℃.The synthesis method was the same as that of S1, and a yellowish powdery solid of 75 mg was obtained in a yield of 70%. Mp 211.6-212.8 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.52(br,1H),12.38(br,1H),8.78(s,1H),8.04(dd,J 1＝J 2＝7.2Hz,1H),7.86(d,J＝7.6Hz,1H),7.64(dd,J 1＝9.2Hz,J 2＝2.4Hz,1H),7.55-7.50(m,2H),7.42(t,J＝7.2Hz,1H),7.37-7.34(m,2H).HRMS(ESI)calcd for C 17H 11N 3O 2SClFNa[M+Na] +398.0142,found 398.0133. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.52 (br, 1H), 12.38 (br, 1H), 8.78 (s, 1H), 8.04 (dd, J 1 = J 2 = 7.2Hz, 1H), 7.86 (d, J = 7.6 Hz, 1H), 7.64 (dd, J 1 = 9.2 Hz, J 2 = 2.4 Hz, 1H), 7.55-7.50 (m, 2H), 7.42 (t, J = 7.2) Hz, 1H), 7.37-7.34 (m, 2H). HRMS (ESI) calcd for C 17 H 11 N 3 O 2 SClFNa [M+Na] + 398.0142, found 398.0133.
(E)-4-(2-氯苯基)-2-[2-(2-羧基-4-甲基苄叉基)肼基]噻唑S25(E)-4-(2-chlorophenyl)-2-[2-(2-carboxy-4-methylbenzylidene)indenyl]thiazole S25
Figure PCTCN2018083596-appb-000127
Figure PCTCN2018083596-appb-000127
合成方法同S1，得亮黄色粉末状固体75mg，产率70％。Mp 221.6-222.5℃.The synthesis method was the same as that of S1 to obtain a bright yellow powdery solid of 75 mg, yield 70%. Mp 221.6-222.5 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.37(br,1H),12.31(br,1H),8.78(s,1H),7.91-7.86(m,2H),7.70(s,1H),7.53(d,J＝7.6Hz,1H),7.45(d,J＝9.2Hz,1H),7.41(d,J＝7.6Hz,1H),7.37-7.34(m,2H),2.38(s,3H).HRMS(ESI)calcd for C 18H 15N 3O 2SCl[M+H] +372.0574,found 372.0568. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.37 (br, 1H), 12.31 (br, 1H), 8.78 (s, 1H), 7.91-7.86 (m, 2H), 7.70 (s, 1H), 7.53 (d, J = 7.6 Hz, 1H), 7.45 (d, J = 9.2 Hz, 1H), 7.41 (d, J = 7.6 Hz, 1H), 7.37-7.34 (m, 2H), 2.38 ( s,3H).HRMS(ESI)calcd for C 18 H 15 N 3 O 2 SCl[M+H] + 372.0574,found 372.0568.
4-(2-氯苯基)-2-(1-乙基肼基)噻唑8d4-(2-chlorophenyl)-2-(1-ethylindenyl)thiazole 8d
Figure PCTCN2018083596-appb-000128
Figure PCTCN2018083596-appb-000128
称取8c(0.5g，1.9mmol)于100mL圆底烧瓶中，加入碳酸铯(3.0g，5.6mmol)，20mL无水DMF，氩气保护下，滴入碘乙烷(0.185mL，2.2mmol)，升温至60℃，TLC跟踪反应，约10h后原料转化完全，将反应液降至室温，过滤，滤液加入200mL水，乙酸乙酯萃取三次，有机层饱和NaCl水溶液洗三次，无水NaSO 4干燥，旋干溶剂，得黄棕色油状物，产物未经纯化直接用于下一步。将得到的中间体溶于15mL THF，加入10mL水和10滴浓盐酸，氩气保护下于50℃反应约3h，待原料转化完全后用乙酸乙酯萃取三次，有机层先后用饱和NaHCO 3水溶液和饱和NaCl水溶液洗涤，无水NaSO 4干燥，旋干溶剂，粗品硅胶柱层析(DCM:MeOH＝100:1，v/v)分离，得棕黄色固体0.26g，产率55％。 8c (0.5g, 1.9mmol) was weighed into a 100 mL round bottom flask, cesium carbonate (3.0 g, 5.6 mmol), 20 mL of anhydrous DMF was added under argon, and iodoethane (0.185 mL, 2.2 mmol) was added dropwise. The temperature was raised to 60 ° C, and the reaction was traced by TLC. After about 10 h, the starting material was completely converted. The reaction solution was cooled to room temperature, filtered, and the filtrate was added to 200 mL of water, extracted with ethyl acetate three times, and the organic layer was washed three times with saturated aqueous NaCl solution and dried over anhydrous NaSO 4 The solvent was evaporated to give a brown brown oil. The resulting intermediate was dissolved in 15mL THF, 10mL of water was added next and 10 drops of concentrated hydrochloric acid under argon atmosphere at 50 deg.] C reaction was about 3h, complete conversion of starting material to be extracted three times with ethyl acetate, the organic layer was successively washed with saturated aqueous NaHCO 3 and washed with saturated aqueous NaCl, dried over anhydrous NaSO 4, rotary evaporation, the crude product by silica gel column chromatography (DCM: MeOH = 100: 1 , v / v) , was isolated as a tan solid 0.26g, 55% yield.
1H NMR(400MHz,DMSO-d 6,ppm):δ7.87(d,J＝7.8Hz,1H),7.48(d,J＝7.6Hz,1H),7.38(t,J＝7.6Hz,1H),7.30(t,J＝7.8Hz,1H),7.14(s,1H),5.16(s,2H),3.66(q,J＝7.2Hz,2H),1.84(t,J＝7.2Hz,3H). 1 H NMR (400MHz, DMSO- d 6, ppm): δ7.87 (d, J = 7.8Hz, 1H), 7.48 (d, J = 7.6Hz, 1H), 7.38 (t, J = 7.6Hz, 1H ), 7.30 (t, J = 7.8 Hz, 1H), 7.14 (s, 1H), 5.16 (s, 2H), 3.66 (q, J = 7.2 Hz, 2H), 1.84 (t, J = 7.2 Hz, 3H) ).
(E)-4-(2-氯苯基)-2-[1-乙基-2-(2-羧基苄叉基)肼基]噻唑S8(E)-4-(2-chlorophenyl)-2-[1-ethyl-2-(2-carboxybenzylidene)indenyl]thiazole S8
Figure PCTCN2018083596-appb-000129
Figure PCTCN2018083596-appb-000129
称取中间体8d(60mg，0.63mmol)与邻羧基苯甲醛(104mg，0.69mmol)于50mL圆底烧瓶中，加入10mL乙醇，氩气保护下加入回流，TLC监测反应至原料转化完全，将反应降至室温，旋干溶剂，硅胶柱层析(DCM:MeOH＝50:1,v/v)分离，得黄色粉末状固体100mg，产率43％。Mp 203.3-204.1℃.Intermediate 8d (60 mg, 0.63 mmol) and o-carboxybenzaldehyde (104 mg, 0.69 mmol) were weighed in a 50 mL round bottom flask, 10 mL of ethanol was added, and refluxed under argon. The reaction was monitored by TLC until the starting material was completely converted. The mixture was cooled to room temperature, and the solvent was evaporated,jjjjjjjjjj Mp 203.3-204.1 ° C.
1H NMR(500MHz,DMSO-d 6,ppm):δ13.32(br,1H),8.64(s,1H),7.98–7.91(m,3H),7.66(t,J＝7.5Hz,1H),7.56–7.46(m,2H),7.45–7.39(m,2H),7.34(t,J＝6.8Hz,1H),4.32(q,J＝6.8Hz,2H),1.27(t,J＝7.0Hz,3H). 13C NMR(125MHz,DMSO-d 6,ppm):δ168.56,168.36,147.34,137.00,135.42,133.53,132.50,131.53,131.12,130.92,130.72,130.22,129.42,129.19,127.62,126.62,111.22,40.38,10.33.HRMS(ESI)calcd for C 19H 17N 3O 2SCl[M+H] +386.0730,found 386.0728. 1 H NMR (500MHz, DMSO- d 6, ppm): δ13.32 (br, 1H), 8.64 (s, 1H), 7.98-7.91 (m, 3H), 7.66 (t, J = 7.5Hz, 1H) , 7.56–7.46 (m, 2H), 7.45–7.39 (m, 2H), 7.34 (t, J = 6.8 Hz, 1H), 4.32 (q, J = 6.8 Hz, 2H), 1.27 (t, J = 7.0) Hz,3H). 13 C NMR (125MHz, DMSO-d 6, ppm): δ168.56, 168.36, 147.34, 137.00, 135.42, 133.53, 132.50, 131.53, 131.12, 130.92, 130.72, 130.22, 129.42, 129.19, 127.62, 126.62 , 111.22, 40.38, 10.33. HRMS (ESI) calcd for C 19 H 17 N 3 O 2 SCl [M+H] + 386.0730, found 386.0728.
4-(2-氯苯基)-2-(1-异丙基肼基)噻唑9d4-(2-chlorophenyl)-2-(1-isopropylindenyl)thiazole 9d
Figure PCTCN2018083596-appb-000130
Figure PCTCN2018083596-appb-000130
合成方法同8d，得棕色针状固体190mg，产率76％。The synthesis method was the same as that of 8d, and 190 mg of a brown needle-like solid was obtained, and the yield was 76%.
1H NMR(400MHz,DMSO-d 6,ppm):δ7.87(d,J＝7.6Hz,1H),7.48(d,J＝8.0Hz,1H),7.37(t,J＝7.4Hz,1H),7.29(t,J＝7.6Hz,1H),7.13(s,1H),4.91(s,2H),4.56(hept,J＝6.8Hz,1H),1.14(d,J＝6.8Hz,6H).LC-MS(ESI)cald for C 12H 15ClN 3S[M+H] +268.07,found 268.10. 1 H NMR (400MHz, DMSO- d 6, ppm): δ7.87 (d, J = 7.6Hz, 1H), 7.48 (d, J = 8.0Hz, 1H), 7.37 (t, J = 7.4Hz, 1H ), 7.29 (t, J = 7.6 Hz, 1H), 7.13 (s, 1H), 4.91 (s, 2H), 4.56 (hept, J = 6.8 Hz, 1H), 1.14 (d, J = 6.8 Hz, 6H) ). LC-MS (ESI) cald for C 12 H 15 ClN 3 S [M+H] + 268.07, found 268.10.
(E)-4-(2-氯苯基)-2-[1-异丙基-2-(2-羧基苄叉基)肼基]噻唑S9(E)-4-(2-chlorophenyl)-2-[1-isopropyl-2-(2-carboxybenzylidene)indenyl]thiazole S9
Figure PCTCN2018083596-appb-000131
Figure PCTCN2018083596-appb-000131
合成方法同S8，得黄色粉末状固体130mg，产率93％。Mp185.6-187.0℃.The synthesis method was the same as that of S8, yielding a yellow powdery solid 130 mg, yield 93%. Mp185.6-187.0 °C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.35(br,1H),8.91(s,1H),7.99(d,J＝8.0Hz,1H),7.95-7.92(m,2H),7.67(t,J＝7.6Hz,1H),7.54(d,J＝8.0Hz,1H),7.52(t,J＝7.6Hz,1H),7.46-7.42(m,2H),7.36(t,J＝7.6Hz,1H),5.22-5.11(m,1H),1.57(d,J＝6.8Hz,6H). 13C NMR(100MHz,DMSO-d 6,ppm):δ168.22,168.21,146.90,137.32,135.23,133.14,132.07,131.06,130.64,130.58,130.39,129.88,128.97,128.78,127.28,125.91,111.12,49.61,18.07,18.07.HRMS(ESI)calcd for C 20H 19N 3O 2SCl[M+H] +400.0887,found 400.0885. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.35 (br, 1H), 8.91 (s, 1H), 7.99 (d, J = 8.0Hz, 1H), 7.95-7.92 (m, 2H) , 7.67 (t, J = 7.6 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.46 - 7.42 (m, 2H), 7.36 (t, J = 7.6 Hz, 1H), 5.22 - 5.11 (m, 1H), 1.57 (d, J = 6.8 Hz, 6H). 13 C NMR (100 MHz, DMSO-d 6, ppm): δ 168.22, 168.21, 146.90, 137.32 , 135.23, 133.14, 132.07, 131.06, 130.64, 130.58, 130.39, 129.88, 128.97, 128.78, 127.28, 125.91, 111.12, 49.61, 18.07, 18.07. HRMS (ESI) calcd for C 20 H 19 N 3 O 2 SCl[M +H] + 400.0887, found 400.0885.
4-(2-氯苯基)-2-(1-羟乙基肼基)噻唑10d4-(2-chlorophenyl)-2-(1-hydroxyethylindenyl)thiazole 10d
Figure PCTCN2018083596-appb-000132
Figure PCTCN2018083596-appb-000132
合成方法同8d，得黄色粉末状固体120mg，产率50％。The synthesis method was the same as that of 8d to obtain 120 mg of a yellow powdery solid, yield 50%.
1H NMR(400MHz,DMSO-d 6,ppm):δ7.86(d,J＝7.6Hz,1H),7.48(d,J＝7.6Hz,1H),7.37(t,J＝7.0Hz,1H),7.30(t,J＝7.6Hz,1H),7.14(s,1H),5.22(s,2H),4.81(br,1H),3.72(s,4H).LC-MS(ESI)calcd for C 11H 13ClN 3OS[M+H] +270.0,found 270.0. 1 H NMR (400MHz, DMSO- d 6, ppm): δ7.86 (d, J = 7.6Hz, 1H), 7.48 (d, J = 7.6Hz, 1H), 7.37 (t, J = 7.0Hz, 1H ), 7.30 (t, J = 7.6 Hz, 1H), 7.14 (s, 1H), 5.22 (s, 2H), 4.81 (br, 1H), 3.72 (s, 4H). LC-MS (ESI) calcd for C 11 H 13 ClN 3 OS[M+H] + 270.0,found 270.0.
(E)-4-(2-氯苯基)-2-[1-羟乙基-2-(2-羧基苄叉基)肼基]噻唑S10(E)-4-(2-chlorophenyl)-2-[1-hydroxyethyl-2-(2-carboxybenzylidene)indenyl]thiazole S10
Figure PCTCN2018083596-appb-000133
Figure PCTCN2018083596-appb-000133
合成方法同S8，得土黄色粉末状固体93mg，产率46％。Mp 187.9-188.9℃.The synthesis method was the same as that of S8 to obtain 93 mg of a yellowish powdery solid, yield 46%. Mp 187.9-188.9 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.24(br,1H),8.75(s,1H),7.98-7.01(m,3H),7.66(t,J＝7.6Hz,1H),7.54(d,J＝8.0Hz,1H),7.49(t,J＝7.6Hz,1H),7.45-7.41(m,2H),7.36(td,J 1＝7.6Hz,J 2＝1.6Hz,1H),4.35(t,J＝6.4Hz,2H),3.76(t,J＝6.4Hz,2H). 13C NMR(100MHz,DMSO-d 6,ppm):δ168.64,168.23,146.87,136.89,134.91,133.15,131.99,131.19,130.71,130.46,130.32,130.16,129.04,128.79,127.22,126.28,110.78,56.24,47.46.HRMS(ESI)calcd for C 19H 17N 3O 3SCl[M+H] +402.0679,found 402.0678. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.24 (br, 1H), 8.75 (s, 1H), 7.98-7.01 (m, 3H), 7.66 (t, J = 7.6Hz, 1H) , 7.54 (d, J = 8.0 Hz, 1H), 7.49 (t, J = 7.6 Hz, 1H), 7.45 - 7.41 (m, 2H), 7.36 (td, J 1 = 7.6 Hz, J 2 = 1.6 Hz, 1H), 4.35 (t, J = 6.4 Hz, 2H), 3.76 (t, J = 6.4 Hz, 2H). 13 C NMR (100 MHz, DMSO-d 6, ppm): δ 168.64, 168.23, 146.87, 136.89, 134.91 , 133.15, 131.99, 131.19, 130.71, 130.46, 130.32, 130.16, 129.04, 128.79, 127.22, 126.28, 110.78, 56.24, 47.46. HRMS (ESI) calcd for C 19 H 17 N 3 O 3 SCl[M+H] + 402.0679, found 402.0678.
4-(2-氯苯基)-2-(1-正丙基肼基)噻唑11d4-(2-chlorophenyl)-2-(1-n-propyldecyl)thiazole 11d
Figure PCTCN2018083596-appb-000134
Figure PCTCN2018083596-appb-000134
合成方法同8d，得棕色固体100mg，产率75％。The synthesis method was the same as that of 8d, and a brown solid 100 mg was obtained in a yield of 75%.
1H NMR(400MHz,DMSO-d 6,ppm):δ7.86(dd,J 1＝8.0Hz,J 2＝1.6Hz,1H),7.48(dd,J 1＝8.0Hz,J 2＝1.6Hz,1H),7.37(td,J 1＝7.6Hz,J 2＝1.2Hz,1H),7.30(td,J 1＝7.6Hz,J 2＝1.2Hz,1H),7.12(s,1H),5.16(br,2H),3.59(t,J＝7.2Hz,2H),1.73-1.63(m,2H),0.89(t,J＝7.2Hz,3H).LC-MS(ESI)calcd for C 12H 15ClN 3S[M+H] +268.1,found 268.1. 1 H NMR (400 MHz, DMSO-d 6 , ppm): δ 7.86 (dd, J 1 = 8.0 Hz, J 2 = 1.6 Hz, 1H), 7.48 (dd, J 1 = 8.0 Hz, J 2 = 1.6 Hz , 1H), 7.37 (td, J 1 = 7.6 Hz, J 2 = 1.2 Hz, 1H), 7.30 (td, J 1 = 7.6 Hz, J 2 = 1.2 Hz, 1H), 7.12 (s, 1H), 5.16 (br, 2H), 3.59 (t, J = 7.2 Hz, 2H), 1.73-1.63 (m, 2H), 0.89 (t, J = 7.2 Hz, 3H). LC-MS (ESI) calcd for C 12 H 15 ClN 3 S[M+H] + 268.1,found 268.1.
(E)-4-(2-氯苯基)-2-[1-正丙基-2-(2-羧基苄叉基)肼基]噻唑S11(E)-4-(2-chlorophenyl)-2-[1-n-propyl-2-(2-carboxybenzylidene)indenyl]thiazole S11
Figure PCTCN2018083596-appb-000135
Figure PCTCN2018083596-appb-000135
合成方法同S8，得黄色粉末状固体60mg，产率76％。Mp 203.3-204.1℃.The synthesis method was the same as that of S8 to obtain 60 mg of a yellow powdery solid, yield 76%. Mp 203.3-204.1 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.35(br,1H),8.65(s,1H),7.98(d,J＝8.0Hz,1H),7.95-7.92(m,2H),7.67(t,J＝7.2Hz,1H),7.54(d,J＝8.0Hz,1H),7.5(t,J＝7.6Hz,1H),7.45-7.42(m,2H),7.36(t,J＝7.6Hz,1H),4.25(t,J＝7.2Hz,2H),1.82-1.73(m,2H),0.97(t,J＝7.4Hz,1H). 13C NMR(100MHz,DMSO-d6,ppm):δ168.54,168.22 146.95,136.63,134.96,133.17,132.11,131.10,130.74,130.55,130.34,129.82,129.04,128.80,127.26,126.09,110.77,46.31,17.98,11.17.HRMS(ESI)calcd for C 20H 19N 3O 2SCl[M+H] +400.0887,found 400.0879. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.35 (br, 1H), 8.65 (s, 1H), 7.98 (d, J = 8.0Hz, 1H), 7.95-7.92 (m, 2H) , 7.67 (t, J = 7.2 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.5 (t, J = 7.6 Hz, 1H), 7.45 - 7.42 (m, 2H), 7.36 (t, J = 7.6 Hz, 1H), 4.25 (t, J = 7.2 Hz, 2H), 1.82-1.73 (m, 2H), 0.97 (t, J = 7.4 Hz, 1H). 13 C NMR (100 MHz, DMSO-d6) ,ppm): δ168.54,168.22 146.95,136.63,134.96,133.17,132.11,131.10,130.74,130.55,130.34,129.82,129.04,128.80,127.26,126.09,110.77,46.31,17.98,11.17.HRMS(ESI)calcd for C 20 H 19 N 3 O 2 SCl[M+H] + 400.0887, found 400.0879.
4-(2-氯苯基)-2-[1-(2-丁基)肼基]噻唑12d4-(2-chlorophenyl)-2-[1-(2-butyl)indenyl]thiazole 12d
Figure PCTCN2018083596-appb-000136
Figure PCTCN2018083596-appb-000136
合成方法同8d，得棕色粘稠固体100mg，产率62％。The synthesis method was the same as that of 8d, and a brown viscous solid 100 mg was obtained with a yield of 62%.
1H NMR(400MHz,DMSO-d 6,ppm):δ7.86(dd,J 1＝8.0Hz,J 2＝1.6Hz,1H),7.48(dd,J 1＝8.0Hz,J 2＝1.2Hz,1H),7.37(td,J 1＝7.6Hz,J 2＝1.2Hz,1H),7.29(td,J 1＝7.6Hz,J 2＝1.2Hz,1H),7.10(s,1H),4.85(s,2H),4.40-4.32(m,1H),1.73-1.61(m,1H),1.52-1.42(m,1H),1.12(d,J＝6.8Hz,3H),0.85(t,J＝7.4Hz,3H). 1 H NMR (400 MHz, DMSO-d 6 , ppm): δ 7.86 (dd, J 1 = 8.0 Hz, J 2 = 1.6 Hz, 1H), 7.48 (dd, J 1 = 8.0 Hz, J 2 = 1.2 Hz , 1H), 7.37 (td, J 1 = 7.6 Hz, J 2 = 1.2 Hz, 1H), 7.29 (td, J 1 = 7.6 Hz, J 2 = 1.2 Hz, 1H), 7.10 (s, 1H), 4.85 (s, 2H), 4.40-4.32 (m, 1H), 1.73-1.61 (m, 1H), 1.52-1.42 (m, 1H), 1.12 (d, J = 6.8 Hz, 3H), 0.85 (t, J =7.4Hz, 3H).
(E)-4-(2-氯苯基)-2-[1-(2-丁基)-2-(2-羧基苄叉基)肼基]噻唑S12(E)-4-(2-chlorophenyl)-2-[1-(2-butyl)-2-(2-carboxybenzylidene)indenyl]thiazole S12
Figure PCTCN2018083596-appb-000137
Figure PCTCN2018083596-appb-000137
合成方法同S8，得黄色粉末状固体105mg，产率80％。Mp 170.5-170.6℃.The synthesis method was the same as that of S8, yielding a yellow powdery solid 105 mg, yield 80%. Mp 170.5-170.6 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.32(br,1H),8.91(s,1H),7.99(d,J＝8.0Hz,1H),7.95-7.90(m,2H),7.67(t,J＝7.6Hz,1H),7.55-7.48(m,2H),7.46-7.42(m,2H),7.36(t,J＝7.6Hz,1H),5.00-4.93(m,1H),2.35-2.24(m,1H),1.92-1.81(m,1H),1.54(d,J＝6.8Hz,3H),0.88(t,J＝7.2Hz,3H). 13C NMR(100MHz,DMSO-d 6,ppm):δ168.66,168.19,146.97,137.03,135.24,133.19,132.13,131.04,130.67,130.58,130.39,129.70,128.98,128.77,127.29,125.91,111.04,55.67,25.26,16.33,11.14.HRMS(ESI)calcd for C 21H 21N 3O 2SCl[M+H] +414.1043,found 414.1029. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.32 (br, 1H), 8.91 (s, 1H), 7.99 (d, J = 8.0Hz, 1H), 7.95-7.90 (m, 2H) , 7.67 (t, J = 7.6 Hz, 1H), 7.55-7.48 (m, 2H), 7.46-7.42 (m, 2H), 7.36 (t, J = 7.6 Hz, 1H), 5.00-4.93 (m, 1H) ), 2.35-2.24 (m, 1H), 1.92-1.81 (m, 1H), 1.54 (d, J = 6.8 Hz, 3H), 0.88 (t, J = 7.2 Hz, 3H). 13 C NMR (100 MHz, DMSO-d 6 ,ppm): δ168.66,168.19,146.97,137.03,135.24,133.19,132.13,131.04,130.67,130.58,130.39,129.70,128.98,128.77,127.29,125.91,111.04,55.67,25.26,16.33,11.14. HRMS (ESI) calcd for C 21 H 21 N 3 O 2 SCl [M+H] + 414.1043, found 414.1029.
4-(2-氯苯基)-2-[1-(2-戊基)肼基]噻唑13d4-(2-chlorophenyl)-2-[1-(2-pentyl)indenyl]thiazole 13d
Figure PCTCN2018083596-appb-000138
Figure PCTCN2018083596-appb-000138
合成方法同8d，得棕色粘稠固体120mg，产率65％。The synthesis method was the same as that of 8d, and a brown viscous solid of 120 mg was obtained, and the yield was 65%.
1H NMR(400MHz,DMSO-d 6,ppm):δ7.86(dd,J 1＝7.6Hz,J 2＝1.6Hz,1H),7.47(d,J＝7.6Hz,1H),7.37(td,J 1＝7.6Hz,J 2＝1.2Hz,1H),7.29(td,J 1＝7.6Hz,J 2＝1.6Hz,1H),7.10(s,1H),4.85(br,2H),4.54-4.45(m,1H),1.73-1.64(m,1H),1.40-1.36(m,1H),1.32-1.26(m,2H), 1.11(d,J＝6.8Hz,3H),0.89(t,J＝6.8Hz,3H).LC-MS(ESI)calcd for C 14H 19ClN 3S[M+H] +296.1,found 296.1. 1 H NMR (400MHz, DMSO- d 6, ppm): δ7.86 (dd, J 1 = 7.6Hz, J 2 = 1.6Hz, 1H), 7.47 (d, J = 7.6Hz, 1H), 7.37 (td , J 1 = 7.6 Hz, J 2 = 1.2 Hz, 1H), 7.29 (td, J 1 = 7.6 Hz, J 2 = 1.6 Hz, 1H), 7.10 (s, 1H), 4.85 (br, 2H), 4.54 -4.45(m,1H),1.73-1.64(m,1H),1.40-1.36(m,1H),1.32-1.26(m,2H), 1.11(d,J=6.8Hz,3H),0.89(t , J = 6.8 Hz, 3H). LC-MS (ESI) calcd for C 14 H 19 ClN 3 S [M+H] + 296.1, found 296.1.
(E)-4-(2-氯苯基)-2-[1-(2-戊基)-2-(2-羧基苄叉基)肼基]噻唑S13(E)-4-(2-chlorophenyl)-2-[1-(2-pentyl)-2-(2-carboxybenzylidene)indolyl]thiazole S13
Figure PCTCN2018083596-appb-000139
Figure PCTCN2018083596-appb-000139
合成方法同S8，得黄色固体70mg，产率68％。Mp 146.7-148.0℃.The synthesis method was the same as that of S8, yielding a yellow solid 70 mg, yield 68%. Mp 146.7-148.0 °C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.35(br,1H),8.91(s,1H),7.98(d,J＝7.6Hz,1H),7.94(d,J＝8.0Hz,1H),7.91(dd,J 1＝7.6Hz,J 2＝1.6Hz,1H),7.67(t,J＝7.6Hz,1H),7.53(d,J＝8.0Hz,1H),7.49(t,J＝7.6Hz,1H),7.46-7.42(m,2H),7.36(td,J 1＝7.6Hz,J 2＝1.6Hz,1H),5.14-5.06(m,1H),2.34-2.25(m,1H),1.82-1.73(m,1H),1.53(d,J＝6.8Hz,3H),1.34-1.24(m,2H),0.89(t,J＝7.4Hz,1H). 13C NMR(100MHz,DMSO-d 6,ppm):δ168.68,168.20,146.98,137.04,135.30,133.20,132.14,131.00,130.68,130.59,130.40,129.68,128.99,127.30,125.90,111.09,53.81,34.20,19.46,16.46,13.60.HRMS(ESI)calcd for C 22H 23N 3O 2SCl[M+H] +428.1200,found 428.1193. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.35 (br, 1H), 8.91 (s, 1H), 7.98 (d, J = 7.6Hz, 1H), 7.94 (d, J = 8.0Hz , 1H), 7.91 (dd, J 1 = 7.6 Hz, J 2 = 1.6 Hz, 1H), 7.67 (t, J = 7.6 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.49 (t , J = 7.6 Hz, 1H), 7.46-7.42 (m, 2H), 7.36 (td, J 1 = 7.6 Hz, J 2 = 1.6 Hz, 1H), 5.14 - 5.06 (m, 1H), 2.34 - 2.25 ( m,1H), 1.82-1.73 (m, 1H), 1.53 (d, J = 6.8 Hz, 3H), 1.34-1.24 (m, 2H), 0.89 (t, J = 7.4 Hz, 1H). 13 C NMR (100MHz, DMSO-d 6 , ppm): δ168.68, 168.20, 146.98, 137.04, 135.30, 133.20, 132.14, 131.00, 130.68, 130.59, 130.40, 129.68, 128.99, 127.30, 125.90, 111.09, 53.81, 34.20, 19.46, 16.46 , 13.60. HRMS (ESI) calcd for C 22 H 23 N 3 O 2 SCl [M+H] + 428.1200, found 428.1193.
5-甲基-4-(2-氯苯基)-2-[1-(2-丁基)肼基]噻唑14d5-methyl-4-(2-chlorophenyl)-2-[1-(2-butyl)indenyl]thiazole 14d
Figure PCTCN2018083596-appb-000140
Figure PCTCN2018083596-appb-000140
合成方法同8d，得棕色粘稠固体105mg，产率50％。The synthesis method was the same as that of 8d, and a brown viscous solid of 105 mg was obtained in a yield of 50%.
1H NMR(400MHz,DMSO-d 6,ppm):δ7.51-7.49(m,1H),7.40-7.36(m,3H),4.71(s,2H),4.36-4.26(m,1H),2.05(s,3H),1.71-1.57(m,1H),1.36-1.26(m,3H),1.06(d,J＝6.4Hz,3H),0.87(t,J＝7.2Hz,3H).LC-MS(ESI)calcd for C 15H 21ClN 3S[M+H] +310.11,found 310.10. 1 H NMR (400MHz, DMSO- d 6, ppm): δ7.51-7.49 (m, 1H), 7.40-7.36 (m, 3H), 4.71 (s, 2H), 4.36-4.26 (m, 1H), 2.05(s,3H),1.71-1.57(m,1H),1.36-1.26(m,3H),1.06(d,J=6.4Hz,3H),0.87(t,J=7.2Hz,3H).LC -MS(ESI)calcd for C 15 H 21 ClN 3 S[M+H] + 310.11,found 310.10.
(E)-5-甲基-4-(2-氯苯基)-2-[1-(2-戊基)-2-(2-羧基苄叉基)肼基]噻唑S14(E)-5-Methyl-4-(2-chlorophenyl)-2-[1-(2-pentyl)-2-(2-carboxybenzylidene)indenyl]thiazole S14
Figure PCTCN2018083596-appb-000141
Figure PCTCN2018083596-appb-000141
合成方法同S8，得黄色固体130mg，产率65％。Mp 99.9-100.1℃.The synthesis method was the same as that of S8 to obtain a yellow solid, 130 mg, yield 65%. Mp 99.9-100.1 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.29(br,1H),8.85(s,1H),7.98(d,J＝8.0Hz,1H),7.92(d,J＝7.6Hz,1H),7.65(t,J＝7.6Hz,1H),7.56-7.54(m,1H),7.51-7.41(m,4H),5.05-4.96(m,1H),2.29-2.22(m,1H),2.16(s,3H),1.75-1.67(m,1H),1.46(d,J＝7.2Hz,3H),1.28-1.23(m,2H),0.87(t,J＝7.6Hz,3H). 13C NMR(100MHz,DMSO-d 6,ppm):δ168.23,166.06,144.08,136.14,135.46,134.09,132.79,132.09,131.93,130.58,129.64,129.60,129.48,128.56,126.95,125.73,121.62,53.39,34.01,19.41,16.35,13.58,11.52.HRMS(ESI)calcd for C 23H 25N 3O 2SCl[M+H] +442.1356,found 442.1354. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.29 (br, 1H), 8.85 (s, 1H), 7.98 (d, J = 8.0Hz, 1H), 7.92 (d, J = 7.6Hz , 1H), 7.65 (t, J = 7.6 Hz, 1H), 7.56-7.54 (m, 1H), 7.51-7.41 (m, 4H), 5.05-4.96 (m, 1H), 2.29-2.22 (m, 1H) ), 2.16 (s, 3H), 1.75-1.67 (m, 1H), 1.46 (d, J = 7.2 Hz, 3H), 1.28-1.23 (m, 2H), 0.87 (t, J = 7.6 Hz, 3H) 13 C NMR (100 MHz, DMSO-d 6 , ppm): δ 168.23, 166.06, 144.08, 136.14, 135.46, 134.09, 132.79, 132.09, 131.93, 130.58, 129.64, 129.60, 129.48, 128.56, 126.95, 125.73, 121.62, 53.39 , 34.01, 19.41, 16.35, 13.58, 11.52. HRMS (ESI) calcd for C 23 H 25 N 3 O 2 SCl [M+H] + 442.1356, found 442.1354.
2-甲基-1-(2-羧基苄叉基)氨基硫脲7h2-methyl-1-(2-carboxybenzylidene)thiosemicarbazide 7h
Figure PCTCN2018083596-appb-000142
Figure PCTCN2018083596-appb-000142
称取化合物7g(80mg，0.76mmol)于50mL单口瓶中，加入20mL乙醇，搅拌下加入邻羧基苯甲醛(114mg，0.76mmol)，加热至回流，TLC监测反应至原料转化完全，将反应液冷至室温，旋干溶剂，硅胶柱层析(DCM/MeOH＝120:1,v/v)，得白色粉末状固体100mg，产率56％。The compound 7g (80mg, 0.76mmol) was weighed into a 50mL single-mouth bottle, 20mL of ethanol was added, o-carboxybenzaldehyde (114mg, 0.76mmol) was added with stirring, heated to reflux, and the reaction was monitored by TLC until the conversion of the starting material was complete. The solvent was evaporated to dryness <RTI ID=0.0>
1H NMR(400MHz,DMSO-d 6,ppm):δ13.36(br,1H),8.56(s,1H),8.51(s,1H),8.31(d,J＝7.6Hz,1H),8.25(s,1H),7.88(d,J＝8Hz,1H),7.59(t,J＝7.2Hz,1H),7.50(t,J＝7.2Hz,1H),3.77(s,3H).LC-MS(ESI)calcd for C 10H 12N 3O 2S[M] +238.1,found 238.1. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.36 (br, 1H), 8.56 (s, 1H), 8.51 (s, 1H), 8.31 (d, J = 7.6Hz, 1H), 8.25 (s, 1H), 7.88 (d, J = 8 Hz, 1H), 7.59 (t, J = 7.2 Hz, 1H), 7.50 (t, J = 7.2 Hz, 1H), 3.77 (s, 3H). LC- MS (ESI) calcd for C 10 H 12 N 3 O 2 S [M] + 238.1, found 238.1.
(E)-4-(2-氯苯基)-2-[1-甲基-2-(2-羧基苄叉基)肼基]噻唑S7(E)-4-(2-chlorophenyl)-2-[1-methyl-2-(2-carboxybenzylidene)indenyl]thiazole S7
Figure PCTCN2018083596-appb-000143
Figure PCTCN2018083596-appb-000143
称取7h(100mg，0.42mmol)于50mL单口瓶中，加入10mL乙醇，搅拌下加入2’-氯-2-溴苯乙酮(65μL，0.42mmol)，升温至回流，TLC跟踪反应至原料转化完全，将反应液冷至室温，旋干溶剂，硅胶柱层析(DCM/MeOH＝120:1,v/v)分离，得黄色粉末状固体106mg，产率68％。Mp 210.4-211.0℃.Weigh 7h (100mg, 0.42mmol) in a 50mL single-mouth bottle, add 10mL of ethanol, add 2'-chloro-2-bromoacetophenone (65μL, 0.42mmol), stir to reflux, TLC tracking reaction to conversion of raw materials After completion, the reaction mixture was cooled to room temperature, and the solvent was evaporated. mjjjjjjjjj Mp 210.4-211.0 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.30(s,1H),8.62(s,1H),8.02(d,J＝7.6Hz,1H),7.98–7.90(m,2H),7.66(t,J＝7.6Hz,1H),7.56–7.49(m,2H),7.47(s,1H),7.43(td,J 1＝7.4Hz,J 2＝1.2Hz,1H),7.36(td,J 1＝7.6Hz,J 2＝1.6Hz,1H),3.68(s,3H). 13C NMR(125MHz,DMSO-d 6,ppm):δ168.98,168.57,147.11,136.94,135.17,133.42,132.48,131.51,131.09,130.98,130.75,130.16,129.45,129.19,127.63,126.51,111.41,32.88.HRMS(ESI)calcd for C 18H 15N 3O 2SCl[M+H] +372.0574,found 372.0575. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.30 (s, 1H), 8.62 (s, 1H), 8.02 (d, J = 7.6Hz, 1H), 7.98-7.90 (m, 2H) , 7.66 (t, J = 7.6 Hz, 1H), 7.56 - 7.49 (m, 2H), 7.47 (s, 1H), 7.43 (td, J 1 = 7.4 Hz, J 2 = 1.2 Hz, 1H), 7.36 ( Td, J 1 = 7.6 Hz, J 2 = 1.6 Hz, 1H), 3.68 (s, 3H). 13 C NMR (125 MHz, DMSO-d 6 , ppm): δ 168.98, 168.57, 147.11, 136.94, 135.17, 133.42, 132.48, 131.51, 131.09, 130.98, 130.75, 130.16, 129.45, 129.19, 127.63, 126.51, 111.41, 32.88. HRMS (ESI) calcd for C 18 H 15 N 3 O 2 SCl [M+H] + 372.0574, found 372.0575.
(E)-4-苯基-2-[1-甲基-2-(2-羧基苄叉基)肼基]噻唑S15(E)-4-phenyl-2-[1-methyl-2-(2-carboxybenzylidene)indenyl]thiazole S15
Figure PCTCN2018083596-appb-000144
Figure PCTCN2018083596-appb-000144
合成方法同S7，得黄色粉末状固体78mg，产率85％。Mp 200.6-201.8℃.The synthesis method was the same as that of S7, yielding a yellow powdery solid 78mg, yield 85%. Mp 200.6-201.8 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.31(br,1H),8.62(s,1H),8.02(d,J＝7.6Hz,1H),7.94-7.91(m,3H),7.66(t,J＝7.2Hz,1H),7.49(t,J＝7.2Hz,1H),7.45-7.40(m,3H),7.31(t,J＝7.2Hz,1H),3.71(s,3H). 13C NMR(100MHz,DMSO-d 6,ppm):δ169.45,168.20,150.18,136.35,134.80,134.49,132.07,130.60,129.71,128.76,128.56,128.56,127.59,126.09,125.54,125.54,105.97,32.51.HRMS(ESI)calcd for C 18H 16N 3O 2S[M+H] +338.0963,found 338.0963. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.31 (br, 1H), 8.62 (s, 1H), 8.02 (d, J = 7.6Hz, 1H), 7.94-7.91 (m, 3H) , 7.66 (t, J = 7.2 Hz, 1H), 7.49 (t, J = 7.2 Hz, 1H), 7.45-7.40 (m, 3H), 7.31 (t, J = 7.2 Hz, 1H), 3.71 (s, 3H). 13 C NMR (100MHz, DMSO-d 6 , ppm): δ 169.45, 168.20, 150.18, 136.35, 134.80, 134.49, 132.07, 130.60, 129.71, 128.76, 128.56, 128.56, 127.59, 126.09, 125.54, 125.54, 105.97 , 32.51. HRMS (ESI) calcd for C 18 H 16 N 3 O 2 S [M+H] + 338.0963, found 338.0963.
(E)-4-(3-氯苯基)-2-[1-甲基-2-(2-羧基苄叉基)肼基]噻唑S16(E)-4-(3-chlorophenyl)-2-[1-methyl-2-(2-carboxybenzylidene)indenyl]thiazole S16
Figure PCTCN2018083596-appb-000145
Figure PCTCN2018083596-appb-000145
合成方法同S7，得黄色粉末状固体80mg，产率69％。Mp 244.7-245.4℃.The synthesis method was the same as that of S7 to obtain a yellow powdery solid, 80 mg, yield 69%. Mp 244.7-245.4 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.32(br,1H),8.63(s,1H),8.01(d,J＝7.6Hz,1H),7.97(s,1H),7.93(d,J＝7.6Hz,1H),7.88(d,J＝8.0Hz,1H),7.66(t,J＝7.6Hz,1H),7.61(s,1H),7.50(t,J＝7.6Hz,1H),7.45(t,J＝7.6Hz,1H),7.37(d,J＝8.0Hz,1H),3.71(s,3H). 13C NMR(100MHz,DMSO-d 6,ppm):δ169.57,168.18,148.56,136.64,136.50,134.72,133.48,132.06,130.59,130.44,129.76,128.81,127.28,126.12,125.16,124.05,107.56,32.52.HRMS(ESI)calcd for C 18H 15N 3O 2SCl[M+H] +372.0574,found 372.0574. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.32 (br, 1H), 8.63 (s, 1H), 8.01 (d, J = 7.6Hz, 1H), 7.97 (s, 1H), 7.93 (d, J = 7.6 Hz, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.66 (t, J = 7.6 Hz, 1H), 7.61 (s, 1H), 7.50 (t, J = 7.6 Hz) , 1H), 7.45 (t, J = 7.6 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 3.71 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6 , ppm): δ 169 .57,168.18,148.56,136.64,136.50,134.72,133.48,132.06,130.59,130.44,129.76,128.81,127.28,126.12,125.16,124.05,107.56,32.52.HRMS(ESI)calcd for C 18 H 15 N 3 O 2 SCl [M+H] + 372.0574, found 372.0574.
(E)-4-(2,5-二氯苯基)-2-[1-甲基-2-(2-羧基苄叉基)肼基]噻唑S17(E)-4-(2,5-Dichlorophenyl)-2-[1-methyl-2-(2-carboxybenzylidene)indenyl]thiazole S17
Figure PCTCN2018083596-appb-000146
Figure PCTCN2018083596-appb-000146
合成方法同S7，得黄色粉末状固体100mg，产率72％。Mp 268.4-269.5℃.The synthesis method was the same as that of S7 to obtain 100 mg of a yellow powdery solid, yield 72%. Mp 268.4-269.5 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.31(br,1H),8.63(s,1H),8.02-8.00(m,2H),7.93(d,J＝7.2Hz,1H),7.67(t,J＝7.6Hz,1H),7.63(s,1H),7.58(d,J＝7.6Hz,1H),7.50(t,J＝7.2Hz,1H),7.43(dd,J＝7.2Hz,1H),3.68(s,3H). 13C NMR(100MHz,DMSO-d 6,ppm):δ168.68,168.15,145.13,136.79,134.70,134.21,132.14,132.06,131.85,130.59,130.17,129.76,129.20,128.84,128.58,126.13,112.31,32.49.HRMS(ESI)calcd for C 18H 14N 3O 2SCl 2[M+H] +406.0184,found 406.0187. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.31 (br, 1H), 8.63 (s, 1H), 8.02-8.00 (m, 2H), 7.93 (d, J = 7.2Hz, 1H) , 7.67 (t, J = 7.6 Hz, 1H), 7.63 (s, 1H), 7.58 (d, J = 7.6 Hz, 1H), 7.50 (t, J = 7.2 Hz, 1H), 7.43 (dd, J = 7.2 Hz, 1H), 3.68 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6 , ppm): δ 168.68, 168.15, 145.13, 136.79, 134.70, 134.21, 132.14, 132.06, 131.85, 130.59, 130.17, 129.76 , 129.20, 128.84, 128.58, 126.13, 112.31, 32.49. HRMS (ESI) calcd for C 18 H 14 N 3 O 2 SCl 2 [M+H] + 406.0184, found 406.0187.
(E)-4-(2-氯苯基)-2-[1-甲基-2-(2-羧基苄叉基)肼基]噻唑S18(E)-4-(2-chlorophenyl)-2-[1-methyl-2-(2-carboxybenzylidene)indenyl]thiazole S18
Figure PCTCN2018083596-appb-000147
Figure PCTCN2018083596-appb-000147
合成方法同S7，得黄色粉末状固体78mg，产率70％。Mp 208.8-209.8℃.The synthesis method was the same as that of S7, yielding 78 mg of a yellow powdery solid, yield 70%. Mp 208.8-209.8 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.46(br,1H),8.60(s,1H),8.01(d,J＝8.0Hz,1H),7.92(d,J＝8.0Hz,1H),7.64(t,J＝7.4Hz,1H),7.56(d,J＝7.6Hz,1H),7.49-7.39(m,4H),3.56(s,3H),2.15(s,3H). 13C NMR(100MHz,DMSO-d 6,ppm):δ168.98,166.46,144.56,136.46,135.29,134.54,133.25,132.50,132.31,131.05,130.72,130.26,130.01,129.09,127.49,126.42,121.85,32.46,12.16.HRMS(ESI)calcd for C 19H 17N 3O 2SCl[M+H] +386.0730,found 386.0727. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.46 (br, 1H), 8.60 (s, 1H), 8.01 (d, J = 8.0Hz, 1H), 7.92 (d, J = 8.0Hz , 1H), 7.64 (t, J = 7.4 Hz, 1H), 7.56 (d, J = 7.6 Hz, 1H), 7.49-7.39 (m, 4H), 3.56 (s, 3H), 2.15 (s, 3H) 13 C NMR (100 MHz, DMSO-d 6, ppm): δ 168.98, 166.46, 144.56, 136.46, 135.29, 134.54, 133.25, 132.50, 132.31, 131.05, 130.72, 130.26, 130.01, 129.09, 127.49, 126.42, 121.85, 32.46 , 12.16. HRMS (ESI) calcd for C 19 H 17 N 3 O 2 SCl [M+H] + 386.0730, found 386.0727.
(E)-5-甲基-4-苯基-2-[1-甲基-2-(2-羧基苄叉基)肼基]噻唑S19(E)-5-Methyl-4-phenyl-2-[1-methyl-2-(2-carboxybenzylidene)indenyl]thiazole S19
Figure PCTCN2018083596-appb-000148
Figure PCTCN2018083596-appb-000148
合成方法同S7，得黄色粉末状固体0.5g，产率60％。Mp 222.7-224.9℃.The synthesis method was the same as that of S7 to obtain 0.5 g of a yellow powdery solid, yield 60%. Mp 222.7-224.9 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.32(br,1H),8.58(s,1H),8.01(d,J＝8.0Hz,1H),7.92(d,J＝7.6Hz,1H),7.68-7.63(m,3H),7.50-7.43(m,3H)，7.34(t,J＝7.4Hz,1H),3.62(s,3H),2.44(s,3H). 13C NMR(100MHz,DMSO-d 6,ppm):δ168.24,165.36,145.47,135.66,135.13,134.90,131.98,130.58,129.70,128.59,128.25,128.25,127.86,127.86,127.09,125.94,119.44,31.93,12.24.HRMS(ESI)calcd for C 19H 16N 3O 2S[M-H] -350.0963,found 350.0951. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.32 (br, 1H), 8.58 (s, 1H), 8.01 (d, J = 8.0Hz, 1H), 7.92 (d, J = 7.6Hz , 1H), 7.68-7.63 (m, 3H), 7.50-7.43 (m, 3H), 7.34 (t, J = 7.4 Hz, 1H), 3.62 (s, 3H), 2.44 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6, ppm): δ 168.24, 165.36, 145.47, 135.66, 135.13, 134.90, 131.98, 130.58, 129.70, 128.59, 128.25, 128.25, 127.86, 127.86, 127.09, 125.94, 119.44, 31.93, 12.24. HRMS (ESI) calcd for C 19 H 16 N 3 O 2 S[MH] - 350.0963, found 350.0951.
2-甲酰基-5-三氟甲基苯甲酸20f2-formyl-5-trifluoromethylbenzoic acid 20f
Figure PCTCN2018083596-appb-000149
Figure PCTCN2018083596-appb-000149
将正丁基锂(3mL，7.4mmol，2.5mol/L in hexane)用注射器加入预先装有10mL无水THF的100mL低温反应瓶中，降温至-78℃，缓慢滴加2-溴-5-三氟甲基苯甲酸(1.0g，3.7mmol)的THF溶液，-78℃下搅拌1h，缓慢滴加1mL无水DMF，慢慢升至室温，室温下反应6h。在反应液中加入适量2N NaOH，用***萃取，合并水层，用浓盐酸调pH至酸性，EA萃取三次，有机层用饱和NaCl洗，合并有机层，无水Na 2SO 4干燥，旋干溶剂后硅胶柱层析(PE/EA/AcOH＝6/1/0.1,v/v/v)分离，得70mg乳白色固体，产率18％。 Add n-butyllithium (3 mL, 7.4 mmol, 2.5 mol/L in hexane) to a 100 mL cryogenic reaction flask prefilled with 10 mL of anhydrous THF with a syringe, cool to -78 ° C, and slowly add 2-bromo-5- A solution of trifluoromethylbenzoic acid (1.0 g, 3.7 mmol) in THF was stirred at -78 ° C for 1 h, and 1 mL of anhydrous DMF was slowly added dropwise, and then warmed to room temperature and allowed to react at room temperature for 6 h. Added to the reaction mixture an appropriate amount of 2N NaOH, extracted with ether, the aqueous layer were combined, acidified with concentrated hydrochloric acid to acidic pH, extracted three times with EA, the organic layer was washed with saturated NaCl, the organic layers were combined, dried over anhydrous Na 2 SO 4, rotary evaporation The solvent was separated by silica gel column chromatography (EtOAc/EtOAc/EtOAc/EtOAc.
1H NMR(400MHz,DMSO-d 6,ppm):δ8.17-8.13(m,2H),7.91(d,J＝8.0Hz,1H).GC-MS(EI)calcd for C 9H 5F 3O 3[M] +218.0,found 218.0. 1 H NMR (400MHz, DMSO- d 6, ppm): δ8.17-8.13 (m, 2H), 7.91 (d, J = 8.0Hz, 1H) .GC-MS (EI) calcd for C 9 H 5 F 3 O 3 [M] + 218.0, found 218.0.
2-甲基-1-(2-羧基-4-三氟甲基苄叉基)氨基硫脲20h2-methyl-1-(2-carboxy-4-trifluoromethylbenzylidene)thiosemicarbazide 20h
Figure PCTCN2018083596-appb-000150
Figure PCTCN2018083596-appb-000150
称取2-甲酰基-5-三氟甲基苯甲酸(46mg，0.21mmol)于50mL圆底烧瓶中，称取2-甲基氨基硫脲(26mg，0.21mmol)，加入6mL乙醇，加热回流至原料转化完全，旋干溶剂，硅胶柱层析(DCM/MeOH＝100/1，v/v)，得亮黄色粉末状固体。2-formyl-5-trifluoromethylbenzoic acid (46 mg, 0.21 mmol) was weighed in a 50 mL round bottom flask, and 2-methylthiosemicarbazide (26 mg, 0.21 mmol) was weighed, and 6 mL of ethanol was added and heated to reflux. To a complete conversion of the starting material, the solvent was evaporated to dryness eluting elut elut elut elut
1H NMR(400MHz,DMSO-d 6,ppm):δ8.81(s,1H),8.58(s,1H),8.50(d,J＝8.4Hz,1H),8.40(s,1H),8.12(s,1H),7.75(d,J＝8.4Hz,1H),5.77(s,3H).LC-MS(ESI)calcd for C 11H 11F 3N 3O 2S[M+H] +306.05,found 306.05. 1 H NMR (400MHz, DMSO- d 6, ppm): δ8.81 (s, 1H), 8.58 (s, 1H), 8.50 (d, J = 8.4Hz, 1H), 8.40 (s, 1H), 8.12 (s, 1H), 7.75 (d, J = 8.4 Hz, 1H), 5.77 (s, 3H). LC-MS (ESI) calcd for C 11 H 11 F 3 N 3 O 2 S [M+H] + 306.05, found 306.05.
(E)-4-(2-氯苯基)-2-[1-甲基-2-(4-三氟甲基-2-羧基苄叉基)肼基]噻唑S20(E)-4-(2-chlorophenyl)-2-[1-methyl-2-(4-trifluoromethyl-2-carboxybenzylidene)indenyl]thiazole S20
Figure PCTCN2018083596-appb-000151
Figure PCTCN2018083596-appb-000151
合成方法同S7，得土黄色粉末状固体50mg，产率56％。Mp 209.3-210.7℃.The synthesis method was the same as that of S7 to obtain 50 mg of a yellowish powdery solid, yield 56%. Mp 209.3-210.7 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ14.02(br,1H),8.66(s,1H),8.21(d,J＝8.0Hz,1H),8.17(s,1H),8.02(d,J＝8.0Hz,1H),7.95(d,J＝7.6Hz,1H),7.56-7.53(m,2H),7.43(t,J＝7.6Hz,1H),7.37(t,J＝7.6Hz,1H),3.70(s,3H). 13C NMR(100MHz,DMSO-d 6,ppm):δ168.33,167.17,146.79,138.38,135.01,132.91,131.12,130.70,130.37,129.14,128.57,128.25,128.20,127.26,127.04,125.10,122.40,111.51,32.68.HRMS(ESI)calcd for C 19H 14N 3O 2SClF 3[M+H] +440.0447,found 440.0433. 1 H NMR (400MHz, DMSO- d 6, ppm): δ14.02 (br, 1H), 8.66 (s, 1H), 8.21 (d, J = 8.0Hz, 1H), 8.17 (s, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.95 (d, J = 7.6 Hz, 1H), 7.56-7.53 (m, 2H), 7.43 (t, J = 7.6 Hz, 1H), 7.37 (t, J = 7.6 Hz, 1H), 3.70 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6, ppm): δ 168.33, 167.17, 146.79, 138.38, 135.01, 132.91, 131.12, 130.70, 130.37, 129.14, 128.57, 128.25 , 128.20, 127.26, 127.04, 125.10, 122.40, 111.51, 32.68. HRMS (ESI) calcd for C 19 H 14 N 3 O 2 SClF 3 [M+H] + 440.0447, found 440.0433.
2-甲酰基-5-甲基苯甲酸21f2-formyl-5-methylbenzoic acid 21f
Figure PCTCN2018083596-appb-000152
Figure PCTCN2018083596-appb-000152
合成方法同20f，得白色粉末状固体0.4g，产率26％。The synthesis method was the same as 20f, yielding 0.4 g of a white powdery solid, yield 26%.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.56(br,1H),10.42(br,1H),7.68-7.57(m,3H),2.44(s,3H).LC-MS(ESI)calcd for C 9H 7O 3[M-H] -163.04,163.05. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.56 (br, 1H), 10.42 (br, 1H), 7.68-7.57 (m, 3H), 2.44 (s, 3H) .LC-MS ( ESI)calcd for C 9 H 7 O 3 [MH] - 163.04,163.05.
2-甲基-1-(2-羧基-4-甲基苄叉基)氨基硫脲21h2-methyl-1-(2-carboxy-4-methylbenzylidene)thiosemicarbazide 21h
Figure PCTCN2018083596-appb-000153
Figure PCTCN2018083596-appb-000153
合成方法同20h，得白色粉末状固体0.36g，产率60％。The synthesis method was the same as 20h, yielding a white powdery solid, 0.36g, yield 60%.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.28(br,1H),8.52(s,1H),8.47(br,1H),8.23-8.21(m,2H),7.69(s,1H),7.40(d,J＝8.0Hz,1H),3.75(s,3H),2.38(s,3H). 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.28 (br, 1H), 8.52 (s, 1H), 8.47 (br, 1H), 8.23-8.21 (m, 2H), 7.69 (s, 1H), 7.40 (d, J = 8.0 Hz, 1H), 3.75 (s, 3H), 2.38 (s, 3H).
(E)-4-(2-氯苯基)-2-[1-甲基-2-(4-甲基-2-羧基苄叉基)肼基]噻唑S21(E)-4-(2-chlorophenyl)-2-[1-methyl-2-(4-methyl-2-carboxybenzylidene)indenyl]thiazole S21
Figure PCTCN2018083596-appb-000154
Figure PCTCN2018083596-appb-000154
合成方法同S7，得黄色粉末状固体120mg，产率76％。Mp 231.3-232.5℃.The synthesis method was the same as that of S7 to obtain a yellow powdery solid 120 mg, yield 76%. Mp 231.3-232.5 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.30(br,1H),8.59(s,1H),7.96(d,J＝7.6Hz,1H),7.92(d,J＝8.0Hz,1H),7.75(s,1H),7.54(d,J＝7.6Hz,1H),7.49-7.46(m,2H),7.43(t,J＝7.6Hz,1H),7.36(t,J＝7.6Hz,1H),3.66(s,3H),2.38(s,3H). 13C NMR(100MHz,DMSO-d 6,ppm):δ168.60,168.35,146.68,138.54,136.64,133.03,132.70,132.07,131.11,130.86,130.67,130.34,129.83,129.00,127.21,126.04,110.84,32.39,20.69.HRMS(ESI)calcd for C 19H 17N 3O 2SCl[M+H] +386.0730,found 386.0738. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.30 (br, 1H), 8.59 (s, 1H), 7.96 (d, J = 7.6Hz, 1H), 7.92 (d, J = 8.0Hz , 1H), 7.75 (s, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.49-7.46 (m, 2H), 7.43 (t, J = 7.6 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 3.66 (s, 3H), 2.38 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6, ppm): δ 168.60, 168.35, 146.68, 138.54, 136.64, 133.03, 132.70, 132.07, 131.11,130.86,130.67,130.34,129.83,129.00,127.21,126.04,110.84,32.39,20.69.HRMS(ESI)calcd for C 19 H 17 N 3 O 2 SCl[M+H] + 386.0730,found 386.0738.
(E)-5-甲基-4-苯基-2-[1-甲基-2-(4-甲基-2-羧基苄叉基)肼基]噻唑S22(E)-5-Methyl-4-phenyl-2-[1-methyl-2-(4-methyl-2-carboxybenzylidene)indolyl]thiazole S22
Figure PCTCN2018083596-appb-000155
Figure PCTCN2018083596-appb-000155
合成方法同S7，得黄色粉末状固体0.46g，产率70％。Mp 243.2-245.2℃.The synthesis method was the same as that of S7 to obtain a yellow powdery solid of 0.46 g, yield 70%. Mp 243.2-245.2 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ13.24(br,1H),8.54(s,1H),7.91(d,J＝8.0Hz,1H),7.73(s,1H),7.64-7.53(m,2H),7.46-7.42(m,3H),7.33(t,J＝7.4Hz,1H),3.60(s,3H),2.44(s,3H),2.38(s,3H). 13C NMR(100MHz,DMSO-d 6,ppm):δ168.35,165.40,145.43,138.33,135.76,135.16,132.68,132.22,130.86,129.62,128.24,128.24,127.85,127.85,127.06,125.89,119.27,31.85,20.68,12.24.HRMS(ESI)calcd for C 20H 20N 3O 2S[M+H] +366.1276,found 366.1273. 1 H NMR (400MHz, DMSO- d 6, ppm): δ13.24 (br, 1H), 8.54 (s, 1H), 7.91 (d, J = 8.0Hz, 1H), 7.73 (s, 1H), 7.64 -7.53 (m, 2H), 7.46-7.42 (m, 3H), 7.33 (t, J = 7.4 Hz, 1H), 3.60 (s, 3H), 2.44 (s, 3H), 2.38 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6 , ppm): δ 168.35, 165.40, 145.43, 138.33, 135.76, 135.16, 132.68, 132.22, 130.86, 129.62, 128.24, 128.24, 127.85, 127.85, 127.06, 125.89, 119.27, 31.85, 20.68, 12.24. HRMS (ESI) calcd for C 20 H 20 N 3 O 2 S [M+H] + 366.1276, found 366.1273.
2-甲酰基-5-氟苯甲酸23f2-formyl-5-fluorobenzoic acid 23f
Figure PCTCN2018083596-appb-000156
Figure PCTCN2018083596-appb-000156
合成方法同20f，得淡黄色粉末状固体68mg，产率15％。The synthesis method was the same as 20f, yielding a pale yellow powdery solid, 68 mg, yield 15%.
1H NMR(400MHz,DMSO-d 6,ppm):δ7.76-7.75(m,1H),7.69-7.62(m,2H).LC-MS(ESI)calcd for C 8H 4FO 3[M-H] -167.01,found 167.10. 1 H NMR (400MHz, DMSO- d 6, ppm): δ7.76-7.75 (m, 1H), 7.69-7.62 (m, 2H) .LC-MS (ESI) calcd for C 8 H 4 FO 3 [MH ] - 167.01, found 167.10.
1-(2-丙叉基)-2-甲基氨基硫脲23a1-(2-propionyl)-2-methylthiosemicarbazide 23a
Figure PCTCN2018083596-appb-000157
Figure PCTCN2018083596-appb-000157
称取7g(0.63g，6.0mmol)原料于50mL单口瓶中，加入25mL乙醇作溶剂，搅拌下加入丙酮(0.45mL，6.0mmol)，滴入5滴冰醋酸，加热至回流，TLC跟踪反应至原料转化完全， 硅胶柱层析(DCM/MeOH＝100/1,v/v)，得白色粉末状产物0.5g，产率58％。Weigh 7g (0.63g, 6.0mmol) of raw material in a 50mL single-mouth bottle, add 25mL of ethanol as a solvent, add acetone (0.45mL, 6.0mmol) with stirring, add 5 drops of glacial acetic acid, heat to reflux, and trace the reaction by TLC. The material was completely converted to silica gel column chromatography (DCM / MeOH = 100/1, v/v).
1H NMR(400MHz,DMSO-d 6,ppm):δ8.56(s,1H),5.58(s,1H),3.10(s,3H),1.24(s,6H).4-(2-氯苯基)-2-(1-甲基肼基)噻唑23d 1 H NMR (400MHz, DMSO- d 6, ppm): δ8.56 (s, 1H), 5.58 (s, 1H), 3.10 (s, 3H), 1.24 (s, 6H) .4- (2- chloro Phenyl)-2-(1-methylindenyl)thiazole 23d
Figure PCTCN2018083596-appb-000158
Figure PCTCN2018083596-appb-000158
合成方法同8d，棕色针状固体1.2g，产率61％。The synthesis method was the same as that of 8d, 1.2g of brown needle-like solid, and the yield was 61%.
1H NMR(400MHz,DMSO-d 6,ppm):δ7.88(dd,J 1＝7.6Hz,J 2＝1.6Hz,1H),7.49(dd,J 1＝8.0Hz,J 2＝1.6Hz,1H),7.38(td,J 1＝7.6Hz,J 2＝1.6Hz,1H),7.30(td,J 1＝8.0Hz,J 2＝1.6Hz,1H),7.17(s,1H),5.22(s,2H),3.25(s,3H). 1 H NMR (400 MHz, DMSO-d 6 , ppm): δ 7.88 (dd, J 1 = 7.6 Hz, J 2 = 1.6 Hz, 1H), 7.49 (dd, J 1 = 8.0 Hz, J 2 = 1.6 Hz , 1H), 7.38 (td, J 1 = 7.6 Hz, J 2 = 1.6 Hz, 1H), 7.30 (td, J 1 = 8.0 Hz, J 2 = 1.6 Hz, 1H), 7.17 (s, 1H), 5.22 (s, 2H), 3.25 (s, 3H).
(E)-4-(2-氯苯基)-2-[1-甲基-2-(2-羧基-4-氟苄叉基)肼基]噻唑S23(E)-4-(2-chlorophenyl)-2-[1-methyl-2-(2-carboxy-4-fluorobenzylidene)indolyl]thiazole S23
Figure PCTCN2018083596-appb-000159
Figure PCTCN2018083596-appb-000159
合成方法同S8，得亮黄色粉末状固体35mg，产率57％。Mp 236.2-237.1℃.The synthesis method was the same as that of S8 to give a bright yellow powdery solid, 35 mg, yield 57%. Mp 236.2-237.1 ° C.
1H NMR(400MHz,DMSO-d 6,ppm):δ8.61(s,1H),8.06-8.02(dd,J 1＝5.6Hz,J 2＝8.4Hz,1H),7.96(d,J＝7.2Hz,1H),7.67-7.64(dd,J 1＝9.6Hz,J 2＝2.4Hz,1H),7.55-7.51(m,2H),7.47(s,1H),7.43(t,J＝7.2Hz,1H),7.36(t,J＝7.2Hz,1H),3.68(s,3H). 13C NMR(100MHz,DMSO-d 6,ppm):δ168.55,168.01,159.74(d, 1J＝249Hz),146.67,133.68,133.10,131.50,131.12,130.72,130.32,130.10(d, 3J＝8.8Hz),129.06,127.23,125.53(d, 4J＝3.1Hz),121.75(d, 3J＝11.8Hz),118.76(d, 2J＝22Hz),111.13,32.28.HRMS(ESI)calcd for C 18H 14N 3O 2FSCl[M+H] +390.0479,found 390.0475. 1 H NMR (400MHz, DMSO- d 6, ppm): δ8.61 (s, 1H), 8.06-8.02 (dd, J 1 = 5.6Hz, J 2 = 8.4Hz, 1H), 7.96 (d, J = 7.2 Hz, 1H), 7.67-7.64 (dd, J 1 = 9.6 Hz, J 2 = 2.4 Hz, 1H), 7.55-7.51 (m, 2H), 7.47 (s, 1H), 7.43 (t, J = 7.2) Hz, 1H), 7.36 (t, J = 7.2 Hz, 1H), 3.68 (s, 3H). 13 C NMR (100 MHz, DMSO-d 6, ppm): δ 168.55, 168.01, 159.74 (d, 1 J = 249 Hz ), 146.67, 133.68, 133.10, 131.50, 131.12, 130.72, 130.32, 130.10 (d, 3 J=8.8 Hz), 129.06, 127.23, 125.53 (d, 4 J=3.1 Hz), 121.75 (d, 3 J=11.8) Hz), 118.76 (d, 2 J=22 Hz), 111.13, 32.28. HRMS (ESI) calcd for C 18 H 14 N 3 O 2 FSCl [M+H] + 390.0479, found 390.0475.
实施例9.活性检测Example 9. Activity detection
本发明人检测了本发明的化合物以及阳性对照药物布喹那、蒽环类药物(柔红霉素、去甲氧柔红霉素或米托蒽醌)和阿糖胞苷等对急性髓细胞白血病细胞系的半数抑制浓度。The present inventors examined the compounds of the present invention as well as positive control drugs such as buquina, anthracyclines (daunorubicin, demethoxydaunorubicin or mitoxantrone) and cytarabine against acute myeloid cells. The half inhibitory concentration of leukemia cell lines.
本实施例使用的实验材料如下：CCK8试剂购自Beyotime；THP-1、MV4-11、RS4-11、HL60细胞购自美国ATCC，MOLM13、MOLM14、SIG-M5、AML2、AML3、AML5、U937、MONOMAC6购自德国DSMZ公司；培养基购自美国Hylcone；胎牛血清购自美国Gibco公司；CO 2培养箱购自美国Thermo公司，型号为TM3111；生物安全柜购自Heal Force；超纯水仪购自Millipore Synergy UV；液氮罐购自乐山市东亚机电工贸有限公司；立式冷藏陈列柜购自浙江星星家电股份有限公司，型号为LSC-218C；台式低速离心机购自长沙湘仪离心机仪器有限公司，型号为L500；96孔板购美国Thermo公司；细胞计数仪购自美国Invitrogen公司；多功能酶标仪购自美国BioTek公司，型号为Synergy2；移液枪购自德国eppendorf公司；离心管、移液管、培养皿等耗材均购自美国Thermo公司；DMSO等试剂购自上海凌峰化学试剂有限公司。 The experimental materials used in this example were as follows: CCK8 reagent was purchased from Beyotime; THP-1, MV4-11, RS4-11, HL60 cells were purchased from ATCC, MOLM13, MOLM14, SIG-M5, AML2, AML3, AML5, U937, MONOMAC6 was purchased from DSMZ, Germany; culture medium was purchased from Hylcone, USA; fetal bovine serum was purchased from Gibco, USA; CO 2 incubator was purchased from Thermo Company, USA, model TM3111; biosafety cabinet was purchased from Heal Force; ultrapure water was purchased. From Millipore Synergy UV; liquid nitrogen tank purchased from Leshan East Asia Machine Electric Co., Ltd.; vertical refrigerated display cabinet purchased from Zhejiang Star Appliance Co., Ltd., model LSC-218C; desktop low speed centrifuge purchased from Changsha Xiangyi centrifuge Instrument Co., Ltd., model L500; 96-well plate purchased from Thermo Company, USA; cell counter is purchased from Invitrogen, USA; multi-function microplate reader is purchased from BioTek, USA, model is Synergy2; pipetting gun is purchased from eppendorf, Germany; Consumables such as tubes, pipettes, and petri dishes were purchased from Thermo Corporation of the United States; reagents such as DMSO were purchased from Shanghai Lingfeng Chemical Reagent Co., Ltd.
实验方法：用含10％胎牛血清的培养基配成单个细胞悬液，以每孔8万/mL接种于96孔培养板中，每孔体积为100μL，然后将培养板移入CO 2培养箱中，在温度为37℃、5％CO 2 及饱和湿度条件下培养24h。取新鲜配制的化合物母液，并计算好所需的抑制剂浓度和稀释梯度(一般以10μM为起始浓度)，用培养基进行稀释获得化合物物梯度稀释液，加入到96孔板对应的孔中，拍打均匀，与细胞进行共同孵育，在细胞培养箱中培养孵育72h。孵育结束后每孔加入CCK8试剂10μL，再放入培养箱中孵育4-8小时，450nm下测定OD值。按以下公式计算药物对细胞生长的存活率：存活率(％)＝(OD 加药-OD 空白)/(OD 对照-OD 空白)×100％，拟合得IC 50及抑制曲线。 Experimental method: a single cell suspension was prepared with a medium containing 10% fetal bovine serum, and inoculated into a 96-well culture plate at a volume of 80,000/mL per well at a volume of 100 μL per well, and then the culture plate was transferred to a CO 2 incubator. The medium was cultured for 24 hours at 37 ° C, 5% CO 2 and saturated humidity. Take the mother formula of the freshly prepared compound, calculate the desired inhibitor concentration and dilution gradient (generally starting at 10 μM), dilute with the medium to obtain a gradient dilution of the compound, and add to the corresponding well of the 96-well plate. Beat evenly, incubate with cells, incubate in a cell culture incubator for 72 h. After the incubation, 10 μL of CCK8 reagent was added to each well, and then incubated in an incubator for 4-8 hours, and the OD value was measured at 450 nm. The survival rate of the drug on cell growth was calculated according to the following formula: survival rate (%) = (OD dosing - OD blank ) / (OD control - OD blank ) x 100%, fitting IC 50 and inhibition curve.
表1.化合物对急性髓细胞白血病细胞系的半数抑制浓度Table 1. Half-inhibitory concentration of compounds on acute myeloid leukemia cell lines
IC 50(nM) IC 50 (nM) THP-1THP-1 SIG-M5SIG-M5 AML2AML2 AML5AML5 HL60HL60 MONOMAC6MONOMAC6 AML3AML3 U937U937 MOLM14MOLM14 MOLM13MOLM13
BrequinarBrequinar 274274 188188 128128 148148 926926 198198 10331033 344344 410410 235235
S1S1 22612261 11301130 723723 649649 15571557 10011001 37803780 18721872 16031603 630630
S3S3 10961096 610610 272272 391391 61526152 594594 752752 683683 336336 132132
S4S4 13191319 659659 422422 378378 908908 584584 20912091 18991899 934934 367367
S5S5 19341934 11531153 669669 802802 741741 476476 17991799 891891 763763 13491349
S6S6 44974497 16051605 561561 372372 26952695 12731273 59045904 15041504 821821 328328
S7S7 122122 6161 3939 3535 8484 5454 204204 101101 145145 345345
S8S8 14101410 725725 302302 418418 18701870 10001000 22062206 288288 324324 302302
S9S9 20392039 952952 280280 464464 10421042 15861586 54595459 894894 745745 914914
S10S10 39173917 22692269 242242 365365 36743674 603603 42594259 25772577 12281228 16291629
S11S11 239239 107107 104104 4949 269269 6262 218218 198198 9797 238238
S12S12 700700 417417 241241 289289 26882688 414414 14281428 631631 466466 573573
S13S13 548548 326326 189189 226226 21052105 324324 11171117 494494 506506 499499
S14S14 440440 262262 152152 182182 16891689 261261 900900 397397 314314 204204
S15S15 709709 422422 244244 293293 27222722 420420 14471447 639639 556556 418418
S16S16 304304 181181 105105 126126 11671167 180180 620620 274274 193193 277277
S17S17 810810 482482 279279 334334 31083108 479479 16501650 729729 659659 537537
S18S18 10201020 607607 351351 421421 39163916 603603 20782078 919919 853853 648648
S19S19 252252 150150 8787 104104 969969 149149 513513 204204 199199 626626
S20S20 18151815 801801 173173 345345 53895389 792792 42074207 645645 716716 583583
S21S21 247247 238238 341341 631631 359359 195195 18341834 364364 472472 312312
S22S22 328328 9393 120120 119119 10411041 413413 579579 290290 315315 240240
S23S23 586586 299299 121121 170170 25992599 297297 13241324 516516 433433 295295
4444 622622 303303 200200 175175 420420 270270 10081008 505505 751751 13451345
4545 521521 305305 100100 200200 502502 624624 12041204 774774 720720 15451545
                     
从表1可以看，本发明的化合物对AML细胞的增殖均有抑制作用，普遍优于阳性对照药，其中化合物S7对AML细胞的增殖抑制效果甚至优于阳性对照药布喹那(Brequinar)。It can be seen from Table 1 that the compound of the present invention has an inhibitory effect on the proliferation of AML cells, and is generally superior to the positive control drug, wherein the compound S7 inhibits the proliferation of AML cells even better than the positive control drug Brequinar.
在本发明提及的所有文献都在本申请中引用作为参考，就如同每一篇文献被单独引用作为参考那样。此外应理解，在阅读了本发明的上述讲授内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。All documents mentioned in the present application are hereby incorporated by reference in their entirety in their entireties in the the the the the the the the In addition, it should be understood that various modifications and changes may be made by those skilled in the art in the form of the appended claims.

Claims (13)

  1. 式I所示化合物在制备治疗白血病的药物中的用途，The use of a compound of formula I for the manufacture of a medicament for the treatment of leukemia,
    Figure PCTCN2018083596-appb-100001
    Figure PCTCN2018083596-appb-100001
    式中，In the formula,
    R a选自：氢、C 1-C 3烷基、
    Figure PCTCN2018083596-appb-100002
    R a is selected from the group consisting of hydrogen, C 1 -C 3 alkyl,
    Figure PCTCN2018083596-appb-100002
    R b选自：H、C 1-C 6烷基、卤素取代的C 1-C 6烷基、C 1-C 3烷基羰基、任选取代的苯甲酰基、羧基、氨基羰基、C 1-C 6烷氧基羰基、羟基、C 1-C 6烷氧基、任选取代的C 6-C 10芳基或杂芳基、氨基、NR 6R 7； R b is selected from the group consisting of: H, C 1 -C 6 alkyl, halogen-substituted C 1 -C 6 alkyl, C 1 -C 3 alkylcarbonyl, optionally substituted benzoyl, carboxyl, aminocarbonyl, C 1 -C 6 alkoxycarbonyl, hydroxy, C 1 -C 6 alkoxy, optionally substituted C 6 -C 10 aryl or heteroaryl, amino, NR 6 R 7 ;
    R 6和R 7各自独立选自：H、或任选取代的羰基C 1-C 3烷基(优选C 1-C 3烷基或C 3-C 6环烷基取代的羰基；最优选环丙基取代的羰基)； R 6 and R 7 are each independently selected from: H, or an optionally substituted carbonyl C 1 -C 3 alkyl group (preferably a C 1 -C 3 alkyl group or a C 3 -C 6 cycloalkyl substituted carbonyl group; most preferably a ring) Propyl substituted carbonyl);
    R 2选自：H、C 1-C 10烷基或C 1-C 10卤代烷基、C 1-C 10烷氧基或C 1-C 10卤代烷氧基、或羟基C 1-C 6烷基或羟基C 1-C 6卤代烷基； R 2 is selected from the group consisting of: H, C 1 -C 10 alkyl or C 1 -C 10 haloalkyl, C 1 -C 10 alkoxy or C 1 -C 10 haloalkoxy, or hydroxy C 1 -C 6 alkyl Or a hydroxy C 1 -C 6 haloalkyl group;
    R c选自：Ar或
    Figure PCTCN2018083596-appb-100003
    R c is selected from: Ar or
    Figure PCTCN2018083596-appb-100003
    R 3选自：H、C 1-C 6烷基或C 1-C 6卤代烷基、C 1-C 6烷氧基羰基、任选取代的苯基、C 1-C 4烷基羰基、任选取代的苯甲酰基、C 1-C 3烷基羧基、酰胺基、任选取代的苯胺甲酰基； R 3 is selected from the group consisting of: H, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, C 1 -C 6 alkoxycarbonyl, optionally substituted phenyl, C 1 -C 4 alkylcarbonyl, any a substituted benzoyl group, a C 1 -C 3 alkylcarboxy group, an amide group, an optionally substituted benzoyl group;
    Ar选自：任选取代的C 6-C 14芳基、任选取代的C 6-C 14杂环基、任选取代的C 6-C 14芳基羰基、任选取代的C 6-C 14杂环基羰基、任选取代的C 6-C 14芳氧基烷基羰基； Ar is selected from the group consisting of: an optionally substituted C 6 -C 14 aryl group, an optionally substituted C 6 -C 14 heterocyclic group, an optionally substituted C 6 -C 14 arylcarbonyl group, an optionally substituted C 6 -C a 14 heterocyclylcarbonyl group, an optionally substituted C 6 -C 14 aryloxyalkylcarbonyl group;
    R 1选自：H、卤素、C 1-C 6烷基或C 1-C 6卤代烷基； R 1 is selected from the group consisting of: H, halogen, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl;
    R 5选自：H、卤素、OH、NR 8R 9、C 1-C 6烷氧基或C 1-C 6卤代烷氧基； R 5 is selected from the group consisting of: H, halogen, OH, NR 8 R 9 , C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy;
    R 8和R 9各自独立选自：H、或C 1-C 3烷基、或C 1-C 3卤代烷基； R 8 and R 9 are each independently selected from: H, or C 1 -C 3 alkyl, or C 1 -C 3 haloalkyl;
    R选自：醛基CHO，羧基COOH，C 1-C 6烷氧基羰基； R is selected from the group consisting of: aldehyde group CHO, carboxyl group COOH, C 1 -C 6 alkoxycarbonyl group;
    A选自：C 1-C 6烷基(优选C 1-C 3烷基)。 A is selected from the group consisting of C 1 -C 6 alkyl groups (preferably C 1 -C 3 alkyl groups).
  2. 如权利要求1所述的用途，其特征在于，所述白血病包括但不限于：急性淋巴细胞白血病(ALL)、急性髓细胞白血病、慢性粒细胞白血病、慢性淋巴细胞白血病；优选急性髓细胞白血病。The use according to claim 1, wherein the leukemia comprises, but is not limited to, acute lymphocytic leukemia (ALL), acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia; preferably acute myeloid leukemia.
  3. 如权利要求1或2所述的用途，其特征在于，式I所示化合物具有式Ia所示结构：The use according to claim 1 or 2, wherein the compound of formula I has the structure of formula Ia:
    Figure PCTCN2018083596-appb-100004
    Figure PCTCN2018083596-appb-100004
    式中，In the formula,
    R 3选自：C 1-C 6烷基、C 1-C 6烷氧基羰基、任选取代的苯基、C 1-C 4烷基羰基、任选取代的苯甲酰基、C 1-C 3烷基羧基、酰胺基、任选取代的苯胺甲酰基；和 R 3 is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxycarbonyl, optionally substituted phenyl, C 1 -C 4 alkylcarbonyl, optionally substituted benzoyl, C 1 - a C 3 alkylcarboxy group, an amide group, an optionally substituted benzoic acid group;
    Ar、R b如权利要求1所述。 Ar, R b are as claimed in claim 1.
  4. 如权利要求3所述的用途，其特征在于，Ar上具有0-5个取代基，所述取代基选自：C 1-C 10烷基、C 3-C 8环烷基、C 1-C 4烷氧基、任选取代的苯基、任选取代的苯氧基、苄氧基、CF 3、卤素。 The use according to claim 3, wherein Ar has 0 to 5 substituents selected from the group consisting of C 1 -C 10 alkyl, C 3 -C 8 cycloalkyl, C 1 - C 4 alkoxy, optionally substituted phenyl, optionally substituted phenoxy, benzyloxy, CF 3 , halogen.
  5. 如权利要求3所述的用途，其特征在于，R b选自：C 1-C 6烷基、CF 3、苯基、乙酰基、苯甲酰基、羧基、氨基甲酰基、C 1-C 6烷氧基羰基、氨基；更优选甲基、CF 3或苯基。 The use according to claim 3, wherein R b is selected from the group consisting of C 1 -C 6 alkyl, CF 3 , phenyl, acetyl, benzoyl, carboxyl, carbamoyl, C 1 -C 6 Alkoxycarbonyl, amino; more preferably methyl, CF 3 or phenyl.
  6. 如权利要求3所述的用途，其特征在于，R 3选自：C 1-C 6烷基、苯基、C 1-C 3烷基羰基、任选取代的苯甲酰基、羧基、C 1-C 6烷氧基羰基、酰胺基、任选取代的苯胺甲酰基；优选C 1-C 3烷基羰基，C 1-C 3烷氧基羰基。 The use according to claim 3, wherein R 3 is selected from the group consisting of C 1 -C 6 alkyl, phenyl, C 1 -C 3 alkylcarbonyl, optionally substituted benzoyl, carboxyl, C 1 -C 6 alkoxycarbonyl, amide, optionally substituted benzoyl; preferably C 1 -C 3 alkylcarbonyl, C 1 -C 3 alkoxycarbonyl.
  7. 如权利要求3所述的用途，其特征在于，式I所示化合物选自化合物1-100。The use according to claim 3, wherein the compound of formula I is selected from the group consisting of compounds 1-100.
  8. 如权利要求1或2所述的用途，其特征在于，式I所示化合物具有式Ib所示结构：The use according to claim 1 or 2, wherein the compound of formula I has the structure of formula Ib:
    Figure PCTCN2018083596-appb-100005
    Figure PCTCN2018083596-appb-100005
    式中，In the formula,
    R 4选自：H、卤素、C 1-C 6烷基或C 1-C 6卤代烷基、或C 1-C 6烷氧基或C 1-C 6卤代烷氧基； R 4 is selected from the group consisting of: H, halogen, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, or C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy;
    m＝0～3的整数；An integer of m=0 to 3;
    R、R 1、R 2、R 3、R 5如权利要求1所述。 R, R 1 , R 2 , R 3 and R 5 are as defined in claim 1.
  9. 如权利要求8所述的用途，其特征在于，式I所示化合物具有式Ic所示结构：The use according to claim 8 wherein the compound of formula I has the structure of formula Ic:
    Figure PCTCN2018083596-appb-100006
    Figure PCTCN2018083596-appb-100006
    R 1选自H、F、Cl、Br、C 1-C 3烷基或C 1-C 3卤代烷基； R 1 is selected from H, F, Cl, Br, C 1 -C 3 alkyl or C 1 -C 3 haloalkyl;
    R 2选自H、C 1-C 6烷基或C 1-C 6卤代烷基、C 1-C 6烷氧基或C 1-C 6卤代烷氧基、或羟基C 1-C 3烷基或羟基C 1-C 3卤代烷基； R 2 is selected from H, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy, or hydroxy C 1 -C 3 alkyl or a hydroxy C 1 -C 3 haloalkyl group;
    R 3自H、C 1-C 3烷基或C 1-3卤代烷基； R 3 is from H, C 1 -C 3 alkyl or C 1-3 haloalkyl;
    R 4选自H、F、Cl、Br、C 1-C 3烷基或C 1-C 3卤代烷基、C 1-C 3烷氧基或C 1-C 3卤代烷氧基； R 4 is selected from H, F, Cl, Br, C 1 -C 3 alkyl or C 1 -C 3 haloalkyl, C 1 -C 3 alkoxy or C 1 -C 3 haloalkoxy;
    R 5选自H、F、Cl、Br、OH、NH 2、OCH 3。 R 5 is selected from the group consisting of H, F, Cl, Br, OH, NH 2 , OCH 3 .
  10. 如权利要求8或9所述的用途，其特征在于，Use according to claim 8 or 9, characterized in that
    R 1选自H、C 1-C 3烷基； R 1 is selected from the group consisting of H, C 1 -C 3 alkyl;
    R 2选自C 1-C 3烷基； R 2 is selected from C 1 -C 3 alkyl;
    R 3选自H、C 1-C 3烷基； R 3 is selected from the group consisting of H, C 1 -C 3 alkyl;
    R 4选自H或Cl； R 4 is selected from H or Cl;
    R 5选自H。 R 5 is selected from H.
  11. 如权利要求8所述的用途，其特征在于，式I所示化合物选自下组化合物：The use according to claim 8 wherein the compound of formula I is selected from the group consisting of the following compounds:
    Figure PCTCN2018083596-appb-100007
    Figure PCTCN2018083596-appb-100007
    Figure PCTCN2018083596-appb-100008
    Figure PCTCN2018083596-appb-100008
  12. 如权利要求11所述的用途，其特征在于，式I所示化合物选自下组化合物：The use according to claim 11 wherein the compound of formula I is selected from the group consisting of:
    Figure PCTCN2018083596-appb-100009
    Figure PCTCN2018083596-appb-100009
  13. 一种非淋巴细胞性白血病的治疗方法，包括将治疗有效量的权利要求1-12中任一所述的化合物给予需要治疗白血病的患者。A method of treating non-lymphocytic leukemia comprising administering a therapeutically effective amount of a compound of any of claims 1-12 to a patient in need of treatment for leukemia.
PCT/CN2018/083596 2017-04-20 2018-04-18 Application of thiazole derivative in treatment of nonlymphocytic leukemia WO2018192535A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710262810.8A CN108721283A (en) 2017-04-20 2017-04-20 Application of the thiazole in treating non-lymphocytic leukemia
CN201710262810.8 2017-04-20

Publications (1)

Publication Number Publication Date
WO2018192535A1 true WO2018192535A1 (en) 2018-10-25

Family

ID=63856888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/083596 WO2018192535A1 (en) 2017-04-20 2018-04-18 Application of thiazole derivative in treatment of nonlymphocytic leukemia

Country Status (2)

Country Link
CN (1) CN108721283A (en)
WO (1) WO2018192535A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023011312A1 (en) * 2021-08-02 2023-02-09 上海汇伦医药股份有限公司 Multi-substituted thiazole derivative and application thereof in disease treatment

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114222732B (en) * 2019-10-28 2023-04-04 南京明德新药研发有限公司 Uric acid excretion promoter, synthesis method thereof and application thereof in medicine
CN112707874A (en) * 2020-12-29 2021-04-27 广东中科药物研究有限公司 Antiviral compound and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319026A (en) * 1980-08-14 1982-03-09 Gulf Oil Corporation Heterocyclic-substituted hydrazides and hydrazones as plant growth regulators
CN1684959A (en) * 2002-08-02 2005-10-19 Ab科学公司 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors
CN102151272A (en) * 2011-02-25 2011-08-17 中国药科大学 Polo like kinase1 (PLK1) inhibitor and use thereof
CN103006653A (en) * 2011-09-27 2013-04-03 华东理工大学 Applications of 2,4-disubstituted thiazoles derivatives being taken as DHODH (dihydroorotate dehydrogenase) inhibitor
CN103127095A (en) * 2011-11-23 2013-06-05 华东理工大学 Synthesis and application of dihydrothiophenone derivative as pfDHODH inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103058949A (en) * 2011-10-18 2013-04-24 华东理工大学 Thiazole derivative acting as DHODH inhibitor and its application
US9757378B2 (en) * 2013-05-17 2017-09-12 Universite De Montreal Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation
CN106892878B (en) * 2015-12-18 2020-01-10 华东理工大学 Thiazole derivative and application thereof in inhibiting dihydroorotate dehydrogenase
CN107382902B (en) * 2016-05-17 2022-08-12 华东理工大学 Thiazole derivative and application thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319026A (en) * 1980-08-14 1982-03-09 Gulf Oil Corporation Heterocyclic-substituted hydrazides and hydrazones as plant growth regulators
CN1684959A (en) * 2002-08-02 2005-10-19 Ab科学公司 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors
CN102151272A (en) * 2011-02-25 2011-08-17 中国药科大学 Polo like kinase1 (PLK1) inhibitor and use thereof
CN103006653A (en) * 2011-09-27 2013-04-03 华东理工大学 Applications of 2,4-disubstituted thiazoles derivatives being taken as DHODH (dihydroorotate dehydrogenase) inhibitor
CN103127095A (en) * 2011-11-23 2013-06-05 华东理工大学 Synthesis and application of dihydrothiophenone derivative as pfDHODH inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI, S.L. ET AL.: "Rational Design of Benzylidenehydrazinyl-Substituted Thiazole Derivatives as Potent Inhibitors of Human Dihydroorotate Dehydrogenase with in Vivo Anti-arthritic Activity", SCIENTIFIC REPORTS, vol. 5, 7 October 2015 (2015-10-07), pages 1 - 19, XP055540082 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023011312A1 (en) * 2021-08-02 2023-02-09 上海汇伦医药股份有限公司 Multi-substituted thiazole derivative and application thereof in disease treatment

Also Published As

Publication number Publication date
CN108721283A (en) 2018-11-02

Similar Documents

Publication Publication Date Title
CN111138301B (en) Biphenyl compound, intermediate, preparation method, pharmaceutical composition and application
EP0570594B1 (en) Hydroxamic acid derivative based on aromatic sulfonamide
EP1067109B1 (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
WO2019128918A1 (en) Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
JPWO2006059744A1 (en) Activator of peroxisome proliferator activated receptor δ
JPWO2003091213A1 (en) Novel amide derivative or salt thereof
WO2018192535A1 (en) Application of thiazole derivative in treatment of nonlymphocytic leukemia
MXPA06003313A (en) Salts and polymorphs of a potent antidiabetic compound.
CZ234292A3 (en) Amides, process of their preparation and pharmaceutical compositions in which said amides are comprised
WO2016023460A1 (en) Carboxylic acid compound, method for preparation thereof, and use thereof
WO2007037543A1 (en) Biarylamide derivative
WO2003103654A1 (en) NF-κB ACTIVATION INHIBITORS
TW200406198A (en) O-substituted hydroxyaryl derivatives
WO2008006319A1 (en) BIBENZIMIDAZOLE DERIVATIVES HAVING PPARγ AGONIST ACTIVITY AND THEIR USES
WO2019154412A1 (en) Compound acting as antibiotics
CA2721576A1 (en) Compound having npy y5 receptor antagonist activity
JP7012289B2 (en) Benzoylglycine derivatives and methods for their preparation and use
WO2007068815A2 (en) Heterocyclic derivatives, preparation and therapeutic use thereof
WO2008044729A1 (en) Carboxylic acid derivative
CN110234318A (en) Amide compound and its application
JP7205529B2 (en) Method for producing oxazolidinone compound
AU2003268735A1 (en) Quinazolin-4-one derivatives
US20030162813A1 (en) Processes for the preparation of substituted isoxazoles and 2-isoxazolines
WO2008044731A1 (en) N-phenyloxamidic acid derivative
KR102114389B1 (en) Novel sodium channel inhibitor compound, preparation method thereof, and pharmaceutical composition for prevention or treatment of sodium channel related diseases containing the same as an active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18788041

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18788041

Country of ref document: EP

Kind code of ref document: A1